Combination therapy for treating non-small cell lung cancer

Through the combination of anti-clusterin antibodies and taxane, the treatment of non-small cell lung cancer patients who failed to treat immune checkpoint antibodies, especially those with low PD-L1 expression or no PD-L1 expression, has solved the effect of existing therapies. The clinical benefits of lesion reduction and prolonged survival are achieved.

CN118900700APending Publication Date: 2024-11-05ALETHIA BIOTHERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380028327.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-22
Filing Date
2023-02-06
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Existing methods for the treatment of non-small cell lung cancer (NSCLC), especially immune checkpoint inhibitors and chemotherapy, have limited effect on some patients, especially in patients with immunocold tumors, and docetaxel is treated in the second or third line. The efficacy of the treatment is limited and new treatments are urgently needed.

Method used

Anti-clusterin antibodies or antigen-binding fragments thereof combined with taxanes (such as docetaxel) are used to target NSCLC patients who fail to treat immune checkpoint antibodies, especially those with low PD-L1 expression or no PD-L1. Patients expressed are treated with docetaxel by binding fragments such as anti-clusterin antibodies containing specific CDRs.

Benefits of technology

In some patients, the reduction or stability of the target lesion size, the regression of the non-target lesion, and the prolonged progression-free survival were observed, and some patients showed partial remission or stable disease according to the RECIST 1.1 standard, providing a failure to treat immune checkpoint antibodies. Patient alternatives significantly improve clinical benefits.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118900700A_ABST
    Figure CN118900700A_ABST
Patent Text Reader

Abstract

The present disclosure relates generally to combination therapies comprising an anti-clusterin antibody or antigen-binding fragment thereof and a taxane and their use in treating subjects suffering from non-small cell lung cancer (NSCLC). The combination therapy can be used for treating NSCLC patients. Included are NSCLC patients that fail in a previous treatment comprising an immune checkpoint antibody, NSCLC patients having one or more lesions exhibiting low expression of programmed death ligand 1 (PD-L1), NSCLC patients without evidence of PD-L1 expression, or NSCLC patients that are not suitable for treatment comprising an anti-PD-1 or anti-PD-L1 immune checkpoint antibody or are less likely to benefit from such treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure generally relates to combination therapies comprising an anti-clusterin antibody or antigen-binding fragment thereof and a taxane and their use in treating a subject with non-small cell lung cancer (NSCLC).

[0002] background

[0003] With the identification of key regulators, the molecular mechanisms responsible for metastatic carcinogenesis are beginning to be elucidated. Accumulating evidence suggests that epithelial-mesenchymal transition (EMT) of tumor cells is an important contributing process to the evolution of metastasis. The emergence of EMT during tumor progression allows non-invasive and non-metastatic epithelial tumor cells to migrate from the primary tumor, invade surrounding tissues, enter the bloodstream, and eventually spread to secondary sites and proliferate there. In addition, epithelial cancer cells that undergo EMT adopt behaviors very similar to cancer stem cells (CSCs), including intrinsic resistance to chemotherapy and immune evasion (Shibue et al., 2017; Terry et al., 2017).

[0004] Although first- and second-line therapies such as chemotherapeutic agents and immune checkpoint inhibitors are effective in the short term in cancer treatment, a high proportion of subjects become refractory to these therapies due to tumor cell resistance to anti-neoplastic agents and survival of tumor-initiating cells, two events that ultimately lead to increased metastasis and poor subject survival.

[0005] The mechanisms of resistance to immune checkpoint inhibitors can vary. However, it is generally believed that checkpoint inhibitors are most effective against so-called immune-hot tumors, which are tumors that have been invaded by T cells to produce an inflamed tumor. In contrast, immune-cold tumors respond poorly to immunotherapy because, for unknown reasons, these tumors have not yet been recognized or have not yet triggered a strong immune response, so T cells have not infiltrated the tumor or its microenvironment.

[0006] Patients who have received a prior first-line immune checkpoint inhibitor as a single agent are offered platinum-based chemotherapy in the second line. Single-agent docetaxel may be administered as a second- or third-line therapy after failure of concurrently or sequentially administered immune checkpoint inhibition and platinum doublet chemotherapy.

[0007] Because most patients eventually progress after immunochemotherapy and because docetaxel has very limited efficacy in this setting, novel therapies are urgently needed. SUMMARY OF THE INVENTION

[0009] The present disclosure relates to combination therapies comprising an anti-clusterin antibody or antigen-binding fragment thereof and a taxane such as docetaxel.

[0010] The present disclosure also relates to methods of treating lung cancer in a subject in need thereof by administering a combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and a taxane such as docetaxel.

[0011] The combination therapies disclosed herein are used to treat patients with lung cancer (e.g., lung cancer), and may more specifically provide clinical benefit to patients with non-small cell lung cancer who have failed prior treatment with an anti-programmed death 1 (anti-PD-1) or anti-programmed death ligand 1 (PD-L1) immune checkpoint antibody and a platinum-containing combination therapy.

[0012] In some embodiments, the combination therapy of the present disclosure is used to treat lung cancer in a subject in need thereof. In a specific embodiment, the combination therapy is used to treat non-small cell lung cancer in a subject in need thereof. In another specific embodiment, the combination therapy is used to treat metastatic non-small cell lung cancer in a subject in need thereof.

[0013] In some embodiments, a therapeutically effective combination therapy is administered to a subject in need thereof.

[0014] For most patients treated, administration of the combination therapy resulted in a reduction in the size or stabilization of the target lesions. Complete regression of non-target lesions was also observed in one patient. Surprisingly, clinical benefit was observed after only two treatment cycles and persisted for several weeks in some cases.

[0015] Furthermore, the current data suggest prolonged progression-free survival compared with single-agent docetaxel in the same patient population.

[0016] The combination therapy of the present application represents an alternative for NSCLC patients who have failed prior treatment with immune checkpoint antibodies. In addition, evidence of partial remission (as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria) has been observed in 4 patients with tumors with a PD-L1 tumor proportion score (TPS) ≤ 15%, including 1 patient with a KRAS mutation. Evidence of stable disease defined by RECIST 1.1 was also observed in NSCLC patients with tumors carrying KRAS mutations.

[0017] The combination therapies of the present disclosure may represent an alternative approach for NSCLC patients who are not suitable for or are unlikely to benefit from treatments comprising immune checkpoint antibodies.

[0018] Furthermore, the combination therapies of the present disclosure may represent an alternative to immune checkpoint antibody monotherapy or combination therapy for NSCLC patients with tumors that have no evidence of PD-L1 expression or low PD-L1 expression.

[0019] Although the combination therapy disclosed herein includes docetaxel, a person skilled in the art, such as a physician, a researcher, etc., may select another taxane. Therefore, exemplary embodiments of taxanes include docetaxel, paclitaxel, and derivatives or analogs thereof, including, for example, but not limited to Cabazitaxel, lalopaclitaxel, milataxel, otazitaxel, tecitaxel, and other derivatives or analogs described in Ojima et al., Expert Opin Ther Pat. 2016:26(1):1-20 (the entire contents of which are incorporated herein by reference).

[0020] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is selected from antibodies or antigen-binding fragments that inhibit epithelial to mesenchymal transition in cancer cells.

[0021] The anti-clusterin antibody or antigen-binding fragment thereof of the present disclosure may include, for example, an anti-clusterin antibody or antigen-binding fragment thereof that is capable of binding to the C-terminal portion of the human agrin β subunit.

[0022] In some embodiments, the anti-clusterin antibodies or antigen-binding fragments thereof of the present disclosure may include, for example, anti-clusterin antibodies or antigen-binding fragments thereof that are capable of binding to amino acids 421 and 443 of the C-terminal portion of the human clusterin β subunit or an epitope contained within amino acids 421 and 443.

[0023] The anti-clusterin antibodies or antigen-binding fragments thereof of the present disclosure may comprise, for example, a light chain variable region comprising the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO:12 and a heavy chain variable region comprising the CDRs of the heavy chain variable region shown in SEQ ID NO:13.

[0024] The anti-clusterin antibodies or antigen-binding fragments thereof disclosed herein may comprise, for example, a light chain variable region comprising CDRs having the amino acid sequences shown in SEQ ID NO: 1 (CDRL1), SEQ ID NO: 2 (CDRL2), and SEQ ID NO: 3 (CDRL3), and a heavy chain variable region comprising CDRs having the amino acid sequences shown in SEQ ID NO: 4 (CDRH1), SEQ ID NO: 5 (CDRH2), and SEQ ID NO: 6 (CDRH3).

[0025] The anti-clusterin antibodies or antigen-binding fragments thereof disclosed herein may comprise, for example, a light chain variable region comprising CDRs having the amino acid sequences shown in SEQ ID NO: 1 (CDRL1), SEQ ID NO: 2 (CDRL2), and SEQ ID NO: 3 (CDRL3), and a heavy chain variable region comprising CDRs having the amino acid sequences shown in SEQ ID NO: 7 (CDRH1), SEQ ID NO: 8 (CDRH2), and SEQ ID NO: 9 (CDRH3).

[0026] In another example, the anti-clusterin antibody or antigen-binding fragment thereof of the present disclosure may comprise a light chain variable region having the amino acid sequence shown in SEQ ID NO:12 and a heavy chain variable region having the amino acid sequence shown in SEQ ID NO:13.

[0027] In yet another example, the anti-clusterin antibody or antigen-binding fragment thereof of the present disclosure may comprise a light chain having the amino acid sequence shown in SEQ ID NO:14 and a heavy chain having the amino acid sequence shown in SEQ ID NO:15.

[0028] Other exemplary embodiments of the anti-clusterin antibodies or antigen-binding fragments thereof disclosed herein include those that can compete with an antibody or antigen-binding fragment thereof comprising a light chain variable region shown in SEQ ID NO:12 and a heavy chain variable region containing CDRs of the heavy chain variable region shown in SEQ ID NO:13.

[0029] In some embodiments, the combination therapies of the present disclosure can be used to treat a subject having lung cancer (eg, lung carcinoma).

[0030] More specifically, the combination therapies of the present disclosure can be used to treat subjects suffering from non-small cell lung cancer.

[0031] In some embodiments, the non-small cell lung cancer is metastatic non-small cell lung cancer.

[0032] In some embodiments, the metastatic non-small cell lung cancer is stage III non-small cell lung cancer.

[0033] In some embodiments, the metastatic non-small cell lung cancer is stage IV non-small cell lung cancer.

[0034] In some embodiments, the non-small cell lung cancer is adenocarcinoma.

[0035] In some embodiments, the non-small cell lung cancer is squamous cell lung cancer.

[0036] In some embodiments, the non-small cell lung cancer is large cell carcinoma.

[0037] In some embodiments, the non-small cell lung cancer is adenosquamous carcinoma.

[0038] In some embodiments, the non-small cell lung cancer (eg, metastatic non-small cell lung cancer) is characterized by a KRAS mutation.

[0039] Thus, in one aspect thereof, the combination therapy comprises an anti-Clusterin antibody or antigen-binding fragment thereof and a taxane for treating a subject having non-small cell lung cancer, such as metastatic non-small cell lung cancer, wherein the anti-Clusterin antibody or antigen-binding fragment thereof is as described herein.

[0040] In some embodiments, the combination therapies of the present disclosure may be used to obtain clinical benefit in a subject suffering from non-small cell lung cancer.

[0041] In other embodiments, the combination therapies of the present disclosure may be used to obtain clinical benefit in a subject suffering from metastatic non-small cell lung cancer.

[0042] Thus, the combination therapy comprises an anti-Clusterin antibody or antigen-binding fragment thereof and a taxane for obtaining clinical benefit in a subject with non-small cell lung cancer, such as metastatic non-small cell lung cancer, wherein the anti-Clusterin antibody or antigen-binding fragment thereof is as described herein.

[0043] In certain embodiments, the combination therapy is administered at a therapeutically effective dose.

[0044] In certain embodiments, the combination therapy is administered at a safe dose.

[0045] In certain embodiments, the combination therapy is administered at a tolerable dose.

[0046] In certain embodiments, the combination therapy is administered according to a therapeutically effective administration regimen.

[0047] In certain embodiments, the combination therapy is administered according to a tolerated administration schedule.

[0048] In certain embodiments, the combination therapy is administered according to a safe administration schedule.

[0049] In certain embodiments, the combination therapy is administered according to a therapeutically effective treatment regimen.

[0050] In certain embodiments, the combination therapy is administered according to a safe treatment regimen.

[0051] In certain embodiments, the combination therapy is administered as a tolerable treatment regimen.

[0052] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of between about 3 mg / kg and about 20 mg / kg.

[0053] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is formulated for intravenous infusion.

[0054] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is formulated for injection at a concentration of about 10 mg / mL.

[0055] In some embodiments, the taxane is formulated for administration at a dose of between about 50 mg / m 2 About 100 mg / m 2 Between, for example but not limited to between about 60 mg / m 2 With 100mg / m 2 Between, about 50mg / m 2 and 80 mg / m 2 Between, about 50mg / m 2 and 75 mg / m 2 Between, about 60mg / m 2 and 75 mg / m 2 Dosages between.

[0056] In some embodiments, the taxane is docetaxel and is formulated for administration at a dose of between about 50 mg / m 2 About 100 mg / m 2 , for example but not limited to between about 60 mg / m 2 With 100mg / m 2 Between, about 50mg / m 2 and 80 mg / m 2 Between, about 50mg / m 2 and 75 mg / m 2 Between, about 60mg / m 2 and 75 mg / m 2 Dosages between.

[0057] In some embodiments, docetaxel is formulated as an intravenous infusion.

[0058] In some embodiments, docetaxel is formulated for injection at a concentration between about 10 mg / mL and about 40 mg / mL.

[0059] In an exemplary embodiment, the combination therapy comprises an anti-clusterin antibody or antigen-binding fragment thereof and docetaxel for treating a subject with non-small cell lung cancer (such as metastatic non-small cell lung cancer), wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of about 3 mg / kg to about 20 mg / kg and comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12, the heavy chain variable region comprises the CDRs of the heavy chain variable region shown in SEQ ID NO: 13, and the docetaxel is formulated for administration at about 50 mg / kg. 2 About 100 mg / m 2 dosage administration.

[0060] In another exemplary embodiment, the combination therapy comprises an anti-clusterin antibody or antigen-binding fragment thereof and docetaxel for treating a subject with non-small cell lung cancer (such as metastatic non-small cell lung cancer), wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of about 12 mg / kg and comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12 and a heavy chain variable region having the CDRs of the heavy chain variable region shown in SEQ ID NO: 13, and docetaxel is formulated for administration at a dose of about 50 mg / m 2 Up to about 70 mg / m 2 dosage administration.

[0061] In another exemplary embodiment, the combination therapy comprises an anti-clusterin antibody or an antigen-binding fragment thereof and docetaxel for treating a subject with non-small cell lung cancer (such as metastatic non-small cell lung cancer), wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of about 12 mg / kg and comprises a light chain variable region having the amino acid sequence shown in SEQ ID NO: 12 and a heavy chain variable region having the amino acid sequence shown in SEQ ID NO: 13, and docetaxel is formulated for administration at a dose of about 50 mg / m 2 Up to about 75 mg / m 2 dosage administration.

[0062] In another exemplary embodiment, a combination therapy comprises an anti-clusterin antibody or antigen-binding fragment thereof and docetaxel for obtaining a clinical benefit for a subject with non-small cell lung cancer (such as metastatic non-small cell lung cancer), wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of about 3 mg / kg to about 20 mg / kg and comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12 and a heavy chain variable region having the CDRs of the heavy chain variable region shown in SEQ ID NO: 13, and docetaxel is formulated for administration at about 50 mg / m 2 About 100 mg / m 2 dosage administration.

[0063] In another exemplary embodiment, a combination therapy comprises an anti-clusterin antibody or antigen-binding fragment thereof and docetaxel for obtaining a clinical benefit for a subject with non-small cell lung cancer (such as metastatic non-small cell lung cancer), wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of about 12 mg / kg and comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12 and a heavy chain variable region having the CDRs of the heavy chain variable region shown in SEQ ID NO: 13, and docetaxel is formulated for administration at a dose of about 50 mg / m 2 Up to about 75 mg / m 2 dosage administration.

[0064] In another exemplary embodiment, the combination therapy comprises an anti-clusterin antibody or antigen-binding fragment thereof and docetaxel for obtaining a clinical benefit for a subject with non-small cell lung cancer (such as metastatic non-small cell lung cancer), wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of about 12 mg / kg and comprises a light chain variable region having the amino acid sequence shown in SEQ ID NO: 12 and a heavy chain variable region having the amino acid sequence shown in SEQ ID NO: 13, and the docetaxel is formulated for administration at a dose of about 50 mg / m 2 Up to about 75 mg / m 2 dosage administration.

[0065] In another exemplary embodiment, the combination therapy is used to obtain clinical benefit for a subject with non-small cell lung cancer, wherein the combination therapy is used for at least two treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody at a dose of about 3 mg / kg to about 20 mg / kg once a week, once every two weeks, once every three weeks, once every four weeks, and at about 50 mg / m 2 Up to 100 mg / m 2The taxane is administered once every two to three weeks at a dose of 1:1, wherein the anti-clusterin antibody comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12 and a heavy chain variable region having the CDRs of the heavy chain variable region shown in SEQ ID NO: 13.

[0066] In yet another exemplary embodiment, the combination therapy is used to obtain clinical benefit for a subject with non-small cell lung cancer, wherein the combination therapy is used for at least two treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody at a dose of about 12 mg / kg once a week, once every two weeks, once every three weeks, once every four weeks, and at a dose of about 75 mg / m 2 The taxane is administered once every three weeks at a dose of 100 mg / kg / day, wherein the anti-clusterin antibody comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12 and a heavy chain variable region having the CDRs of the heavy chain variable region shown in SEQ ID NO: 13.

[0067] In yet another exemplary embodiment, the combination therapy is used to obtain clinical benefit for a subject with non-small cell lung cancer, wherein the combination therapy is used for at least two treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody at a dose of about 12 mg / kg once a week, once every two weeks, once every three weeks, once every four weeks, and at a dose of about 75 mg / m 2 The taxane is administered once every two weeks at a dose of 1:10, wherein the anti-clusterin antibody comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO:12 and a heavy chain variable region having the CDRs of the heavy chain variable region shown in SEQ ID NO:13.

[0068] In some embodiments, clinical benefit is defined according to RECIST 1.1 guidelines.

[0069] In some embodiments, the combination therapy is used to achieve a clinical benefit that persists for at least 6 weeks. In certain embodiments, the combination therapy is used to achieve a clinical benefit that persists for at least 6 weeks after a response to treatment is first determined.

[0070] In some embodiments, the combination therapy is used to achieve a clinical benefit that persists for at least 12 weeks. In certain embodiments, the combination therapy is used to achieve a clinical benefit that persists for at least 12 weeks after a response to treatment is first determined.

[0071] In some embodiments, the combination therapy is used to achieve a clinical benefit that persists for at least 18 weeks. In certain embodiments, the combination therapy is used to achieve a clinical benefit that persists for at least 18 weeks after a response to treatment is first determined.

[0072] In some embodiments, the combination therapy is used to achieve a clinical benefit that persists for at least 24 weeks. In certain embodiments, the combination therapy is used to achieve a clinical benefit that persists for at least 24 weeks after a response to treatment is first determined.

[0073] In some embodiments, the combination therapy is used to achieve clinical benefit for at least 30 weeks. In certain embodiments, the combination therapy is used to achieve clinical benefit for at least 30 weeks after a response to treatment is first determined.

[0074] In some embodiments, the combination therapy is used to obtain clinical benefit for at least 36 weeks. In certain embodiments, the combination therapy is used to obtain clinical benefit for at least 36 weeks after the response to treatment is first determined. In certain embodiments, the combination therapy is used to obtain clinical benefit for at least 42 weeks after the response to treatment is first determined. In certain embodiments, the combination therapy is used to obtain clinical benefit for at least 42 weeks after the response to treatment is first determined.

[0075] In some embodiments, the combination therapy is used to achieve clinical benefit for at least 48 weeks. In certain embodiments, the combination therapy is used to achieve clinical benefit for at least 48 weeks after a response to treatment is first determined.

[0076] In some embodiments, the combination therapy is used to achieve clinical benefit for at least 54 weeks. In certain embodiments, the combination therapy is used to achieve clinical benefit for at least 54 weeks after a response to treatment is first determined.

[0077] In some embodiments, the combination therapy is used to achieve clinical benefit for at least 60 weeks. In certain embodiments, the combination therapy is used to achieve clinical benefit for at least 60 weeks after a response to treatment is first determined.

[0078] In some embodiments, the combination therapy is used to achieve clinical benefit for at least 66 weeks. In certain embodiments, the combination therapy is used to achieve clinical benefit for at least 66 weeks after a response to treatment is first determined.

[0079] According to the present disclosure, a subject in need thereof is a subject as described herein.

[0080] Accordingly, the present disclosure includes methods involving administering combination therapies to a subject in need thereof.

[0081] According to the present disclosure, the anti-clusterin antibody or antigen-binding fragment thereof is administered once a week.

[0082] According to the present disclosure, the anti-clusterin antibody or antigen-binding fragment thereof is administered once every two weeks.

[0083] According to the present disclosure, the anti-clusterin antibody or antigen-binding fragment thereof is administered once every three weeks.

[0084] According to the present disclosure, the anti-clusterin antibody or antigen-binding fragment thereof is administered once every four weeks.

[0085] According to the present disclosure, docetaxel is administered once a week.

[0086] According to the present disclosure, docetaxel is administered once every two weeks.

[0087] According to the present disclosure, docetaxel is administered once every three weeks.

[0088] According to the present disclosure, docetaxel is administered once every four weeks.

[0089] It should be understood herein that the treatment frequency (i.e., once a week, once every two weeks, once every three weeks, once every four weeks, etc.) is not strict and allows for some variation. For example, a physician may decide to administer the drug earlier than planned or postpone administration by a few days or more. Likewise, it is possible to skip one or more doses without affecting treatment.

[0090] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of between about 3 mg / kg and about 20 mg / kg.

[0091] In some embodiments, the dosage is between about 50 mg / m 2 About 100 mg / m 2 Between, for example but not limited to between about 60 mg / m 2 About 100 mg / m 2 Between, about 50mg / m 2 About 80 mg / m 2 Between, about 50mg / m 2 About 75 mg / m 2 Between, about 60mg / m 2 About 75 mg / m 2 Taxanes were administered at doses between .

[0092] In some embodiments, the taxane is docetaxel and is administered at a dose of between about 50 mg / m 2 About 100 mg / m 2 Between, for example but not limited to between about 60 mg / m 2 About 100 mg / m 2 Between, about 50mg / m 2 About 80 mg / m 2 Between, about 50mg / m 2 About 75 mg / m 2 Between, about 60mg / m 2 About 75 mg / m2 Dosages between.

[0093] In some embodiments, the taxane is docetaxel and is administered at a dose between 50 mg / m 2 With 100mg / m 2 Between, for example but not limited to between 60mg / m 2 With 100mg / m 2 Between 50mg / m 2 and 80 mg / m 2 Between 50mg / m 2 and 75 mg / m 2 Between 60mg / m 2 and 75 mg / m 2 Dosages between.

[0094] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 12 mg / kg once weekly, once every two weeks, or once every three weeks, and at a dose of 75 mg / m 2 Docetaxel was administered once every three weeks.

[0095] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 12 mg / kg once weekly, once every two weeks, or once every three weeks, and at a dose of 60 mg / m 2 Docetaxel was administered once every three weeks.

[0096] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 9 mg / kg once weekly, once every two weeks, or once every three weeks, and at a dose of 75 mg / m 2 Docetaxel was administered once every three weeks.

[0097] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 9 mg / kg once weekly, once every two weeks, or once every three weeks, and docetaxel is administered at a dose of 60 mg / m2 once every three weeks.

[0098] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 6 mg / kg once a week, once every two weeks, or once every three weeks, and at a dose of 75 mg / m 2 Docetaxel was administered once every three weeks.

[0099] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 6 mg / kg once a week, once every two weeks, or once every three weeks, and at a dose of 60 mg / m 2 Docetaxel was administered once every three weeks.

[0100] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 3 mg / kg once a week, once every two weeks, or once every three weeks, and at a dose of 75 mg / m 2 Docetaxel was administered once every three weeks.

[0101] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 3 mg / kg once a week, once every two weeks, or once every three weeks, and at a dose of 60 mg / m 2 Docetaxel was administered once every three weeks.

[0102] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 12 mg / kg once weekly, once every two weeks, or once every three weeks, and at a dose of 50 mg / m 2 Docetaxel was administered once every three weeks.

[0103] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 9 mg / kg once a week, once every two weeks, or once every three weeks, and at a dose of 50 mg / m 2 Docetaxel was administered once every three weeks.

[0104] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 6 mg / kg once a week, once every two weeks, or once every three weeks, and at a dose of 50 mg / m 2 Docetaxel was administered once every three weeks.

[0105] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 3 mg / kg once weekly, once every two weeks, or once every three weeks, and at a dose of 50 mg / m 2 Docetaxel was administered once every three weeks.

[0106] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 12 mg / kg once weekly, once every two weeks, or once every three weeks, and at a dose of 50 mg / m 2 Docetaxel was administered at a dose of once every two weeks.

[0107] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 9 mg / kg once a week, once every two weeks, or once every three weeks, and at a dose of 50 mg / m 2 Docetaxel was administered at a dose of once every two weeks.

[0108] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 6 mg / kg once weekly, once every two weeks, or once every three weeks, and at a dose of 50 mg / m 2 Docetaxel was administered at a dose of once every two weeks.

[0109] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 3 mg / kg once a week, once every two weeks, or once every three weeks, and at a dose of 50 mg / m 2 Docetaxel was administered at a dose of once every two weeks.

[0110] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel can be administered on the same day.

[0111] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel can be administered separately on the same day.

[0112] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof and / or docetaxel can be administered by infusion.

[0113] In some embodiments, both the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel are administered during the entire treatment period.

[0114] In some embodiments, both the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel are administered during each treatment cycle.

[0115] Accordingly, the present disclosure relates to methods of treating a subject having non-small cell lung cancer with the combination therapies disclosed herein.

[0116] The present disclosure also relates to methods of treating a subject having metastatic non-small cell lung cancer with the combination therapies disclosed herein.

[0117] Thus, in certain aspects, the present disclosure provides methods of treating a subject having non-small cell lung cancer, such as metastatic non-small cell lung cancer, comprising administering a combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and docetaxel, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 3 mg / kg to about 20 mg / kg and comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12 and a heavy chain variable region having the CDRs of the heavy chain variable region shown in SEQ ID NO: 13, and is administered at about 50 mg / kg. 2 About 100 mg / m 2 Docetaxel was administered at a dose of

[0118] In an exemplary embodiment, the method is a method of treating a subject having non-small cell lung cancer, such as metastatic non-small cell lung cancer, comprising administering a combination therapy comprising an anti-clusterin antibody or an antigen-binding fragment thereof and docetaxel, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 12 mg / kg and comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12 and a heavy chain variable region having the CDRs of the heavy chain variable region shown in SEQ ID NO: 13, and is administered at a dose of about 50 mg / m 2 Up to about 75 mg / m 2 Docetaxel was administered at a dose of

[0119] In an exemplary embodiment, the method is a method of treating a subject having non-small cell lung cancer, such as metastatic non-small cell lung cancer, comprising administering a combination therapy comprising an anti-clusterin antibody or an antigen-binding fragment thereof and docetaxel, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 12 mg / kg and comprises a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 12 and a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 13, and is administered at a dose of about 50 mg / m 2 Up to about 75 mg / m 2 Docetaxel was administered at a dose of

[0120] In certain embodiments, the disclosure relates to methods of treating non-small cell lung cancer (NSCLC) in a subject in need thereof, the methods comprising administering a combination therapy for at least one treatment cycle comprising administering an anti-clusterin antibody at a dose of about 12 mg / kg once weekly, once every two weeks, once every three weeks, or once every four weeks and administering a combination therapy at a dose of about 50 mg / m 2 Up to about 75 mg / m 2 Docetaxel is administered once every two to three weeks at a dose of 100 mg / kg / day, wherein the anti-clusterin antibody comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12 and a heavy chain variable region having the CDRs of the heavy chain variable region shown in SEQ ID NO: 13.

[0121] The present disclosure also relates to methods of treating a subject having non-small cell lung cancer with the combination therapies disclosed herein to achieve and / or maintain a clinical benefit.

[0122] The present disclosure also relates to methods of treating a subject having metastatic non-small cell lung cancer with the combination therapies disclosed herein to achieve and / or maintain a clinical benefit.

[0123] Thus, in certain aspects, the present disclosure provides methods of treating a subject having non-small cell lung cancer, such as metastatic non-small cell lung cancer, comprising administering a combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and docetaxel to obtain a clinical benefit, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 3 mg / kg to about 20 mg / kg and comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12 and a heavy chain variable region having the CDRs of the heavy chain variable region shown in SEQ ID NO: 13, and is administered at about 50 mg / kg. 2 About 100 mg / m 2 Docetaxel was administered at a dose of

[0124] In an exemplary embodiment, the method is a method of treating a subject having non-small cell lung cancer, such as metastatic non-small cell lung cancer, comprising administering a combination therapy comprising an anti-clusterin antibody or an antigen-binding fragment thereof and docetaxel to obtain a clinical benefit, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 12 mg / kg and comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12 and a heavy chain variable region having the CDRs of the heavy chain variable region shown in SEQ ID NO: 13, and is administered at a dose of about 50 mg / m 2 Up to about 75 mg / m 2 Docetaxel was administered at a dose of

[0125] In an exemplary embodiment, the method is a method of treating a subject having non-small cell lung cancer, such as metastatic non-small cell lung cancer, comprising administering a combination therapy comprising an anti-clusterin antibody or an antigen-binding fragment thereof and docetaxel to obtain a clinical benefit, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 12 mg / kg and comprises a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 12 and a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 13, and is administered at a dose of about 50 mg / m 2 Up to about 75 mg / m 2 Docetaxel was administered at a dose of

[0126] The present disclosure also relates to methods of obtaining clinical benefit in a subject suffering from non-small cell lung cancer using the combination therapies disclosed herein.

[0127] The present disclosure also relates to methods of obtaining clinical benefit in a subject having metastatic non-small cell lung cancer using the combination therapies disclosed herein.

[0128] Exemplary embodiments of clinical benefit include, but are not limited to, reduction in lesion size, stabilization of lesion size, regression of lesions, complete remission (CR) according to RECIST 1.1 guidelines, partial remission (PR) according to RECIST 1.1 guidelines, stable disease (SD) according to RECIST 1.1 guidelines, improvement of cancer-related symptoms, and / or reduction or elimination of metabolic activity in lesions, etc.

[0129] In some cases, a decrease in size or stabilization or regression may be observed in the target lesion.

[0130] In some cases, a decrease in size or stabilization or regression may be observed in non-target lesions.

[0131] Thus, in certain aspects, the present disclosure provides methods of obtaining clinical benefit for a subject with non-small cell lung cancer, such as metastatic non-small cell lung cancer, comprising administering a combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and docetaxel, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 3 mg / kg to about 20 mg / kg and comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region set forth in SEQ ID NO: 12 and a heavy chain variable region having the CDRs of the heavy chain variable region set forth in SEQ ID NO: 13, and is administered at about 50 mg / kg. 2 About 100 mg / m 2 Docetaxel was administered at a dose of

[0132] In an exemplary embodiment, the method is a method of obtaining a clinical benefit for a subject having non-small cell lung cancer (e.g., metastatic non-small cell lung cancer), comprising administering a combination therapy comprising an anti-clusterin antibody or an antigen-binding fragment thereof and docetaxel, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 12 mg / kg and comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12 and a heavy chain variable region having the CDRs of the heavy chain variable region shown in SEQ ID NO: 13, and is administered at a dose of about 50 mg / m 2 Up to about 75 mg / m 2 Docetaxel was administered at a dose of

[0133] In an exemplary embodiment, the method is a method of obtaining a clinical benefit for a subject having non-small cell lung cancer (e.g., metastatic non-small cell lung cancer), comprising administering a combination therapy comprising an anti-clusterin antibody or an antigen-binding fragment thereof and docetaxel, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 12 mg / kg and comprises a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 12 and a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 13, and is administered at a dose of about 50 mg / m 2 Up to about 75 mg / m 2 Docetaxel was administered at a dose of

[0134] According to the present disclosure, the combination therapy is administered in a dosage sufficient to produce clinical benefit.

[0135] According to the present disclosure, combination therapy is administered for a period of time sufficient to produce clinical benefit.

[0136] In accordance with the present disclosure, combination therapy is administered according to a treatment schedule sufficient to produce clinical benefit.

[0137] In accordance with the present disclosure, combination therapy is administered according to a treatment regimen sufficient to produce clinical benefit.

[0138] In an exemplary embodiment, the combination therapy is administered in one or more treatment cycles comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week, once every two weeks, or once every three weeks, and docetaxel once every three weeks. It should be understood that the treatment intervals can be varied without significantly changing the effect of the combination therapy.

[0139] In certain embodiments, the combination therapy is administered for at least two treatment cycles.

[0140] In certain embodiments, the combination therapy is administered for more than two treatment cycles.

[0141] The present disclosure also provides methods of obtaining clinical benefit for a subject with non-small cell lung cancer in a treatment method comprising administering a combination therapy for at least two treatment cycles, each treatment cycle comprising administering an anti-clusterin antibody at a dose of about 3 mg / kg to about 20 mg / kg once a week, once every two weeks, or once every three weeks, and administering an anti-clusterin antibody at a dose of about 50 mg / m 2 to 100mg / m 2 The taxane is administered once every two to three weeks at a dose of 100 mg / kg / day, wherein the anti-clusterin antibody comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12 and a heavy chain variable region having the CDRs of the heavy chain variable region shown in SEQ ID NO: 13.

[0142] Thus, in other aspects, the disclosure provides methods of obtaining a clinical benefit for a subject with non-small cell lung cancer in a treatment method comprising administering a combination therapy for at least two treatment cycles, each treatment cycle comprising administering an anti-clusterin antibody at a dose of about 12 mg / kg once weekly, once every two weeks, or once every three weeks and administering at a dose of about 75 mg / m 2 Docetaxel is administered once every three weeks at a dose of 100 mg / kg / day, wherein the anti-clusterin antibody comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12 and a heavy chain variable region having the CDRs of the heavy chain variable region shown in SEQ ID NO: 13.

[0143] Thus, in other aspects, the disclosure provides methods of obtaining a clinical benefit for a subject with non-small cell lung cancer in a treatment method comprising administering a combination therapy for at least two treatment cycles, each treatment cycle comprising administering an anti-clusterin antibody at a dose of about 12 mg / kg once weekly, once every two weeks, or once every three weeks and administering at a dose of about 50 mg / m 2 Docetaxel is administered once every two weeks at a dose of 1:1 to 2:1, wherein the anti-clusterin antibody comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12 and a heavy chain variable region having the CDRs of the heavy chain variable region shown in SEQ ID NO: 13.

[0144] In some embodiments, the clinical benefit is regression of target lesions.

[0145] In some embodiments, the clinical benefit is a reduction in the size of the target lesion.

[0146] In some embodiments, the clinical benefit is stabilization of target lesion size.

[0147] In some embodiments, the clinical benefit is a reduction in the number of tumor cells in the target lesion.

[0148] In other embodiments, the clinical benefit is regression of non-target lesions.

[0149] In other embodiments, the clinical benefit is a reduction in the size of non-target lesions.

[0150] In further embodiments, the clinical benefit is stabilization of non-target lesion size.

[0151] In yet another embodiment, the clinical benefit is a reduction in the number of tumor cells in non-target lesions.

[0152] In some embodiments, clinical benefit is defined according to RECIST 1.1 guidelines.

[0153] In some embodiments, the clinical benefit may be qualitative, such as an improvement in quality of life (eg, health-related quality of life).

[0154] It should be understood herein that a clinical benefit may last for a specific period of time. The duration of a clinical benefit may vary from subject to subject.

[0155] According to the present disclosure, combination therapy can reduce tumor burden.

[0156] It should be understood herein that tumor load can be assessed by measuring the size of one or more tumor lesions. In other embodiments, tumor load can be determined by assessing tumor markers in solid biopsies, liquid biopsies, blood samples, serum samples, urine samples, etc. For example, tumor load is assessed by detecting circulating tumor cells (CTCs). In another example, tumor load is assessed by detecting circulating tumor DNA.

[0157] In certain embodiments, the methods achieve a clinical benefit that persists for at least 6 weeks after a response to treatment is first determined.

[0158] In certain embodiments, the methods achieve a clinical benefit that persists for at least 12 weeks after a response to treatment is first determined.

[0159] In certain embodiments, the methods achieve a clinical benefit that is sustained for at least 18 weeks after a response to treatment is first determined.

[0160] In certain embodiments, the methods achieve a clinical benefit that is sustained for at least 24 weeks after a response to treatment is first determined.

[0161] In certain embodiments, the methods achieve a clinical benefit that is sustained for at least 30 weeks after a response to treatment is first determined.

[0162] In certain embodiments, the methods achieve a clinical benefit that is sustained for at least 36 weeks after a response to treatment is first determined.

[0163] In certain embodiments, the methods achieve a clinical benefit that is sustained for at least 42 weeks after a response to treatment is first determined.

[0164] In certain embodiments, the methods achieve a clinical benefit that is sustained for at least 48 weeks after a response to treatment is first determined.

[0165] In certain embodiments, the methods achieve a clinical benefit that is sustained for at least 54 weeks after a response to treatment is first determined.

[0166] In certain embodiments, the methods achieve a clinical benefit that is sustained for at least 60 weeks after a response to treatment is first determined.

[0167] In certain embodiments, the methods achieve a clinical benefit that is sustained for at least 66 weeks after a response to treatment is first determined.

[0168] Once the physician prescribes the combination therapy, the subject's health and condition may be monitored. Monitoring may include a physical examination, interviewing the subject about their quality of life, obtaining biological samples, and / or performing scans to monitor the progression of lung cancer and / or the presence of metastases. Treatment may continue as long as the subject experiences a clinical benefit (qualitative or quantitative). Treatment may be discontinued once tumor progression is observed.

[0169] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered as an IV infusion.

[0170] In some embodiments, docetaxel is administered as an IV infusion.

[0171] In certain embodiments, the combination therapy may promote infiltration of immune cells into the tumor microenvironment of one or more lesions (target and / or non-target lesions).

[0172] In certain embodiments, the combination therapy may promote lymphocyte infiltration into the tumor microenvironment of one or more lesions (target and / or non-target lesions).

[0173] In certain embodiments, the combination therapy may promote T cell infiltration into the tumor microenvironment of one or more lesions (target and / or non-target lesions).

[0174] According to the present disclosure, the methods can result in tumors or lesions being more sensitive to treatment with immunotherapy.

[0175] Thus, the methods of the present disclosure may further comprise the step of administering an immunotherapy subsequent to the combination therapy disclosed herein.

[0176] In some embodiments, immunotherapy includes cellular immunotherapy (CAR-T, TIL, etc.).

[0177] In some embodiments, the immunotherapy comprises an immune checkpoint inhibitor.

[0178] Accordingly, the present disclosure relates to methods of treating NSCLC, such as metastatic NSCLC, by promoting the infiltration of immune cells in one or more lesions.

[0179] In embodiments, the disclosure includes methods of treating NSCLC, such as metastatic NSCLC, by promoting infiltration of immune cells in one or more lesions having low or no evidence of PD-L1 expression.

[0180] According to the present disclosure, a lesion may be characterized as having low PD-L1 expression when the PD-L1 tumor proportion score (TPS) of the lesion is, for example, ≤ 15%.

[0181] More specifically, when the PD-L1 TPS of a lesion is, for example, <5%, such lesion may be characterized as having low PD-L1 expression.

[0182] More specifically, when the PD-L1 TPS of a lesion is, for example, ≤ 1%, such lesion can be characterized as having low PD-L1 expression.

[0183] Even more specifically, when the PD-L1 TPS of a lesion is, for example, <1%, such a lesion may be characterized as having low PD-L1 expression.

[0184] According to the present disclosure, when a lesion has a PD-L1 TPS of 0% or no detectable PD-L1 expression, such lesion is characterized as having no evidence of PD-L1 expression.

[0185] In certain embodiments, combination therapy may promote a reduction in the number of tumor cells in one or more lesions.

[0186] In an exemplary embodiment, the combination treatment may result in a reduction in lesion size.

[0187] It is understood herein that a lesion is considered to have decreased in size when a measurement indicates that the lesion size is smaller than a previous measurement or smaller than a baseline measurement.

[0188] In some exemplary embodiments, administration of the combination therapy may result in a reduction in lesion size of at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%.

[0189] In another exemplary embodiment, the combination therapy may result in stabilization of lesion size.

[0190] In yet another further exemplary embodiment, the combination therapy may result in an increase in lesion size of less than 20%.It is also understood herein that an increase in lesion size of less than about 20% compared to a previous or baseline measurement is considered stable lesion growth.

[0191] In yet another exemplary embodiment, the combination therapy can result in regression of the lesion. In some cases, the regression can be complete. In other cases, the regression can be partial.

[0192] In some embodiments, combination therapy can result in stabilization of lesion size.

[0193] In some cases, the size of the lesion may increase or may remain stable while the number of tumor cells within the lesion decreases. For example, tumor cells may be replaced by fibrotic tissue and inflammatory cells, so that a decrease in the size of the lesion is not detected. Thus, in some cases, the number of viable tumor cells may decrease, while the number of immune cells may increase, resulting in pseudogrowth.

[0194] Thus, in another exemplary embodiment, the combination therapy may result in a decrease in the number of tumor cells in a lesion.

[0195] It should be understood herein that lesion size can be assessed by several methods including, for example, but not limited to, by CT scanning.

[0196] In another exemplary embodiment, the combination therapy may result in a reduction or elimination of metabolic activity in the lesion.It is understood herein that the metabolic activity of a lesion may be assessed by several methods including, for example, but not limited to, by positron emission tomography (PET) scanning.

[0197] It is also to be understood herein that an increase in tumor size combined with a decrease in tumor cell number is also considered to be a stabilization of tumor growth.

[0198] It is also to be understood herein that a reduction in the metabolic activity of a lesion (with or without growth) is also considered to be a stabilization of lesion growth.

[0199] In yet another additional exemplary embodiment, the combination therapy may result in improvement of symptoms associated with lung cancer.

[0200] In another embodiment, administration of the combination therapy can result in a complete response (CR) according to RECIST 1.1 guidelines.

[0201] In further embodiments, administration of the combination therapy may result in a partial response (PR) according to RECIST 1.1 guidelines.

[0202] In yet further embodiments, administration of the combination therapy may result in stable disease (SD) according to RECIST 1.1 guidelines.

[0203] According to the present disclosure, combination therapy may be used or provided for use as long as a clinical benefit is observed.

[0204] According to the present disclosure, the combination therapy is used or is provided for use until tumor progression is observed.

[0205] According to the present disclosure, the combination therapy is used or is provided for use until uncontrollable toxicity occurs.

[0206] In some embodiments, administration of the anti-Clusterin antibody or antigen-binding fragment thereof can be maintained after cessation of the combination therapy.

[0207] In some embodiments, administration of an anti-Clusterin antibody or antigen-binding fragment thereof can be maintained after clinical benefit occurs.

[0208] It is understood herein that clinical benefit may be demonstrated by assessing tumor biomarkers.

[0209] According to the present disclosure, combination therapy is used for the subjects described herein.

[0210] According to the present disclosure, the subject is a human subject.

[0211] According to the present disclosure, the subject is an adult (ie, ≥ 18 years old).

[0212] In some embodiments, the subject has or is selected to have NSCLC.

[0213] In some embodiments, the subject has or is selected to have NSCLC.

[0214] In some embodiments, the subject has or is selected to have NSCLC, such as metastatic NSCLC, a condition that is not amenable to or is unlikely to benefit from treatment involving an immune checkpoint antibody.

[0215] In some embodiments, the subject has or is selected to have NSCLC, such as metastatic NSCLC, that progressed following treatment comprising an immune checkpoint antibody.

[0216] In some embodiments, the subject has or is selected to have NSCLC, such as metastatic NSCLC that has progressed following chemotherapy.

[0217] In other embodiments, the subject has or is selected to have NSCLC, such as metastatic NSCLC, that has failed prior treatment with an immune checkpoint antibody and chemotherapy combination.

[0218] In other embodiments, the subject has or is selected to have NSCLC, such as metastatic NSCLC, that has failed prior treatment with an immune checkpoint antibody and platinum-containing dual therapy.

[0219] In further embodiments, the subject has or is selected to have NSCLC, such as metastatic NSCLC, that has failed prior treatment with an anti-PD-1 or PD-L1 immune checkpoint antibody and platinum-containing doublet therapy.

[0220] According to the present disclosure, dual treatments may be provided simultaneously.

[0221] According to the present disclosure, dual treatments may be provided sequentially.

[0222] In some embodiments, the subject has or is selected to have NSCLC, such as metastatic NSCLC, that has failed prior therapy with an anti-PD-1 immune checkpoint antibody.

[0223] In some embodiments, the subject has or is selected to have NSCLC, such as metastatic NSCLC, that has failed prior treatment with a PD-L1 immune checkpoint antibody.

[0224] In some embodiments, the subject has or is selected to have NSCLC, such as metastatic NSLC, that has failed prior treatment with an anti-PD-1 or PD-L1 immune checkpoint antibody.

[0225] In some embodiments, the subject has or is selected to have NSLC that has failed prior treatment with an anti-PD-1 immune checkpoint antibody and platinum-containing doublet therapy, such as metastatic NSLC.

[0226] In some embodiments, the subject has or is selected to have NSLC, such as metastatic NSLC, that has failed prior treatment with an anti-PD-L1 immune checkpoint antibody and platinum-containing doublet therapy.

[0227] In some embodiments, the subject has or is selected to have NSLC, such as metastatic NSLC, that has failed prior treatment with an anti-PD-1 or PD-L1 immune checkpoint antibody and a platinum-containing doublet therapy.

[0228] In some embodiments, the subject has or is selected to have NSLC, such as metastatic NSLC, that has failed prior treatment with an immune checkpoint antibody selected from ipilimumab, nivolumab, pembrolizumab, cemiplizumab, atezolizumab, avelumab, or durvalumab, either alone or in combination with platinum-based chemotherapy.

[0229] In some embodiments, the subject has or is selected to have NSLC, such as metastatic NSLC, that has failed prior treatment with pembrolizumab alone in combination with a platinum-based doublet therapy.

[0230] In some embodiments, the subject has or is selected to have a PD-L1 tumor proportion score (TPS) of ≥ 50%.

[0231] In some embodiments, the subject has or is selected to have a PD-L1 tumor proportion score (TPS) of <50%.

[0232] In some embodiments, the subject has or is selected to have a PD-L1 Tumor Proportion Score (TPS) between 1% and 49%.

[0233] In some embodiments, the subject has or is selected to have a PD-L1 tumor proportion score of < 1%.

[0234] In some embodiments, the subject has or is selected to have a tumor with poor immune cell infiltration. The level of immune cell infiltration can be determined by a trained pathologist or scientist. The level of immune cell infiltration can be determined by using computer-based quantitative imaging of tumor biopsies.

[0235] In some embodiments, the subject has or is selected to have one or more lesions with EMT features or showing signs of EMT features. The EMT features of a tumor can be determined by a trained pathologist or scientist. The EMT features of a tumor can be determined by using computer-based quantitative imaging of a tumor or tumor biopsy.

[0236] In some embodiments, EMT features can be assessed by one or more EMT biomarkers.For example, EMT features can be associated with the acquisition of interstitial markers and / or with the attenuation of epithelial markers, particularly associated with EMT 3 types (see Zeisber, M. and E. G. Neilson, The Journal of Clin Investig, 119: 1429-1437 (2009).

[0237] EMT biomarkers include, for example, cell surface proteins such as N-cadherin, OB-cadherin, 51 integrin, V6 integrin, syndecan-1, cytoskeletal markers such as FSP1, α-SMA, vimentin, B-catenin, α1(I) collagen, α1(III) collagen, fibronectin, laminin 5, transcription factors such as snail1, snail2, ZEB1, CBF-A / KAP-1 complex, twist, LEF-1, Ets-1, FOXC2, goosecoid, and microRNAs such as miR10b, miR-21 (acquired marker), E-cadherin, ZO-1, cytokeratin, α1(IV) collagen, laminin-1 (attenuated marker) (see Zeisber, M. and E. G. Neilson, The Journal of Clin Investig, 119:1429-1437(2009)).

[0238] According to the present disclosure, a subject in need thereof has a tumor that expresses or secretes aggregated protein.

[0239] In some embodiments, the subject has or is selected to have stage III NSLC.

[0240] In some embodiments, the subject has or is selected to have stage IV NSLC.

[0241] In some embodiments, the subject is not receiving an anti-cancer treatment concurrently with the anti-clusterin antibody or antigen-binding fragment thereof and / or docetaxel.

[0242] In some embodiments, the subject has not been, or has been selected to be, immunosuppressed.

[0243] According to the present disclosure, the subject has not received or has chosen not to receive immunosuppressive drug treatment within 14 days, 13 days, 12 days, 11 days, 10 days, 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days, 2 days or 1 day prior to treatment.

[0244] In some embodiments, the subject has not received or has chosen not to receive immunosuppressive medication within 7 days prior to treatment.

[0245] According to the present disclosure, the subject has not received prior treatment with docetaxel or has been selected not to have received prior treatment with docetaxel.

[0246] The methods of the present disclosure comprise administering one or more treatment cycles to a subject in need thereof.

[0247] In some embodiments, the method comprises administering to a subject in need at least one initial treatment cycle and at least one subsequent treatment cycle. One or more initial treatment cycles and one or more subsequent treatment cycles may be the same or different. For example, one or more initial treatment cycles may include a given dose of an anti-clusterin antibody or an antigen-binding fragment thereof, while one or more subsequent treatment cycles may include a different dose of an anti-clusterin antibody or an antigen-binding fragment thereof. In another example, one or more initial treatment cycles may include a given dose of docetaxel, and then one or more subsequent treatment cycles may include a different dose of docetaxel. In another example, the time interval between the anti-clusterin antibody or an antigen-binding fragment thereof and docetaxel may be different in one or more initial treatment cycles and one or more subsequent treatment cycles. In some embodiments, the initial treatment cycle includes at least one dose of an anti-clusterin antibody or an antigen-binding fragment thereof and at least one dose of a taxane such as docetaxel. In an exemplary embodiment, the initial treatment cycle includes two doses of an anti-clusterin antibody or an antigen-binding fragment thereof and one dose of a taxane such as docetaxel. In an exemplary embodiment, the initial treatment cycle includes three doses of an anti-clusterin antibody or an antigen-binding fragment thereof and one dose of a taxane such as docetaxel. In an exemplary embodiment, the initial treatment cycle includes four doses of an anti-clusterin antibody or antigen-binding fragment thereof and one dose of a taxane such as docetaxel.

[0248] In some embodiments, subsequent treatment cycles include at least one dose of an anti-clusterin antibody or antigen-binding fragment thereof and at least one dose of a taxane such as docetaxel. In an exemplary embodiment, subsequent treatment cycles include two doses of an anti-clusterin antibody or antigen-binding fragment thereof and one dose of a taxane such as docetaxel. In an exemplary embodiment, subsequent treatment cycles include three doses of an anti-clusterin antibody or antigen-binding fragment thereof and one dose of a taxane such as docetaxel. In an exemplary embodiment, subsequent treatment cycles include four doses of an anti-clusterin antibody or antigen-binding fragment thereof and one dose of a taxane such as docetaxel.

[0249] In some embodiments, the initial treatment cycle and subsequent treatment cycles each comprise at least one dose of an anti-clusterin antibody or antigen-binding fragment thereof and at least one dose of docetaxel.

[0250] In some embodiments, a treatment cycle (initial treatment cycle and / or subsequent treatment cycles) is about 21 days. In other embodiments, a treatment cycle is more than 21 days, such as about a month or longer (e.g., about 28-31 days). In other embodiments, a treatment cycle is less than 21 days, such as about 2 weeks (e.g., about 13-16 days).

[0251] According to the present disclosure, a subject receives treatment for one or more treatment cycles.

[0252] In some embodiments, a treatment cycle can last about 21 days and can include administration of an anti-clusterin antibody or antigen-binding fragment thereof (approximately) once every three weeks and administration of docetaxel (approximately) once every three weeks. In this case, a treatment cycle thus includes administration of one dose of an anti-clusterin antibody or antigen-binding fragment thereof and one dose of docetaxel (approximately) every 21 days.

[0253] In some embodiments, a treatment cycle can last about 14 days and can include administration of an anti-clusterin antibody or antigen-binding fragment thereof (approximately) once every two weeks and administration of docetaxel (approximately) once every two weeks. In this case, a treatment cycle thus includes administration of one dose of an anti-clusterin antibody or antigen-binding fragment thereof and one dose of docetaxel (approximately) every 14 days.

[0254] In some embodiments, a treatment cycle can last about 1 month and can include (approximately) monthly administration of an anti-clusterin antibody or antigen-binding fragment thereof and (approximately) monthly administration of docetaxel. In this case, a treatment cycle thus includes (approximately) monthly administration of one dose of an anti-clusterin antibody or antigen-binding fragment thereof and one dose of docetaxel.

[0255] Using the same dosing interval for both drugs is more convenient and can facilitate compliance because both drugs can be administered on the same day.

[0256] In some embodiments, a treatment cycle is about 21 days and includes administration of the anti-clusterin antibody or antigen-binding fragment thereof once a week and administration of docetaxel once every three weeks.

[0257] In some embodiments, the initial treatment cycle and / or subsequent treatment cycles can each independently comprise administration of an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 3 mg / kg to about 20 mg / kg once a week, once every two weeks, or once every three weeks, and administration of about 50 mg / m 2 Up to 100 mg / m 2 Docetaxel was administered at a dose of once every two weeks or once every three weeks.

[0258] In an exemplary embodiment, the method comprises administering about 75 mg / m 2 Docetaxel is administered at a dose of once every three weeks and the anti-clusterin antibody or antigen-binding fragment thereof is administered weekly, once every two weeks, or once every three weeks.

[0259] In another exemplary embodiment, the method comprises administering an anti-clusterin antibody or antigen-binding fragment thereof once weekly at a dose of about 12 mg / kg and at a dose of about 75 mg / m 2 Docetaxel was administered once every three weeks.

[0260] In another exemplary embodiment, the method comprises administering an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg once every three weeks and at a dose of about 75 mg / kg 2 Docetaxel was administered once every three weeks.

[0261] In some embodiments, the methods of the present disclosure may include administering to a subject in need thereof,

[0262] a) at least one initial treatment cycle comprising administering an anti-clusterin antibody or antigen-binding fragment thereof once weekly at a dose of about 3 mg / kg to about 20 mg / kg and at about 50 mg / m 2 Up to 100 mg / m 2 Docetaxel is administered every three weeks at a dose of ;

[0263] b) at least one subsequent treatment cycle comprising administering the anti-clusterin antibody or antigen-binding fragment thereof once every three weeks at a dose of about 3 mg / kg to about 20 mg / kg and at about 50 mg / m 2 Up to 100 mg / m 2 Docetaxel was administered once every three weeks.

[0264] In other embodiments, the methods of the present disclosure may include administering to a subject in need thereof,

[0265] a) at least one initial treatment cycle comprising once weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg and once weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 75 mg / m 2 Docetaxel is administered every three weeks at a dose of ;

[0266] b) at least one subsequent treatment cycle comprising administering the anti-clusterin antibody or antigen-binding fragment thereof once every three weeks at a dose of about 3 mg / kg to about 20 mg / kg and at about 75 mg / m 2 Docetaxel was administered once every three weeks.

[0267] In yet other embodiments, the methods of the present disclosure may include administering to a subject in need thereof,

[0268] a) at least one initial treatment cycle comprising once weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg and once weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 75 mg / m 2 Docetaxel is administered every three weeks at a dose of ;

[0269] b) at least one subsequent treatment cycle comprising administering the anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg once every three weeks and at a dose of about 75 mg / m 2 Docetaxel was administered once every three weeks.

[0270] In an exemplary embodiment, the method comprises administering about 50 mg / m 2 Docetaxel is administered at a dose of once every two weeks and the anti-clusterin antibody or antigen-binding fragment thereof is administered once a week, once every two weeks, or once every three weeks.

[0271] In another exemplary embodiment, the method comprises administering an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg once weekly and at a dose of about 50 mg / m 2 Docetaxel was administered every two weeks at a dose of .

[0272] In another exemplary embodiment, the method comprises administering an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg once every two weeks and at a dose of about 50 mg / m 2 Docetaxel was administered every two weeks at a dose of .

[0273] In yet other embodiments, the methods of the present disclosure may include administering to a subject in need thereof,

[0274] a) at least one initial treatment cycle comprising once weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg and once weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 50 mg / m 2 Docetaxel is administered every two weeks at a dose of ;

[0275] b) at least one subsequent treatment cycle comprising administering the anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 3 mg / kg to about 20 mg / kg once every two weeks and at about 50 mg / m 2 Docetaxel was administered every two weeks at a dose of .

[0276] In yet other embodiments, the methods of the present disclosure may include administering to a subject in need thereof,

[0277] a) at least one initial treatment cycle comprising once weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg and once weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 50 mg / m 2 Docetaxel is administered every two weeks at a dose of ;

[0278] b) at least one subsequent treatment cycle comprising administering the anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg once every two weeks and at a dose of about 50 mg / m2 Docetaxel was administered every two weeks at a dose of .

[0279] In an exemplary embodiment, the subject receives treatment for at least one treatment cycle.In an exemplary embodiment, the subject receives treatment for at least one initial treatment cycle and at least one subsequent treatment cycle.

[0280] In another exemplary embodiment, the subject receives at least two cycles of treatment. In an exemplary embodiment, the subject receives at least two initial treatment cycles of treatment. In an exemplary embodiment, the subject receives at least two subsequent treatment cycles of treatment. In an exemplary embodiment, the subject receives at least one initial treatment cycle and at least two subsequent treatment cycles of treatment. In an exemplary embodiment, the subject receives at least two initial treatment cycles and at least two subsequent treatment cycles of treatment. In an exemplary embodiment, the subject receives at least two initial treatment cycles and more than two subsequent treatment cycles of treatment. In an exemplary embodiment, the subject receives more than two initial treatment cycles and more than two subsequent treatment cycles of treatment.

[0281] In further exemplary embodiments, the subject receives at least three treatment cycles of treatment. In an exemplary embodiment, the subject receives at least three initial treatment cycles of treatment. In an exemplary embodiment, the subject receives at least three subsequent treatment cycles of treatment. In an exemplary embodiment, the subject receives at least three initial treatment cycles of treatment and at least three subsequent treatment cycles of treatment. In an exemplary embodiment, the subject receives at least three initial treatment cycles of treatment and more than three subsequent treatment cycles of treatment.

[0282] In yet another additional exemplary embodiment, the subject receives at least four treatment cycles of treatment. In an exemplary embodiment, the subject receives at least four initial treatment cycles of treatment. In an exemplary embodiment, the subject receives at least four subsequent treatment cycles of treatment. In an exemplary embodiment, the subject receives at least four initial treatment cycles of treatment and at least four subsequent treatment cycles of treatment. In an exemplary embodiment, the subject receives at least four initial treatment cycles of treatment and more than four subsequent treatment cycles of treatment.

[0283] In other exemplary embodiments, the subject is treated or receives four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fourteen or more, fifteen or more, sixteen or more, seventeen or more, eighteen or more, nineteen or more, twenty or more treatment cycles. In yet another further exemplary embodiment, the subject is treated or receives four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fourteen or more, fifteen or more, sixteen or more, seventeen or more, eighteen or more, nineteen or more, twenty or more initial treatment cycles. In yet another further exemplary embodiment, the subject is treated or receives four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fourteen or more, fifteen or more, sixteen or more, seventeen or more, eighteen or more, nineteen or more, twenty or more initial and / or subsequent treatment cycles. In some embodiments, treatment cycles are continuous.

[0284] In some embodiments, the treatment cycles are uninterrupted.

[0285] In some embodiments, the treatment cycle is interrupted.

[0286] In some embodiments, the treatment cycle is interrupted for a period of time (from one day to several weeks or months). In some embodiments, at least one treatment cycle is interrupted. In other embodiments, more than one treatment cycle is interrupted. In other embodiments, treatment is interrupted after a specific period of time determined by a physician or clinician.

[0287] According to the present disclosure, the combination therapy is administered for at least two consecutive cycles.

[0288] According to the present disclosure, the combination therapy is administered for at least three consecutive cycles.

[0289] According to the present disclosure, the combination therapy is administered for at least four consecutive cycles.

[0290] According to the present disclosure, the combination therapy is administered for at least five consecutive cycles.

[0291] According to the present disclosure, the combination therapy is administered for at least six consecutive cycles.

[0292] According to the present disclosure, the combination therapy is administered for at least seven consecutive cycles.

[0293] According to the present disclosure, the combination therapy is administered for at least eight consecutive cycles.

[0294] According to the present disclosure, the combination therapy is administered for at least 9 consecutive cycles.

[0295] According to the present disclosure, the combination therapy is administered for at least 10 consecutive cycles.

[0296] According to the present disclosure, the combination therapy is administered for at least 11 consecutive cycles.

[0297] According to the present disclosure, the combination therapy is administered for at least 12 consecutive cycles.

[0298] In some embodiments, clinical benefit may be observed or measured after two treatment cycles.

[0299] In some embodiments, clinical benefit may be observed or measured after three treatment cycles.

[0300] In some embodiments, clinical benefit may be observed or measured after four treatment cycles.

[0301] In some embodiments, clinical benefit may be observed or measured after five treatment cycles.

[0302] In some embodiments, a clinical benefit may be observed or measured after more than five treatment cycles.

[0303] In some embodiments, the combination therapy is administered as long as a clinical benefit is observed or measured.

[0304] In some embodiments, the combination therapy is administered until tumor progression.

[0305] In some embodiments, the combination therapy is administered until uncontrollable toxicity occurs.

[0306] In some embodiments, administration of the anti-Clusterin antibody or antigen-binding fragment thereof is maintained after clinical benefit occurs.

[0307] The present disclosure also provides kits comprising one or more containers comprising at least one dose of an anti-clusterin antibody or antigen-binding fragment thereof, one or more containers comprising at least one dose of a taxane, such as docetaxel, for combination therapy, and a package insert comprising instructions for treating a subject as described herein.

[0308] In some embodiments, the package insert states that the combination therapy is intended for treating a subject having NSLC or metastatic NSLC. BRIEF DESCRIPTION OF THE DRAWINGS

[0310] Figure 1: Table showing the percentage reduction of target lesions, duration of treatment for patients as best response according to RECIST 1.1 (PT; patients, BR; best response, PD-L1; PD-L1 tumor proportion score, PR; partial response, SD; stable disease, PD; progressive disease, AE; adverse events).

[0311] Figure 2 : Histological analysis of pre-treatment (a and c) and on-treatment (b and d) biopsies from two patients on study. Tumor sections were stained with hematoxylin and eosin.

[0312] Further scope, applicability and advantages of the present disclosure will become apparent from the non-limiting detailed description given below.It should be understood, however, that the detailed description, while indicating exemplary embodiments of the present disclosure, is given by way of example only with reference to the accompanying drawings. DETAILED DESCRIPTION OF THE INVENTION

[0314] definition

[0315] Unless otherwise indicated, the amino acid numbering of the dimerization domain shown is according to the EU numbering system.

[0316] In the context of describing embodiments (especially in the context of the claims), the use of the terms "a" and "an" and "the" and similar referents are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.

[0317] Unless specifically stated or obvious from the context, the term "or" as used herein should be construed as inclusive, covering both "or" and "and".

[0318] The term "and / or" as used herein is considered a specific disclosure of each specified feature or component with or without the other.

[0319] Unless otherwise noted, the terms "comprising," "having," "including," and "containing" are to be construed as open-ended terms (ie, meaning "including, but not limited to") The term "consisting of is to be construed as closed.

[0320] The term "subject" refers to a human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cow, sheep, horse, or primate) with lung cancer (such as, but not limited to, non-small cell lung cancer, metastatic non-small cell lung cancer) and / or a subject with stage III to IV non-small cell lung cancer. The term "subject" is used interchangeably herein with "individual" or "patient".

[0321] The term "antibody" is used in the broadest sense, covering various antibody forms and structures, including any immunoglobulin, monoclonal antibody, polyclonal antibody, bivalent antibody, monovalent antibody, bispecific antibody, multispecific (multi-specific) antibody, conventional antibody, single domain antibody, single chain antibody, heavy chain only antibody, nano antibody, full length antibody, humanized antibody, chimeric antibody binding to a specific antigen, and any antigen binding fragment showing desired antigen binding activity. Antibodies can be naturally occurring (natural) or the result of recombinant technology. As used herein, the term "conventional antibody" has the same form as naturally occurring human antibodies. It should be understood herein that the sequence of conventional antibodies can be partially and / or entirely derived from non-human animal antibodies or human antibodies, therefore including but not limited to monoclonal antibodies, chimeric antibodies, human antibodies and humanized antibodies.

[0322] For the purposes of this disclosure, the term "treat" or "treating" refers to the act of providing treatment (such as the combination therapy disclosed herein) to a subject. As used herein, the term "treat" or "treating" refers to any method for partially or completely alleviating, improving, alleviating, inhibiting, preventing, delaying onset, reducing severity, reducing incidence, stabilizing and / or controlling one or more symptoms and / or features of a specific disease, disorder and / or illness and / or obtaining or maintaining a clinical benefit defined according to the RECIST1.1 guidelines. It should be understood that treatment may be effective for some subjects with specific diseases, disorders and / or illnesses, but ineffective for other subjects who have received treatment.

[0323] The term "therapeutically effective" refers to a treatment that results in partial or complete alleviation, amelioration, relief, inhibition, prevention, delayed onset, reduced severity, reduced incidence, stabilization, and / or improved control of one or more symptoms and / or features of a specific disease, disorder, and / or condition, and / or produces a clinical benefit as defined according to the RECIST 1.1 guidelines for some subjects.

[0324] As used herein, the term "EMT signature" refers to changes indicative of a loss of an epithelial phenotype and / or acquisition of a mesenchymal phenotype, which are observable at the cellular level and / or observable or measurable at the genetic or protein level.

[0325] The term "about" or "approximately" relative to a given value means that variations in that value are expected. In some embodiments, the term "about" or "approximately" generally refers to a range within + / -20%, within + / -10%, within + / -5%, within + / -4%, within + / -3%, within + / -2%, or within + / -1% of a given value or range.

[0326] The expression "throughout the treatment period" means that both the anti-clusterin antibody or antigen-binding fragment and docetaxel are administered in each treatment cycle.

[0327] The term "substantially" is used to characterize an action that is performed most of the time or a state that occurs most of the time. For example, the expression "substantially throughout the treatment period" means that the anti-clusterin antibody or antigen-binding fragment and docetaxel are administered in each treatment cycle and during the entire treatment period, but the dose of the anti-clusterin antibody or antigen-binding fragment or docetaxel or the dose of each may be omitted intentionally or unintentionally from time to time.

[0328] The term "functional immune system" with respect to a subject means that the subject's immune system is not substantially affected by the cancer or the drug, or that the subject is immunocompetent or the subject is not immunosuppressed.

[0329] The expression "a treatment comprising an immune checkpoint antibody" refers to a treatment with an immune checkpoint antibody used as a monotherapy or in a combination therapy.

[0330] The expression "adequate organ and immune function" refers to one or more of the parameters provided in Table 7.

[0331] Exemplary embodiments of combination therapy, methods, uses, dosages, regimens and schedules

[0332] The present disclosure provides combination therapies comprising a clusterin antibody or antigen-binding fragment thereof and a taxane.

[0333] More specifically, the present disclosure provides combination therapies comprising an anti-clusterin antibody or antigen-binding fragment thereof and docetaxel.

[0334] The present disclosure provides methods of treating a subject having lung cancer (eg, lung cancer) with the combination therapies disclosed herein.

[0335] More specifically, the present disclosure provides methods of treating a subject having non-small cell lung cancer with the combination therapies disclosed herein.

[0336] More specifically, the present disclosure provides methods of treating a subject having metastatic non-small cell lung cancer with the combination therapies disclosed herein.

[0337] The present disclosure also relates to methods of treating a subject having non-small cell lung cancer with the combination therapies disclosed herein to obtain clinical benefit.

[0338] The present disclosure also relates to methods of treating a subject having metastatic non-small cell lung cancer with the combination therapies disclosed herein to obtain clinical benefit.

[0339] The present disclosure also relates to methods of obtaining clinical benefit in a subject suffering from non-small cell lung cancer using the combination therapies disclosed herein.

[0340] The present disclosure also relates to methods of obtaining clinical benefit in a subject having metastatic non-small cell lung cancer using the combination therapies disclosed herein.

[0341] In some embodiments, the methods may include administering the combination therapy in a dose sufficient to produce a clinical benefit.

[0342] In some embodiments, the methods may include administering the combination therapy for a period of time sufficient to produce a clinical benefit.

[0343] In some embodiments, the methods may include administering the combination therapy according to a treatment schedule sufficient to produce clinical benefit.

[0344] In some embodiments, the methods may include administering the combination therapy according to a treatment regimen sufficient to produce clinical benefit.

[0345] Thus, in certain aspects, the methods of the present disclosure comprise administering a combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and a taxane.

[0346] In other aspects, the methods of the disclosure comprise administering a combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and docetaxel.

[0347] According to the present disclosure, an anti-clusterin antibody or antigen-binding fragment thereof is administered at a therapeutically effective dose.

[0348] According to the present disclosure, an anti-clusterin antibody or antigen-binding fragment thereof is administered at a safe dose.

[0349] According to the present disclosure, docetaxel is administered at a therapeutically effective dose.

[0350] According to the present disclosure, docetaxel is administered at a safe dose.

[0351] In some embodiments, docetaxel is administered at a dose sufficient to allow chemotherapy-induced modulation of tumor immunogenicity.

[0352] According to the present disclosure, docetaxel is administered at an administration interval sufficient to allow for chemotherapy-induced modulation of tumor immunogenicity.

[0353] In some embodiments, the method comprises administering a combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 3 mg / kg to about 20 mg / kg and an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 60 mg / kg. 2 Up to 100 mg / m 2 of docetaxel.

[0354] According to the present disclosure, the dosage may be between about 3 mg / kg and about 20 mg / kg, for example, between about 4 mg / kg and about 20 mg / kg, between about 5 mg / kg and about 20 mg / kg, between about 6 mg / kg and about 20 mg / kg, between about 6 mg / kg and about 18 mg / kg, between about 6 mg / kg and about 17 mg / kg, between about 6 mg / kg and about 16 mg / kg, between about 6 mg / kg and about 15 mg / kg, between about 6 mg / kg and about 14 mg / kg, between about 6 mg / kg and about 13 mg / kg. mg / kg, between about 6 mg / kg and about 12 mg / kg, between about 7 mg / kg and about 18 mg / kg, between about 7 mg / kg and about 17 mg / kg, between about 7 mg / kg and about 16 mg / kg, between about 7 mg / kg and about 15 mg / kg, between about 7 mg / kg and about 14 mg / kg, between about 7 mg / kg and about 13 mg / kg, between about 7 mg / kg and about 12 mg / kg, between about 8 mg / kg and about 18 mg / kg, between about 8 mg / kg and about 17 mg / kg between about 8 mg / kg and about 16 mg / kg, between about 8 mg / kg and about 15 mg / kg, between about 8 mg / kg and about 14 mg / kg, between about 8 mg / kg and about 13 mg / kg, between about 8 mg / kg and about 12 mg / kg, between about 9 mg / kg and about 18 mg / kg, between about 9 mg / kg and about 17 mg / kg, between about 9 mg / kg and about 16 mg / kg, between about 9 mg / kg and about 15 mg / kg, between about 9 ...5 mg / kg, between about 8 mg / kg and about 16 mg / kg, between about 8 mg / kg and about 16 mg / kg, between about 8 mg / kg and about 15 mg / kg, between about 9 mg / kg and about 14 mg / kg, between about 8 mg / kg and about 13 mg / kg, between about 8 mg / kg and about 12 mg / kg, between about 9 mg / kg and about 18 mg / kg, between about 9 mg / kg and about 17 mg / kg The anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of between about 9 mg / kg and about 13 mg / kg, between about 9 mg / kg and about 12 mg / kg, between about 10 mg / kg and about 18 mg / kg, between about 10 mg / kg and about 17 mg / kg, between about 10 mg / kg and about 16 mg / kg, between about 10 mg / kg and about 15 mg / kg, between about 10 mg / kg and about 14 mg / kg, between about 10 mg / kg and about 13 mg / kg, or between about 10 mg / kg and about 12 mg / kg.

[0355] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 3.0 mg / kg.

[0356] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 3.0 mg / kg.

[0357] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 4.0 mg / kg.

[0358] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 4.0 mg / kg.

[0359] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 5.0 mg / kg.

[0360] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 5.0 mg / kg.

[0361] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 6.0 mg / kg.

[0362] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 6.0 mg / kg.

[0363] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 7.0 mg / kg.

[0364] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 7.0 mg / kg.

[0365] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 8.0 mg / kg.

[0366] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 8.0 mg / kg.

[0367] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 9.0 mg / kg.

[0368] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 9.0 mg / kg.

[0369] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 10.0 mg / kg.

[0370] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 10.0 mg / kg.

[0371] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 11.0 mg / kg.

[0372] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 11.0 mg / kg.

[0373] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 12.0 mg / kg.

[0374] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 12.0 mg / kg.

[0375] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 13.0 mg / kg.

[0376] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 13.0 mg / kg.

[0377] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 14.0 mg / kg.

[0378] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 14.0 mg / kg.

[0379] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 15.0 mg / kg.

[0380] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 15.0 mg / kg.

[0381] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 16.0 mg / kg.

[0382] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 16.0 mg / kg.

[0383] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 17.0 mg / kg.

[0384] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 17.0 mg / kg.

[0385] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 18.0 mg / kg.

[0386] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 18.0 mg / kg.

[0387] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 19.0 mg / kg.

[0388] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 19.0 mg / kg.

[0389] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 20.0 mg / kg.

[0390] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of 20.0 mg / kg.

[0391] According to the disclosure, the dosage is between about 50 mg / m 2 About 100 mg / m 2 Between, for example 60mg / m 2 About 100 mg / m 2 Between, about 60mg / m 2 About 95 mg / m 2 Between, about 60mg / m 2 About 90 mg / m 2 Between, about 60mg / m 2 About 85 mg / m 2 Between, about 60mg / m 2 About 80 mg / m 2 Between, about 50mg / m 2 About 75 mg / m 2 Between, about 60mg / m 2 About 75 mg / m 2 Between, about 75mg / m 2 About 95 mg / m 2 Between, about 75mg / m 2 About 90 mg / m 2 Between, about 75mg / m 2 About 85 mg / m 2 Between, about 75mg / m 2 About 80 mg / m 2 Between, about 70mg / m 2 About 95 mg / m 2 Between, about 70mg / m 2 About 90 mg / m 2 Between, about 70mg / m 2 About 85 mg / m 2 Between, about 70mg / m 2 About 80 mg / m2 Between or about 70 mg / m 2 About 75 mg / m 2 The doses administered between the docetaxel competitions.

[0392] In some embodiments, about 50 mg / m 2 Docetaxel was administered at a dose of

[0393] In some embodiments, about 60 mg / m 2 Docetaxel was administered at a dose of

[0394] In some embodiments, about 65 mg / m 2 Docetaxel was administered at a dose of

[0395] In some embodiments, about 70 mg / m 2 Docetaxel was administered at a dose of

[0396] In some embodiments, about 75 mg / m 2 Docetaxel was administered at a dose of

[0397] In some embodiments, about 80 mg / m 2 Docetaxel was administered at a dose of

[0398] In some embodiments, about 85 mg / m 2 Docetaxel was administered at a dose of

[0399] In some embodiments, about 90 mg / m 2 Docetaxel was administered at a dose of

[0400] In some embodiments, about 95 mg / m 2 Docetaxel was administered at a dose of

[0401] In some embodiments, about 100 mg / m 2 Docetaxel was administered at a dose of

[0402] An exemplary embodiment of the methods of the present disclosure is a method of treating a subject having non-small cell lung cancer (e.g., metastatic non-small cell lung cancer), comprising administering a combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and docetaxel, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 3 mg / kg to about 20 mg / kg and comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises the complementarity determining regions (CDRs) of the light chain variable region set forth in SEQ ID NO: 12, and the heavy chain variable region comprises the CDRs of the heavy chain variable region set forth in SEQ ID NO: 13, and the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 50 mg / kg to about 20 mg / kg. 2 About 100 mg / m2 Docetaxel was administered at a dose of

[0403] Another exemplary embodiment of the methods of the present disclosure is a method of treating a subject having non-small cell lung cancer (e.g., metastatic non-small cell lung cancer), comprising administering a combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and docetaxel, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 12 mg / kg and comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region set forth in SEQ ID NO: 12 and a heavy chain variable region having the CDRs of the heavy chain variable region set forth in SEQ ID NO: 13, and is administered at a dose of about 50 mg / m 2 Up to about 75 mg / m 2 Docetaxel was administered at a dose of

[0404] Another exemplary embodiment of the disclosed method is a method of treating a subject having non-small cell lung cancer (e.g., metastatic non-small cell lung cancer), comprising administering a combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and docetaxel, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 12 mg / kg and comprises a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 12 and a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 13, and is administered at a dose of about 50 mg / m 2 Up to about 75 mg / m 2 Docetaxel was administered at a dose of

[0405] Yet another additional exemplary embodiment of the disclosed methods is a method of treating a subject having non-small cell lung cancer (e.g., metastatic non-small cell lung cancer), comprising administering a combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and docetaxel, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 3 mg / kg and comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region set forth in SEQ ID NO: 12 and a heavy chain variable region having the CDRs of the heavy chain variable region set forth in SEQ ID NO: 13, and is administered at a dose of about 50 mg / m 2 About 100 mg / m 2 Docetaxel was administered at a dose of

[0406] Another exemplary embodiment of the disclosed method is a method of treating a subject having non-small cell lung cancer (e.g., metastatic non-small cell lung cancer) comprising administering a combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and docetaxel to obtain a clinical benefit, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 12 mg / kg and comprises a light chain variable region having the complementarity determining regions (CDRs) of the light chain variable region set forth in SEQ ID NO: 12 and a heavy chain variable region having the CDRs of the heavy chain variable region set forth in SEQ ID NO: 13, and is administered at a dose of about 50 mg / m 2 Up to about 70 mg / m 2 Docetaxel was administered at a dose of

[0407] Yet another exemplary embodiment of the methods of the present disclosure is a method of treating a subject having non-small cell lung cancer (e.g., metastatic non-small cell lung cancer), comprising administering a combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and docetaxel to obtain clinical benefit, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 12 mg / kg and comprises a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 12 and a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 13, and the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 50 mg / kg. 2 Up to about 75 mg / m 2 Docetaxel was administered at a dose of

[0408] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered once a week.

[0409] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered twice per week.

[0410] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered once every two weeks.

[0411] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered once every three weeks.

[0412] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered once every four weeks.

[0413] In some embodiments, docetaxel is administered weekly.

[0414] In some embodiments, docetaxel is administered every two weeks.

[0415] In some embodiments, docetaxel is administered every three weeks.

[0416] In some embodiments, docetaxel is administered every four weeks.

[0417] In some embodiments, docetaxel is administered once a week.

[0418] In some embodiments, docetaxel is administered once every two weeks.

[0419] In some embodiments, docetaxel is administered once every three weeks.

[0420] In some embodiments, docetaxel is administered once every four weeks.

[0421] In some embodiments, docetaxel is administered once every five weeks.

[0422] In some embodiments, docetaxel is administered once every six weeks.

[0423] In some embodiments, the treatment cycle is considered complete after a period of about 7 days after the subject receives both the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel.

[0424] In some exemplary embodiments, one treatment cycle is about 7 days.

[0425] In some exemplary embodiments, substantially all treatment cycles are about 7 days.

[0426] In some exemplary embodiments, each treatment cycle is about 7 days.

[0427] According to the present disclosure, a subject may thus receive one treatment cycle every 7 days.

[0428] In some exemplary embodiments, one treatment cycle is about 14 days.

[0429] In some exemplary embodiments, substantially all treatment cycles are about 14 days.

[0430] In some exemplary embodiments, each treatment cycle is about 14 days.

[0431] According to the present disclosure, a subject may thus receive one treatment cycle every 14 days.

[0432] In some exemplary embodiments, one treatment cycle is about 21 days.

[0433] In some exemplary embodiments, substantially all treatment cycles are about 21 days.

[0434] In some exemplary embodiments, each treatment cycle is about 21 days.

[0435] According to the present disclosure, a subject may thus receive one treatment cycle every 21 days.

[0436] In some exemplary embodiments, one treatment cycle is about 28 days.

[0437] In some exemplary embodiments, substantially all treatment cycles are about 28 days.

[0438] In some exemplary embodiments, each treatment cycle is about 28 days.

[0439] According to the present disclosure, a subject may thus receive one treatment cycle every 28 days.

[0440] In an exemplary embodiment, the combination therapy is administered in one or more treatment cycles comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof on days 1, 8, and 15 and administration of docetaxel on day 1.

[0441] It will be appreciated that the interval between administration of the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel may be varied without significantly altering the efficacy of the combination therapy.

[0442] For example, an anti-clusterin antibody or antigen-binding fragment thereof can be administered on days 1, 7, and 14, and docetaxel can be administered on day 1.

[0443] In another example, an anti-clusterin antibody or antigen-binding fragment thereof can be administered on days 1, 7, and 16, and docetaxel can be administered on day 1.

[0444] In another example, an anti-clusterin antibody or antigen-binding fragment thereof can be administered on days 1, 8, and 16, and docetaxel can be administered on day 1.

[0445] In an exemplary embodiment, one treatment cycle comprises administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and administration of docetaxel every three weeks.

[0446] In an exemplary embodiment, one treatment cycle comprises administration of an anti-clusterin antibody or antigen-binding fragment thereof every two weeks and administration of docetaxel every two weeks.

[0447] In an exemplary embodiment, one treatment cycle comprises administration of the anti-clusterin antibody or antigen-binding fragment thereof every two weeks and administration of docetaxel every three weeks.

[0448] In an exemplary embodiment, one treatment cycle comprises administration of an anti-clusterin antibody or antigen-binding fragment thereof every three weeks and administration of docetaxel every three weeks.

[0449] In an exemplary embodiment, one treatment cycle comprises weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof and monthly administration of docetaxel.

[0450] In an exemplary embodiment, one treatment cycle comprises biweekly administration of an anti-clusterin antibody or antigen-binding fragment thereof and monthly administration of docetaxel.

[0451] In an exemplary embodiment, one treatment cycle comprises monthly administration of an anti-clusterin antibody or antigen-binding fragment thereof and monthly administration of docetaxel.

[0452] In an exemplary embodiment, one treatment cycle comprises administration of an anti-clusterin antibody or antigen-binding fragment thereof every two months and administration of docetaxel every two months.

[0453] In an exemplary embodiment, one treatment cycle comprises administration of an anti-clusterin antibody or antigen-binding fragment thereof every three months and administration of docetaxel every three months.

[0454] In some embodiments, the method comprises administering a drug comprising an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 3 mg / kg to about 20 mg / kg and a drug comprising an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 50 mg / kg every two to three weeks. 2 About 100 mg / m 2 Combination therapy with docetaxel.

[0455] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 12 mg / kg and the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 75 mg / m 2 Docetaxel was administered every three weeks.

[0456] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 12 mg / kg and at about 60 mg / m 2 Docetaxel was administered every three weeks.

[0457] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 12 mg / kg and docetaxel is administered at a dose of about 50 mg / m2 every two weeks.

[0458] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 9 mg / kg and at about 75 mg / m 2 Docetaxel was administered every three weeks.

[0459] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 9 mg / kg and at about 60 mg / m 2 Docetaxel was administered every three weeks.

[0460] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 9 mg / kg and at about 50 mg / m 2Docetaxel was administered every two weeks at a dose of .

[0461] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 6 mg / kg and at about 75 mg / m 2 Docetaxel was administered every three weeks.

[0462] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 6 mg / kg and at about 60 mg / m 2 Docetaxel was administered every three weeks.

[0463] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 6 mg / kg and at about 50 mg / m 2 Docetaxel was administered every two weeks at a dose of .

[0464] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 3 mg / kg and at about 75 mg / m 2 Docetaxel was administered every three weeks.

[0465] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 3 mg / kg and at about 60 mg / m 2 Docetaxel was administered every three weeks.

[0466] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 3 mg / kg and at about 50 mg / m 2 Docetaxel was administered every two weeks at a dose of .

[0467] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel can be administered once a week on the same day.

[0468] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel can be administered once a week on the same day.

[0469] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel are administered on the same day every two weeks.

[0470] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel are administered on the same day every 3 weeks.

[0471] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel are administered on the same day every 4 weeks.

[0472] In some embodiments, the method comprises administering a combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 3 mg / kg to about 20 mg / kg once weekly and an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 50 mg / kg. 2 Up to 100 mg / m 2 of docetaxel (every two to three weeks).

[0473] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered once weekly at a dose of about 12 mg / kg and at a dose of about 75 mg / m 2 Docetaxel was administered once every three weeks.

[0474] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered once weekly at a dose of about 12 mg / kg and at about 60 mg / m 2 Docetaxel was administered once every three weeks.

[0475] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered once weekly at a dose of about 12 mg / kg and at a dose of about 50 mg / m 2 Docetaxel was administered once every three weeks.

[0476] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered once weekly at a dose of about 9 mg / kg and at about 75 mg / m 2 Docetaxel was administered once every three weeks.

[0477] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered once weekly at a dose of about 9 mg / kg and at about 60 mg / m 2 Docetaxel was administered once every three weeks.

[0478] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered once weekly at a dose of about 9 mg / kg and at about 50 mg / m 2 Docetaxel was administered once every three weeks.

[0479] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered once weekly at a dose of about 6 mg / kg and at about 75 mg / m 2 Docetaxel was administered once every three weeks.

[0480] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered once weekly at a dose of about 6 mg / kg and at about 60 mg / m 2 Docetaxel was administered once every three weeks.

[0481] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered once weekly at a dose of about 6 mg / kg and at about 50 mg / m 2 Docetaxel was administered once every three weeks.

[0482] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered once weekly at a dose of about 3 mg / kg and at a dose of about 75 mg / kg. 2 Docetaxel was administered once every three weeks.

[0483] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered once weekly at a dose of about 3 mg / kg and at about 60 mg / m 2 Docetaxel was administered once every three weeks.

[0484] In an exemplary embodiment, the anti-clusterin antibody or antigen-binding fragment thereof is administered once weekly at a dose of about 3 mg / kg and at about 50 mg / m 2 Docetaxel was administered once every three weeks.

[0485] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel can be administered on the same day. However, it is also possible to administer them on different days.

[0486] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel can be administered separately on the same day.

[0487] The anti-clusterin antibody or antigen-binding fragment thereof and docetaxel can be administered sequentially.

[0488] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof and / or docetaxel can be administered by infusion.

[0489] In some embodiments, both the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel are administered during the entire treatment period.

[0490] In some embodiments, both the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel are administered during each treatment cycle.

[0491] The anti-clusterin antibody or antigen-binding fragment thereof and docetaxel are administered during each treatment cycle. However, it is possible to miss one or more doses of the anti-clusterin antibody or antigen-binding fragment thereof and / or docetaxel without negatively affecting the treatment. It is also possible to administer one or more additional doses of the anti-clusterin antibody or antigen-binding fragment thereof and / or docetaxel without negatively affecting the treatment.

[0492] According to the present disclosure, a subject may receive at least 1 treatment cycle.

[0493] According to the present disclosure, a subject may receive at least 2 treatment cycles.

[0494] According to the present disclosure, a subject may receive at least 3 treatment cycles.

[0495] According to the present disclosure, a subject may receive at least 4 treatment cycles.

[0496] According to the present disclosure, a subject may receive 4 or more treatment cycles.

[0497] According to the present disclosure, a subject may receive at least 5 treatment cycles.

[0498] According to the present disclosure, a subject may receive at least 6 treatment cycles.

[0499] According to the present disclosure, a subject may receive at least 7 treatment cycles.

[0500] According to the present disclosure, a subject may receive at least 8 treatment cycles.

[0501] According to the present disclosure, a subject may receive at least 9 treatment cycles.

[0502] According to the present disclosure, a subject may receive at least 10 treatment cycles.

[0503] According to the present disclosure, a subject may receive at least 11 treatment cycles.

[0504] According to the present disclosure, a subject may receive at least 12 treatment cycles.

[0505] According to the present disclosure, a subject may receive at least 13 treatment cycles.

[0506] According to the present disclosure, a subject may receive at least 14 treatment cycles.

[0507] According to the present disclosure, a subject may receive at least 15 treatment cycles.

[0508] According to the present disclosure, a subject may receive at least 16 treatment cycles.

[0509] According to the present disclosure, a subject may receive at least 17 treatment cycles.

[0510] According to the present disclosure, a subject may receive at least 18 treatment cycles.

[0511] According to the present disclosure, a subject may receive at least 19 treatment cycles.

[0512] According to the present disclosure, a subject may receive at least 20 treatment cycles.

[0513] According to the present disclosure, a subject may receive more than 20 treatment cycles.

[0514] According to the present disclosure, a subject may receive at least one treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and administration of docetaxel once every three weeks.

[0515] According to the present disclosure, a subject may receive at least two treatment cycles, each cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and administration of docetaxel once every three weeks.

[0516] According to the present disclosure, a subject may receive at least three treatment cycles, each cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and administration of docetaxel once every three weeks.

[0517] According to the present disclosure, a subject may receive at least four treatment cycles, each cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and administration of docetaxel once every three weeks.

[0518] According to the present disclosure, a subject may receive four or more treatment cycles, each cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and administration of docetaxel once every three weeks.

[0519] According to the present disclosure, a subject may receive at least five treatment cycles, each cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and administration of docetaxel once every three weeks.

[0520] According to the present disclosure, a subject may receive at least six treatment cycles, each cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and administration of docetaxel once every three weeks.

[0521] According to the present disclosure, a subject may receive at least seven treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and administration of docetaxel once every three weeks.

[0522] According to the present disclosure, a subject may receive at least eight treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and administration of docetaxel once every three weeks.

[0523] According to the present disclosure, a subject may receive at least nine treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and administration of docetaxel once every three weeks.

[0524] According to the present disclosure, a subject may receive at least ten treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and administration of docetaxel once every three weeks.

[0525] According to the present disclosure, a subject may receive at least eleven treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and administration of docetaxel once every three weeks.

[0526] According to the present disclosure, a subject may receive at least twelve treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and administration of docetaxel once every three weeks.

[0527] According to the present disclosure, a subject may receive more than twelve treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and administration of docetaxel once every three weeks.

[0528] According to the present disclosure, the treatment cycles are continuous.

[0529] According to the present disclosure, all treatment cycles are continuous.

[0530] According to the present disclosure, the treatment cycle is uninterrupted.

[0531] According to the present disclosure, all treatment cycles are uninterrupted.

[0532] The method or use may also include interrupting treatment (single agent or combination therapy) for a period of time (e.g., for one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, ten weeks, at least ten weeks, one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, at least six months, at least ten months, at least one year, one cycle, two cycles, three cycles, four cycles, five cycles, six cycles, seven cycles, eight cycles, nine cycles, ten cycles, at least ten cycles). Treatment may then be restarted.

[0533] In some embodiments, at least one treatment cycle is interrupted.

[0534] In other embodiments, more than one treatment cycle is interrupted.

[0535] In some embodiments, the interruption lasts from one day to one week. In some embodiments, the interruption lasts from one day to two weeks. In some embodiments, the interruption lasts from one day to three weeks. In some embodiments, the interruption lasts from one day to one month. In some embodiments, the interruption lasts from one day to two months. In some embodiments, the interruption lasts from one day to three months. In some embodiments, the interruption lasts from one day to four months. In some embodiments, the interruption lasts from one day to five months. In some embodiments, the interruption lasts from one day to six months. In some embodiments, the interruption lasts from one day to more than six months.

[0536] In some embodiments, the method specifically involves administering an anti-clusterin antibody or antigen-binding fragment thereof, which comprises a light chain variable region comprising CDRs having the amino acid sequences shown in SEQ ID NO: 1 (CDRL1), SEQ ID NO: 2 (CDRL2) and SEQ ID NO: 3 (CDRL3) and a heavy chain variable region comprising CDRs having the amino acid sequences shown in SEQ ID NO: 4 (CDRH1), SEQ ID NO: 5 (CDRH2) and SEQ ID NO: 6 (CDRH3).

[0537] In other embodiments, the method specifically involves administering an anti-clusterin antibody or antigen-binding fragment thereof, which comprises a light chain variable region comprising CDRs having the amino acid sequences shown in SEQ ID NO:1 (CDRL1), SEQ ID NO:2 (CDRL2) and SEQ ID NO:3 (CDRL3) and a heavy chain variable region comprising CDRs having the amino acid sequences shown in SEQ ID NO:7 (CDRH1), SEQ ID NO:8 (CDRH2) and SEQ ID NO:9 (CDRH3).

[0538] In other embodiments, the method specifically involves administering an anti-clusterin antibody or antigen-binding fragment thereof comprising:

[0539] a. a light chain variable region having an amino acid sequence that is at least 80% identical to the amino acid sequence shown in SEQ ID NO: 12, and a heavy chain variable region having an amino acid sequence that is at least 80% identical to the amino acid sequence shown in SEQ ID NO: 13, or;

[0540] b. a light chain having an amino acid sequence that is at least 80% identical to the amino acid sequence shown in SEQ ID NO:14, and a heavy chain having an amino acid sequence that is at least 80% identical to the amino acid sequence shown in SEQ ID NO:15.

[0541] In other embodiments, the method specifically involves administering an anti-clusterin antibody or antigen-binding fragment thereof comprising a light chain variable region having the amino acid sequence shown in SEQ ID No:12 and a heavy chain variable region having the amino acid sequence shown in SEQ ID NO:13.

[0542] In additional embodiments, the method specifically involves administering an anti-clusterin antibody or antigen-binding fragment thereof comprising a light chain having the amino acid sequence shown in SEQ ID NO:14 and a heavy chain having the amino acid sequence shown in SEQ ID NO:15.

[0543] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered by infusion over a period of about 1 hour.

[0544] In some embodiments, docetaxel is administered by infusion over a period of about 1 hour.

[0545] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is administered by infusion within a time frame of about 1 hour and then docetaxel is administered by infusion within a time frame of about 1 hour on the same day.

[0546] In some embodiments, docetaxel is administered by infusion within a time frame of about 1 hour, followed by administration of the anti-clusterin antibody or antigen-binding fragment thereof by infusion within a time frame of about 1 hour on the same day.

[0547] According to the present disclosure, combination therapies or medicaments may be used in subjects with non-small cell lung cancer, such as metastatic NSCLC or stage III to IV NSCLC.

[0548] According to the present disclosure, both the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel are administered substantially throughout the entire treatment period.

[0549] According to the present disclosure, combination therapy can be used for NSCLC patients who progress after treatment with immune checkpoint antibodies alone or in combination with chemotherapy.

[0550] In addition, according to the present disclosure, combination therapy can be used for NSCLC patients with no evidence of PD-L1 expression (e.g., tumor proportion score (TPS) <1%) or with low PD-L1 expression (e.g., tumor proportion score (TPS) ≤15%, i.e., including <5%, ≤1%, <1% and 0%).

[0551] According to the present disclosure, combination therapies can be used for NSCLC that is not amenable to or is unlikely to benefit from treatments comprising immune checkpoint antibodies.

[0552] The present disclosure relates to combination therapies for methods of treating NSCLC, such as metastatic NSCLC, by promoting infiltration of immune cells in one or more lesions.

[0553] Thus, the present disclosure relates to combination therapies for methods of treating NSCLC, such as metastatic NSCLC, by promoting infiltration of immune cells in one or more lesions that have low or no evidence of PD-L1 expression.

[0554] Exemplary embodiments of anti-clusterin antibodies or antigen-binding fragments thereof

[0555] In some embodiments, the anti-clusterin antibodies or antigen-binding fragments thereof of the present disclosure are capable of inhibiting epithelial to mesenchymal transition.

[0556] In some embodiments, the anti-clusterin antibodies or antigen-binding fragments thereof of the present disclosure are capable of binding to amino acids 421 and 443 of the C-terminal portion of the human clusterin α subunit (SEQ ID NO: 41, see PCT / CA2006 / 001505 published as publication number WO2007 / 030930 and International Application No. PCT / CA2010 / 0001882 published as publication number WO2011 / 063523, the entire contents of which are incorporated herein by reference), or an epitope contained within amino acids 421 and 443. Such anti-clusterin antibodies or antigen-binding fragments thereof are exemplified in Table 3, or comprise the CDRs, variable regions, or full chains exemplified in Table 3. It is noted that, in contrast to WO2011 / 063523, which describes a combination of an anti-clusterin antibody and a taxane, the present application provides evidence that the use of the combination therapy described herein, specific doses, treatment regimens, and / or administration schedules can induce tumor regression or stabilization of tumor growth in NSCLC patients.

[0557] In some embodiments, the anti-clusterin antibody or its antigen-binding fragment is an antibody or its antigen-binding fragment that can compete with the anti-clusterin antibody or its antigen-binding fragment of the present disclosure for binding to clusterin (e.g., secreted clusterin (sCLU) or tumor-associated sCLU (TA-sCLU)) or for binding to a polypeptide comprising the amino acid sequence shown in SEQ ID NO:18.

[0558] In some embodiments, CDRs are identified using methods known to those of skill in the art, which are reviewed in Antibody Engineering, Volume 2, Chapter 3, by Andrew CR Martin (incorporated herein by reference in its entirety).

[0559] In a specific embodiment, all CDRs are identified using the Kabat definition (Wu and Kabat, 1970), which is the most commonly used definition.

[0560] In a specific embodiment, all CDRs are identified using the contact definition (MacCallum et al., 1996), which may be most useful for one wishing to perform mutagenesis to alter the affinity of the antibody, since these residues are those involved in interaction with the antigen.

[0561] According to the present disclosure, the anti-aggregin antibody or antigen-binding fragment thereof comprises the CDRs, light chain and heavy chain variable regions or the amino acid sequences of the light chain and heavy chain shown in Table 3.

[0562] In a specific embodiment, the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO:12 and a heavy chain variable region comprising the CDRs of the heavy chain variable region shown in SEQ ID NO:13.

[0563] In some exemplary embodiments, the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region comprising CDRL1 having the amino acid sequence shown in SEQ ID NO:1, CDRL2 having the amino acid sequence shown in SEQ ID NO:2, and CDRL3 having the amino acid sequence shown in SEQ ID NO:3.

[0564] In some exemplary embodiments, the anti-clusterin antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising CDRH1 having the amino acid sequence shown in SEQ ID NO:4, CDRH2 having the amino acid sequence shown in SEQ ID NO:5, and CDRH3 having the amino acid sequence shown in SEQ ID NO:6.

[0565] In some exemplary embodiments, the anti-clusterin antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising CDRH1 having the amino acid sequence shown in SEQ ID NO:7, CDRH2 having the amino acid sequence shown in SEQ ID NO:8, and CDRH3 having the amino acid sequence shown in SEQ ID NO:9.

[0566] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region comprising CDRL1 having the amino acid sequence shown in SEQ ID NO:1, CDRL2 having the amino acid sequence shown in SEQ ID NO:2, and CDRL3 having the amino acid sequence shown in SEQ ID NO:3, and a heavy chain variable region comprising CDRH1 having the amino acid sequence shown in SEQ ID NO:4, CDRH2 having the amino acid sequence shown in SEQ ID NO:5, and CDRH3 having the amino acid sequence shown in SEQ ID NO:6.

[0567] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region comprising CDRL1 having the amino acid sequence shown in SEQ ID NO:1, CDRL2 having the amino acid sequence shown in SEQ ID NO:2, and CDRL3 having the amino acid sequence shown in SEQ ID NO:3, and a heavy chain variable region comprising CDRH1 having the amino acid sequence shown in SEQ ID NO:7, CDRH2 having the amino acid sequence shown in SEQ ID NO:8, and CDRH3 having the amino acid sequence shown in SEQ ID NO:9.

[0568] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region having an amino acid sequence that is at least 80% identical to the amino acid sequence shown in SEQ ID No:10 and a heavy chain variable region having an amino acid sequence that is at least 80% identical to the amino acid sequence shown in SEQ ID NO:11.

[0569] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region having an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID No:10 and a heavy chain variable region having an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:11.

[0570] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region having an amino acid sequence identical to the amino acid sequence shown in SEQ ID NO:10 and a heavy chain variable region having an amino acid sequence identical to the amino acid sequence shown in SEQ ID NO:11.

[0571] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is capable of competing for binding to a clusterin protein (e.g., secreted clusterin (sCLU) or tumor-associated sCLU (TA-sCLU)) with an antibody comprising a light chain variable region having the amino acid sequence shown in SEQ ID NO:10 and a heavy chain variable region having the amino acid sequence shown in SEQ ID NO:11, or competing for binding to a polypeptide comprising the amino acid sequence shown in SEQ ID NO:18.

[0572] According to the present disclosure, an anti-clusterin antibody or an antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region has at least 80%, at least 85%, at least 90%, at least 95%, at least 99% identity to the amino acid sequence shown in SEQ ID NO: 12, or an amino acid sequence that is identical to or includes the amino acid sequence shown in SEQ ID NO: 12, and the heavy chain variable region has at least 80%, at least 85%, at least 90%, at least 95%, at least 99% identity to the amino acid sequence shown in SEQ ID NO: 13, or an amino acid sequence that is identical to or includes the amino acid sequence shown in SEQ ID NO: 13.

[0573] According to the present disclosure, an anti-clusterin antibody or an antigen-binding fragment thereof comprises a light chain and a heavy chain, wherein the light chain has at least 80%, at least 85%, at least 90%, at least 95%, at least 99% identity to the amino acid sequence shown in SEQ ID NO: 14, or an amino acid sequence that is identical to or includes the amino acid sequence shown in SEQ ID NO: 14, and the heavy chain has at least 80%, at least 85%, at least 90%, at least 95%, at least 99% identity to the amino acid sequence shown in SEQ ID NO: 15, or an amino acid sequence that is identical to or includes the amino acid sequence shown in SEQ ID NO: 15.

[0574] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region having an amino acid sequence that is at least 80% identical to the amino acid sequence shown in SEQ ID No:12 and a heavy chain variable region having an amino acid sequence that is at least 80% identical to the amino acid sequence shown in SEQ ID NO:13.

[0575] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region having an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID No:12 and a heavy chain variable region having an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:13.

[0576] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region having an amino acid sequence identical to the amino acid sequence shown in SEQ ID NO:12 and a heavy chain variable region having an amino acid sequence identical to the amino acid sequence shown in SEQ ID NO:13.

[0577] According to the present disclosure, the antibody or its antigen-binding fragment is capable of competing with an antibody comprising a light chain variable region having the amino acid sequence shown in SEQ ID NO: 12 and a heavy chain variable region having the amino acid sequence shown in SEQ ID NO: 13 for binding to a clusterin (e.g., secreted clusterin (sCLU) or tumor-associated sCLU (TA-sCLU)), or competing for binding to a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 18.

[0578] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain and a heavy chain, wherein the light chain has an amino acid sequence that is at least 80% identical to the amino acid sequence shown in SEQ ID NO:14, and the heavy chain has an amino acid sequence that is at least 80% identical to the amino acid sequence shown in SEQ ID NO:15.

[0579] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain having an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:14 and a heavy chain having an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:15.

[0580] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain having an amino acid sequence identical to the amino acid sequence shown in SEQ ID NO:14 and a heavy chain having an amino acid sequence identical to the amino acid sequence shown in SEQ ID NO:15.

[0581] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is capable of competing for binding to a clusterin protein (e.g., secreted clusterin (sCLU) or tumor-associated sCLU (TA-sCLU)) with an antibody comprising a light chain having the amino acid sequence shown in SEQ ID NO:14 and a heavy chain having the amino acid sequence shown in SEQ ID NO:15, or competing for binding to a polypeptide comprising the amino acid sequence shown in SEQ ID NO:18.

[0582] In other specific embodiments, the anti-clusterin antibody or antigen-binding fragment thereof comprises the CDR, variable region or full-chain amino acid sequence of the antibody or antigen-binding fragment thereof listed in Table 3.

[0583] In some embodiments, the anti-Clusterin antibody or antigen-binding fragment thereof is humanized 16B5.

[0584] In some embodiments, the anti-clusterin antibody or antigen-binding fragment thereof is a humanized 16B5 biosimilar.

[0585] The amino acid sequences of murine 16B5, humanized 16B5, murine 21B12, and humanized 21B12 are disclosed in International Application No. PCT / CA2010 / 001882, filed on November 24, 2010, and published on June 3, 2011 as Publication No. WO2011 / 063523 (the entire contents of which are incorporated herein by reference).

[0586] In yet another specific embodiment, the anti-clusterin antibody or antigen-binding fragment thereof may be able to compete with one or more antibodies or antigen-binding fragments thereof listed in Table 3.

[0587] Exemplary embodiments of antibodies or antigen-binding fragments thereof that compete with AB-16B5 include, for example, but are not limited to, antibodies identified as 16B5, 21B12, 20E11, 11E2, and 16C11 disclosed in International Application No. PCT / CA2006 / 001505, filed September 13, 2006, and published as Publication No. WO2007 / 030930 on March 22, 2007, the entire contents of which are incorporated herein by reference. Such anti-clusterin antibodies or antigen-binding fragments thereof are exemplified in Table 3.

[0588] Exemplary embodiments of subjects

[0589] The combination therapies disclosed herein are administered to a subject in need thereof.

[0590] The combination therapies disclosed herein are typically administered to a human subject.

[0591] In some aspects and embodiments of the disclosure, the subject has cancer.

[0592] In other aspects and embodiments of the disclosure, the subject is a subject having cancer and having a functional immune system.

[0593] In other aspects and embodiments of the disclosure, the subject is a subject having cancer and having adequate organ and immune function.

[0594] In some embodiments, the subject has non-small cell lung cancer.

[0595] In some embodiments, the subject has metastatic NSCLC.

[0596] In some embodiments, the subject has stage III to IV NSCLC.

[0597] In other embodiments, the subject has or is selected to have NSCLC that progressed following treatment comprising an immune checkpoint antibody.

[0598] In other embodiments, the subject has or is selected to have NSCLC that progressed following chemotherapy.

[0599] In some embodiments, the subject has received prior treatment with chemotherapy.

[0600] In other embodiments, the subject has or is selected to have NSCLC that is not suitable for or is unlikely to benefit from treatment comprising an immune checkpoint antibody.

[0601] Subjects can be characterized as unsuitable for treatment with PD-1 or PD-L1 immune checkpoint inhibitors based on objective criteria, such as failure of prior therapy containing PD-1 or PD-L1 immune checkpoint inhibitors, expression levels of PD-1 or PD-L1, levels of immune cell infiltration in the tumor environment, etc.

[0602] Based on subjective criteria, such as the physician's assessment of risks and benefits, the subject's overall clinical condition, etc., a subject may be characterized as unlikely to benefit from treatment with a PD-1 or PD-L1 immune checkpoint inhibitor.

[0603] In other embodiments, the subject has or is selected to have NSCLC that has failed prior treatment with an immune checkpoint antibody and platinum-containing dual therapy.

[0604] In some embodiments, the subject has or is selected to have NSCLC that has failed prior therapy comprising an anti-PD-1 immune checkpoint antibody.

[0605] In some embodiments, the subject has or is selected to have NSCLC that has failed prior therapy comprising a PD-L1 immune checkpoint antibody.

[0606] In some embodiments, the subject has or is selected to have NSCLC that has failed prior therapy comprising an anti-PD-1 or PD-L1 immune checkpoint antibody.

[0607] In some embodiments, the subject has or is selected to have NSCLC that has failed prior treatment with an anti-PD-1 immune checkpoint antibody and platinum-containing doublet therapy.

[0608] In some embodiments, the subject has or is selected to have NSCLC that has failed prior treatment with an anti-PD-L1 immune checkpoint antibody and platinum-containing doublet therapy.

[0609] In further embodiments, the subject has or is selected to have NSCLC that has failed prior treatment with an anti-PD-1 or PD-L1 immune checkpoint antibody and platinum-containing doublet therapy.

[0610] According to the present disclosure, dual treatments may be provided simultaneously.

[0611] According to the present disclosure, dual treatments may be provided sequentially.

[0612] In some embodiments, the subject has or is selected to have metastatic NSCLC that has failed prior treatment with an anti-PD-1 or PD-L1 immune checkpoint antibody and platinum-containing doublet therapy.

[0613] In some embodiments, the subject has or is selected to have NSCLC that has failed prior treatment with an immune checkpoint antibody selected from ipilimumab, nivolumab, pembrolizumab, cemiplizumab, atezolizumab, avelumab, or durvalumab, alone or in combination with platinum-based chemotherapy.

[0614] In some embodiments, the subject has or is selected to have NSCLC that has failed prior treatment with pembrolizumab alone or in combination with platinum-based chemotherapy.

[0615] In other embodiments, the subject has or is selected to have metastatic NSCLC that progressed following treatment comprising an immune checkpoint antibody.

[0616] In other embodiments, the subject has or is selected to have metastatic NSCLC that has progressed following chemotherapy.

[0617] In yet other embodiments, the subject has or is selected to have metastatic NSCLC that has failed prior treatment with an immune checkpoint antibody and chemotherapy.

[0618] In other embodiments, the subject has or is selected to have metastatic NSCLC that is not amenable to or is unlikely to benefit from a treatment comprising an immune checkpoint antibody.

[0619] In yet other embodiments, the subject has or is selected to have metastatic NSCLC that has failed prior treatment with an immune checkpoint antibody and platinum-containing doublet therapy.

[0620] In some embodiments, the subject has or is selected to have metastatic NSCLC that has failed prior therapy comprising an anti-PD-1 immune checkpoint antibody.

[0621] In some embodiments, the subject has or is selected to have metastatic NSCLC that has failed prior therapy comprising a PD-L1 immune checkpoint antibody.

[0622] In some embodiments, the subject has or is selected to have metastatic NSCLC that has failed prior therapy comprising an anti-PD-1 or PD-L1 immune checkpoint antibody.

[0623] In some embodiments, the subject has or is selected to have metastatic NSCLC that has failed prior treatment with an anti-PD-1 immune checkpoint antibody and platinum-containing doublet therapy.

[0624] In some embodiments, the subject has or is selected to have metastatic NSCLC that has failed prior treatment with an anti-PD-L1 immune checkpoint antibody and platinum-containing doublet therapy.

[0625] In further embodiments, the subject has or is selected to have metastatic NSCLC that has failed prior treatment with an anti-PD-1 or PD-L1 immune checkpoint antibody and platinum-containing doublet therapy.

[0626] In some embodiments, the subject has or is selected to have metastatic NSCLC that has failed prior treatment with an anti-PD-1 or PD-L1 immune checkpoint antibody and platinum-containing doublet therapy,

[0627] In some embodiments, the subject has or is selected to have metastatic NSCLC that has failed prior treatment with an immune checkpoint antibody selected from ipilimumab, nivolumab, pembrolizumab, cemiplizumab, atezolizumab, avelumab, or durvalumab, alone or in combination with platinum-based chemotherapy.

[0628] In some embodiments, the subject has or is selected to have metastatic NSCLC that has failed prior treatment with pembrolizumab alone or in combination with platinum-based chemotherapy.

[0629] In addition to having or being selected to have NSCLC or metastatic NSCLC, the subject may also have or may be selected to have one or more of the characteristics described herein and / or exemplified below.

[0630] In some embodiments, the subject has or is selected to have one or more lesions with a PD-L1 Tumor Proportion Score ≥ 50%.

[0631] In some embodiments, the subject has or is selected to have one or more lesions with a PD-L1 Tumor Ratio Score <50%.

[0632] In some embodiments, the subject has or is selected to have one or more lesions having a PD-L1 Tumor Ratio Score between 1% and 49%.

[0633] In some embodiments, the subject has or is selected to have one or more lesions with a PD-L1 Tumor Ratio Score ≤ 15%.

[0634] In some embodiments, the subject has or is selected to have one or more lesions with a PD-L1 Tumor Ratio Score < 5%.

[0635] In some embodiments, the subject has or is selected to have one or more lesions with a PD-L1 Tumor Ratio Score ≤ 1%.

[0636] In some embodiments, the subject has or is selected to have one or more lesions with a PD-L1 Tumor Ratio Score < 1%.

[0637] In some embodiments, the subject has or is selected to have one or more lesions with a PD-L1 Tumor Ratio Score of 0%.

[0638] In some embodiments, the tumor proportion score is determined at baseline.

[0639] In some embodiments, the tumor proportion score is determined prior to administration of the combination therapy.

[0640] In some embodiments, the tumor proportion score is determined after first-line treatment.

[0641] In some embodiments, the determination is made at the initiation of combination therapy.

[0642] In some embodiments, the PD-L1 tumor proportion score is determined by a scientist or pathologist.

[0643] In some embodiments, the PD-L1 tumor proportion score is determined according to guidance from a drug regulatory agency (e.g., FDA, EMA, etc.).

[0644] In some embodiments, the subject has or is selected to have one or more lesions that are immunologically cold.

[0645] In some embodiments, the subject has or is selected to have one or more lesions with poor immune cell infiltration. The level of immune cell infiltration can be determined by a trained pathologist. The level of immune cell infiltration can be determined by computer-based quantitative determination of tumor biopsy imaging.

[0646] In some embodiments, the subject has or is selected to have one or more lesions with EMT features or signs showing EMT features. EMT features can be determined by trained pathologists. EMT features can be determined by computer-based quantification of tumor or tumor biopsy imaging.

[0647] According to the present disclosure, the subject is a subject having non-small cell lung cancer (e.g., metastatic non-small cell lung cancer), and is selected based on the following non-exhaustive and non-limiting criteria:

[0648] a) The subject has failed prior treatment with an immune checkpoint antibody, either alone or in combination with chemotherapy;

[0649] b) the subject has one or more lesions poorly infiltrated by immune cells;

[0650] c) the subject has one or more lesions that have EMT characteristics or show signs of EMT characteristics;

[0651] d) The subject has one or more of the criteria listed in any one of a) to c).

[0652] Alternatively, according to the present disclosure, the subject is a subject having non-small cell lung cancer (e.g., metastatic non-small cell lung cancer), and is selected based on the following non-exhaustive and non-limiting criteria;

[0653] a) the subject has not received prior treatment with an anti-PD-L1 antibody, alone or in combination with platinum-based chemotherapy;

[0654] b) The subject has one or more lesions with a PD-L1 tumor proportion score ≤ 15%;

[0655] c) the subject has one or more lesions with poor immune cell infiltration;

[0656] d) the subject has one or more lesions that have or show signs of EMT characteristics, or;

[0657] e) The subject has one or more of the criteria listed in any one of a) to d).

[0658] Thus, subjects may be selected based on one or a combination of criteria disclosed herein.

[0659] In exemplary embodiments, the subject has a functional immune system and / or adequate organ and immune function.

[0660] In an exemplary embodiment, the subject has or is selected to have NSCLC, such as NSCLC, and has not received prior treatment with an anti-PD-L1 antibody.

[0661] In other exemplary embodiments, the subject has or is selected to have NSCLC, such as metastatic NSCLC, and one or more lesions with a PD-L1 Tumor Ratio Score ≤ 15%.

[0662] In another exemplary embodiment, the subject has or is selected to have NSCLC, such as metastatic NSCLC, and has a PD-L1 tumor proportion score ≤ 15%, and has not received prior treatment with an anti-PD-L1 antibody.

[0663] In other exemplary embodiments, the subject has or is selected to have NSCLC, such as metastatic NSCLC, and has a PD-L1 tumor proportion score ≤ 15%, and has one or more lesions with poor immune cell infiltration.

[0664] In other exemplary embodiments, the subject has or is selected to have NSCLC, such as metastatic non-small cell lung cancer, and has a PD-L1 tumor proportion score of <1%.

[0665] In another exemplary embodiment, the subject has or is selected to have NSCLC, such as metastatic non-small cell lung cancer, and has a PD-L1 tumor proportion score <1%, and has not received prior treatment with an anti-PD-L1 antibody.

[0666] In other exemplary embodiments, the subject has or is selected to have NSCLC, such as metastatic non-small cell lung cancer, and has a PD-L1 tumor proportion score <1%, and has one or more lesions with poor immune cell infiltration.

[0667] In some cases, the subject has or is selected to have NSCLC, such as metastatic non-small cell lung cancer, and has failed prior treatment with an immune checkpoint antibody, alone or in combination with chemotherapy.

[0668] In some cases, the subject has or is selected to have NSCLC that has failed first-line, second-line, third-line, or subsequent lines of treatment, such as metastatic non-small cell lung cancer.

[0669] In some cases, the combination therapy is administered as first-line therapy in subjects having or selected to have NSCLC (such as metastatic non-small cell lung cancer) and a PD-L1 tumor proportion score ≤ 15%.

[0670] In some cases, the combination therapy is administered as first-line therapy in subjects having or selected to have NSCLC (such as metastatic non-small cell lung cancer) with a PD-L1 tumor proportion score <1%.

[0671] In some cases, the combination therapy is administered as a second-line therapy in subjects who have NSCLC (such as metastatic non-small cell lung cancer) and who have failed prior treatment with an immune checkpoint antibody, alone or in combination with chemotherapy.

[0672] In some cases, the combination therapy is administered as a second-line therapy in subjects who have NSCLC (such as metastatic non-small cell lung cancer) and who have failed prior treatment with an immune checkpoint antibody, alone or in combination with chemotherapy.

[0673] According to the present disclosure, a subject in need thereof has a tumor that expresses or secretes aggregated protein.

[0674] According to the present disclosure, subjects in need are those who are not immunosuppressed or have not received immunosuppressive drug treatment within 14 days, 13 days, 12 days, 11 days, 10 days, 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days, 2 days or 1 day before treatment. In some embodiments, subjects in need may have received corticosteroids before treatment.

[0675] In some embodiments, the subject is immunocompetent or is selected to be immunocompetent.

[0676] In some embodiments, the subject has not been, or has been selected to be, immunosuppressed.

[0677] In some embodiments, the subject has not received or has chosen not to receive immunosuppressive medication within 7 days prior to treatment.

[0678] According to the present disclosure, a subject in need thereof is a subject who has not received prior treatment with docetaxel.

[0679] It should be understood herein that treatment failure is generally associated with disease progression or undesirable treatment side effects. Thus, in some embodiments, subjects with previous treatment failures include subjects with progressive diseases. In other embodiments, subjects with previous treatment failures include subjects with undesirable side effects associated with previous treatments.

[0680] In some embodiments, the subject has not received prior treatment with docetaxel.

[0681] PD-L1 expression and immune cell infiltration

[0682] PD-L1 expression can be determined using methods known to those skilled in the art.

[0683] In an exemplary embodiment, the PD-L1 tumor proportion score (TPS) is assessed using the 22C3 antibody (Agilent Technologies, Carpinteria, CA, code SK006).

[0684] In another exemplary embodiment, PD-L1 TPS is assessed using the 28-8 antibody (Agilent Technologies, Carpinteria, CA, code SK005; Abeam, Toronto, Canada, catalog number Ab205921).

[0685] In another exemplary embodiment, the D-L1 tumor proportion score TPS is assessed using the SP263 antibody (Roche Diagnostic Ref. 740-4907).

[0686] In additional exemplary embodiments, PD-L1 TPS is assessed using the SP142 antibody (Abeam, Toronto, Canada, Catalog No. Ab228462).

[0687] In additional exemplary embodiments, PD-L1 TPS is assessed using the 73-10 antibody (clone MKP1A07310; Merck KgaA, Darmstadt, Germany; Abeam, Toronto, Canada, catalog number Ab228415).

[0688] PD-L1 expression can be assessed using an anti-PD-L1 antibody appropriate for the type of cancer the subject has.

[0689] PD-L1 expression is usually assessed in tumor cells.

[0690] However, PD-L1 expression can be assessed in tumor cells and tumor-infiltrating immune cells.

[0691] In some cases, PD-L1 expression was assessed by immunohistochemistry.

[0692] In other cases, expression of PD-L1 is assessed by a fluorescence assay, such as by quantitative fluorescence or fluorescence in situ hybridization.

[0693] In some embodiments, the assay is an assay approved by at least one regulatory agency.

[0694] According to the present disclosure, the assay is a diagnostic test (Dx) approved by the U.S. Food and Drug Administration (FDA).

[0695] According to the present disclosure, the assay is an FDA-approved research use test (Rx).

[0696] In an exemplary embodiment, the assay is based on PD-L1 IHC 22C3 pharmDx (Agilent Technologies, Carpinteria, CA, code SK006).

[0697] In another exemplary embodiment, the assay is based on PD-L1 IHC 28-8pharmDx ((Agilent Technologies, Carpinteria, CA, code SK005)).

[0698] In another exemplary embodiment, the assay is based on Ventana PD-L1 (SP263) (Roche Diagnostic Ref. 740-4907).

[0699] In some aspects and embodiments, the immunohistochemistry assay is performed according to the manufacturer's instructions.

[0700] In some embodiments, the assay uses the Autostainer Link 48 immunohistochemistry platform (Dako).

[0701] In some embodiments, the assay uses the Omnis immunohistochemistry platform (Dako).

[0702] In some embodiments, the assay is performed using the Bond-III immunohistochemistry platform (Leica).

[0703] In some embodiments, the assay uses the BenchMark ULTRA immunohistochemistry platform (Ventana).

[0704] Assay results were interpreted using the manufacturer's interpretation manual.

[0705] Exemplary assays are described in Munari, E. et al., 2021, Marchetti, A. et al., 2017, Yoshikawa, K. et al., 2021 (the entire contents of all of which are incorporated herein by reference).

[0706] In some embodiments, the absence or presence of immune cells in the tumor microenvironment can be confirmed by tumor biopsy.

[0707] In other embodiments, the absence or presence of immune cells in the tumor microenvironment can be confirmed by in vivo imaging (e.g., magnetic resonance imaging, e.g., see Jiang X. et al., 2020).

[0708] When the tumor microenvironment is not well infiltrated by immune cells, especially lymphocytes, or when the tumor microenvironment is not inflamed, the tumor can be characterized as "immune cold". Conversely, when infiltration of immune cells, especially lymphocytes, is observed in the tumor microenvironment or when the tumor shows signs of inflammation, the tumor can be characterized as "immune warm" or "immune hot".

[0709] Generally speaking, a pathologist, technologist, trained scientist or trained technician equipped with appropriate reagents and / or instrumentation can determine the absence or presence of immune cells in the tumor microenvironment and thus can evaluate whether a tumor is "immune cold," "immune warm," or "immune hot."

[0710] Exemplary Embodiments of Kits

[0711] In some aspects and embodiments, the present disclosure provides a kit comprising one or more containers comprising at least one dose of an anti-clusterin antibody or antigen-binding fragment thereof, one or more containers comprising at least one dose of a taxane for combination therapy, and a package insert comprising instructions for treating a subject in need thereof.

[0712] The present disclosure provides, in other aspects and embodiments, a kit comprising one or more containers comprising at least one dose of an anti-clusterin antibody or antigen-binding fragment thereof, one or more containers comprising at least one dose of docetaxel for combination therapy, and a package insert comprising instructions for treating a subject in need thereof.

[0713] According to the present disclosure, an anti-clusterin antibody or antigen-binding fragment thereof and docetaxel are provided in separate containers.

[0714] According to the present disclosure, the antibody or antigen-binding fragment thereof is as described herein.

[0715] In some embodiments, the package insert states that the combination therapy is intended for treating a subject described herein.

[0716] In some embodiments, the package insert states that the combination therapy is intended for treating a subject having NSCLC.

[0717] In some embodiments, the package insert states that the combination therapy is intended for treating a subject having metastatic NSCLC, eg, stage III-IV NSCLC.

[0718] In some embodiments, the package insert states that the combination therapy is intended for treating a subject with NSCLC that has progressed following treatment comprising an immune checkpoint antibody.

[0719] In some embodiments, the package insert states that the combination therapy is intended for treating a subject with NSCLC who has failed prior treatment with an immune checkpoint antibody and a platinum-containing doublet therapy.

[0720] In some embodiments, the package insert states that the combination therapy is intended for treating a subject with metastatic NSCLC that has progressed following first-line therapy comprising an immune checkpoint antibody.

[0721] In some embodiments, the package insert states that the combination therapy is intended for treating a subject with metastatic NSCLC who has failed prior treatment comprising an immune checkpoint antibody and a platinum-containing doublet therapy.

[0722] In addition to the embodiments described and provided in this disclosure, the following non-limiting embodiments are specifically contemplated.

[0723] 1. A method of treating a subject having lung cancer, the method comprising administering a combination therapy disclosed herein.

[0724] 2. A method of treating a subject having non-small cell lung cancer, the method comprising administering a combination therapy disclosed herein.

[0725] 3. A method of treating a subject having non-small cell lung cancer, the method comprising administering a combination therapy disclosed herein to achieve and / or maintain clinical benefit.

[0726] 4. The method according to any one of the preceding embodiments, wherein the combination therapy comprises an anti-clusterin antibody or antigen-binding fragment thereof and a taxane.

[0727] 5. A method of obtaining a clinical benefit in a subject suffering from non-small cell lung cancer, the method comprising administering a combination therapy disclosed herein.

[0728] 6. A method of obtaining a clinical benefit in a subject with non-small cell lung cancer in a treatment method comprising administering a combination therapy for at least two treatment cycles, each treatment cycle comprising administering an anti-clusterin antibody once weekly at a dose of about 3 mg / kg to about 20 mg / kg and administering at a dose of about 60 mg / m 2 and 100 mg / m 2 The taxane is administered once every three weeks at a dose of 100 mg / kg to 100 mg / kg of taxane, wherein the anti-clusterin antibody comprises a light chain variable region comprising the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12 and a heavy chain variable region comprising the CDRs of the heavy chain variable region shown in SEQ ID NO: 13.

[0729] 7. A method of obtaining a clinical benefit in a subject with non-small cell lung cancer in a treatment method comprising administering a combination therapy for at least two treatment cycles, each treatment cycle comprising administering an anti-clusterin antibody once weekly at a dose of about 12 mg / kg and administering at a dose of about 75 mg / m 2 Docetaxel is administered once every three weeks at a dose of 100 mg / kg / day, wherein the anti-clusterin antibody comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12, and the heavy chain variable region comprises the CDRs of the heavy chain variable region shown in SEQ ID NO: 13.

[0730] 8. A method of treating a subject having non-small cell lung cancer, the method comprising administering a combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and a taxane, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the complementarity determining regions (CDRs) of the light chain variable region set forth in SEQ ID NO: 12 and a heavy chain variable region comprising the CDRs of the heavy chain variable region set forth in SEQ ID NO: 13.

[0731] 9. A method of treating a subject having non-small cell lung cancer, the method comprising administering a combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and a taxane to obtain a clinical benefit, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the complementarity determining regions (CDRs) of the light chain variable region set forth in SEQ ID NO: 12 and a heavy chain variable region comprising the CDRs of the heavy chain variable region set forth in SEQ ID NO: 13.

[0732] 10. The method according to any one of the preceding embodiments, wherein the taxane is docetaxel or paclitaxel.

[0733] 11. A method of treating non-small cell lung cancer in a subject in need thereof, the method comprising administering a combination therapy for at least two treatment cycles, each treatment cycle comprising administering an anti-clusterin antibody at a dose of about 3 mg / kg to about 20 mg / kg once a week, once every two weeks, or once every three weeks, and administering a combination therapy at a dose of about 50 mg / m 2 About 100 mg / m 2 Docetaxel is administered once every two to three weeks at a dose of 100 mg / kg / day, wherein the anti-clusterin antibody comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12, and the heavy chain variable region comprises the CDRs of the heavy chain variable region shown in SEQ ID NO: 13.

[0734] 12. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of between about 3 mg / kg and about 20 mg / kg.

[0735] 13. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of between about 6 mg / kg and about 20 mg / kg.

[0736] 14. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of between about 6 mg / kg and about 15 mg / kg.

[0737] 15. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of between about 6 mg / kg and about 14 mg / kg.

[0738] 16. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of between about 6 mg / kg and about 13 mg / kg.

[0739] 17. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of between about 6 mg / kg and about 12 mg / kg.

[0740] 18. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of between about 7 mg / kg and about 12 mg / kg.

[0741] 19. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of between about 8 mg / kg and about 12 mg / kg.

[0742] 20. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of between about 9 mg / kg and about 12 mg / kg.

[0743] 21. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of between about 10 mg / kg and about 12 mg / kg.

[0744] 22. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of between about 11 mg / kg and about 12 mg / kg.

[0745] 23. The method of any one of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 3 mg / kg.

[0746] 24. The method of any one of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 6 mg / kg.

[0747] 25. The method of any one of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 9 mg / kg.

[0748] 26. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 12 mg / kg.

[0749] 27. The method according to any one of the preceding embodiments, wherein the taxane is docetaxel.

[0750] 28. The method of any one of the preceding embodiments, wherein the taxane is docetaxel and is administered at a dose of between about 50 mg / m 2 About 100 mg / m 2 Dosages between.

[0751] 29. The method of any one of the preceding embodiments, wherein the taxane is docetaxel and is administered at a dose of between about 60 mg / m 2 About 100 mg / m 2 Dosages between.

[0752] 30. The method of any one of the preceding embodiments, wherein the dosage is between about 60 mg / m 2 About 95 mg / m 2 Docetaxel was administered at doses between 2 and 3 weeks.

[0753] 31. The method of any of the preceding embodiments, wherein the dosage is between about 60 mg / m 2 About 90 mg / m 2 Docetaxel was administered at doses between 2 and 3 weeks.

[0754] 32. The method of any of the preceding embodiments, wherein the dosage is between about 60 mg / m 2 About 85 mg / m 2 Docetaxel was administered at doses between 2 and 3 weeks.

[0755] 33. The method of any of the preceding embodiments, wherein the dosage is between about 60 mg / m 2 About 80 mg / m 2 Docetaxel was administered at doses between 2 and 3 weeks.

[0756] 34. The method of any of the preceding embodiments, wherein the dosage is between about 50 mg / m 2 About 75 mg / m 2 Docetaxel was administered at doses between 2 and 3 weeks.

[0757] 35. The method of any of the preceding embodiments, wherein the dosage is between about 60 mg / m 2 About 75 mg / m 2 Docetaxel was administered at doses between 2 and 3 weeks.

[0758] 36. The method of any of the preceding embodiments, wherein the dosage is between about 75 mg / m 2 About 80 mg / m 2 Docetaxel was administered at doses between 2 and 3 weeks.

[0759] 37. The method of any one of the preceding embodiments, wherein the taxane is docetaxel and is administered at about 50 mg / m 2 dosage administration.

[0760] 38. The method of any one of the preceding embodiments, wherein the taxane is docetaxel and is administered at about 60 mg / m 2 dosage administration.

[0761] 39. The method of any one of the preceding embodiments, wherein the taxane is docetaxel and is administered at about 75 mg / m 2 dosage administration.

[0762] 40. The method of any one of the preceding embodiments, wherein the taxane is docetaxel and the 2 dosage administration.

[0763] 41. The method of any one of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered once a week (once a week).

[0764] 42. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered once every two weeks.

[0765] 43. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered once every three weeks.

[0766] 44. The method of any one of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered once every four weeks.

[0767] 45. The method according to any one of the preceding embodiments, wherein docetaxel is administered once a week.

[0768] 46. ​​The method according to any one of the preceding embodiments, wherein docetaxel is administered once every two weeks.

[0769] 47. The method according to any one of the preceding embodiments, wherein docetaxel is administered once every three weeks.

[0770] 48. The method of any one of the preceding claims, wherein docetaxel is administered once every four weeks.

[0771] 49. A method of treating a subject with non-small cell lung cancer, the method comprising administering a combination therapy to obtain clinical benefit, the combination therapy comprising administering an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg once a week, once every two weeks, once every three weeks, once every four weeks, and administering an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 50 mg / m 2 Up to about 75 mg / m 2 Docetaxel is administered once every two to three weeks at a dose of 100 mg / kg / day, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12, and the heavy chain variable region comprises the CDRs of the heavy chain variable region shown in SEQ ID NO: 13.

[0772] 50. A method of treating non-small cell lung cancer in a subject in need thereof, the method comprising administering a combination therapy for at least two treatment cycles, each treatment cycle comprising administering an anti-clusterin antibody at a dose of about 12 mg / kg once a week, once every two weeks, once every three weeks, or once every four weeks and administering an anti-clusterin antibody at a dose of about 50 mg / m 2 Up to about 75 mg / m 2 Docetaxel is administered once every two to three weeks at a dose of 100 mg / kg / day, wherein the anti-clusterin antibody comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12, and the heavy chain variable region comprises the CDRs of the heavy chain variable region shown in SEQ ID NO: 13.

[0773] 51. The method according to any of the preceding embodiments, wherein the subject is as described herein.

[0774] 52. The method according to any one of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel are administered on the same day.

[0775] 53. The method according to any one of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel are administered on different days.

[0776] 54. The method of any one of the preceding embodiments, wherein the subject has or is selected to have NSCLC that has failed prior treatment with an immune checkpoint antibody.

[0777] 55. The method according to any one of the preceding embodiments, wherein the subject has or is selected to have NSCLC that has failed previous treatment with chemotherapy.

[0778] 56. The method of any one of the preceding embodiments, wherein the subject has or is selected to have NSCLC that has failed prior treatment with an immune checkpoint antibody with or without chemotherapy.

[0779] 57. The method according to any one of the preceding embodiments, wherein the subject has or is selected to have NSCLC that has failed a prior therapy comprising an anti-PD-1 immune checkpoint antibody.

[0780] 58. The method of any one of the preceding embodiments, wherein the subject has or is selected to have NSCLC that has failed prior therapy comprising a programmed death-ligand 1 (PD-L1) immune checkpoint antibody.

[0781] 59. The method of any of the preceding embodiments, wherein the subject has or is selected to have NSCLC that has failed prior therapy comprising an anti-PD-1 or PD-L1 immune checkpoint antibody.

[0782] 60. The method of any one of the preceding embodiments, wherein the subject has or is selected to have NSCLC that has failed prior treatment with immune checkpoint antibodies and chemotherapy.

[0783] 61. The method of any one of the preceding embodiments, wherein the subject has or is selected to have NSCLC that has failed prior treatment with an anti-PD-1 immune checkpoint antibody and platinum-containing doublet therapy.

[0784] 62. The method of any one of the preceding embodiments, wherein the subject has or is selected to have NSCLC that has failed prior treatment with an anti-PD-L1 immune checkpoint antibody and platinum-containing doublet therapy.

[0785] 63. The method of any one of the preceding embodiments, wherein the subject has or is selected to have NSCLC that has failed prior treatment with an anti-PD-1 or PD-L1 immune checkpoint antibody and platinum-containing doublet therapy.

[0786] 64. The method of any one of the preceding embodiments, wherein the immune checkpoint antibody is selected from ipilimumab, nivolumab, pembrolizumab, cemiplizumab, atezolizumab, avelumab, or durvalumab.

[0787] 65. The method of any one of the preceding embodiments, wherein the immune checkpoint antibody is pembrolizumab.

[0788] 66. The method according to any one of the preceding embodiments, wherein the subject has or is selected to have one or more lesions with a PD-L1 Tumor Proportion Score (TPS) ≥ 50%.

[0789] 67. The method according to any one of the preceding embodiments, wherein the subject has or is selected to have one or more lesions with a PD-L1 Tumor Proportion Score (TPS) of less than 50%.

[0790] 68. The method according to any one of the preceding embodiments, wherein the subject has or is selected to have one or more lesions with a PD-L1 Tumor Proportion Score (TPS) between 1% and 49%.

[0791] 69. The method according to any one of the preceding embodiments, wherein the subject has or is selected to have one or more lesions with a PD-L1 Tumor Ratio Score ≤ 15%.

[0792] 70. The method according to any one of the preceding embodiments, wherein the subject has or is selected to have one or more lesions with a PD-L1 Tumor Ratio Score < 5%.

[0793] 71. The method according to any one of the preceding embodiments, wherein the subject has or is selected to have one or more lesions with a PD-L1 Tumor Ratio Score ≤ 1%.

[0794] 72. The method according to any one of the preceding embodiments, wherein the subject has or is selected to have one or more lesions with a PD-L1 Tumor Ratio Score < 1%.

[0795] 73. The method according to any one of the preceding embodiments, wherein the subject has or is selected to have one or more lesions with no evidence of PD-L1 expression.

[0796] 74. The method of any one of the preceding embodiments, wherein the subject has or is selected to have NSCLC that is not suitable for treatment comprising an immune checkpoint antibody.

[0797] 75. The method of any one of the preceding embodiments, wherein the subject has or is selected to have NSCLC and is unlikely to benefit from a treatment comprising an immune checkpoint antibody.

[0798] 76. The method according to any one of the preceding embodiments, wherein the tumor proportion score is determined prior to administration of the combination therapy.

[0799] 77. The method according to any one of the preceding embodiments, wherein the subject has or is selected to have NSCLC characterized as having a KRAS mutation.

[0800] 78. The method according to any one of the preceding embodiments, wherein the subject has or is selected to have NSCLC comprising one or more lesions harboring a KRAS mutation.

[0801] 79. The method according to any one of the preceding embodiments, wherein the subject has or is selected to have a tumor that is poorly infiltrated by immune cells.

[0802] 80. The method of any one of the preceding embodiments, wherein the subject has or is selected to have one or more lesions having EMT characteristics.

[0803] 81. The method of any one of the preceding embodiments, wherein the subject has or is selected to have one or more lesions showing signs of EMT characteristics.

[0804] 82. The method of any one of the preceding embodiments, wherein the combination therapy is administered in a treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof on day 1, day 8, and day 15 and administration of docetaxel on day 1.

[0805] 83. The method according to any of the preceding embodiments, wherein one treatment cycle lasts for 1 week.

[0806] 84. The method according to any of the preceding embodiments, wherein one treatment cycle lasts 2 weeks.

[0807] 85. The method according to any of the preceding embodiments, wherein one treatment cycle lasts 3 weeks.

[0808] 86. The method according to any of the preceding embodiments, wherein one treatment cycle lasts 4 weeks.

[0809] 87. The method according to any of the preceding embodiments, wherein one treatment cycle lasts more than 4 weeks.

[0810] 88. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered by IV infusion.

[0811] 89. The method according to any one of the preceding embodiments, wherein docetaxel is administered by IV infusion.

[0812] 90. The method according to any one of the preceding embodiments, wherein the clinical benefit is regression of lesions.

[0813] 91. The method according to any of the preceding embodiments, wherein the clinical benefit is a reduction in lesion size.

[0814] 92. The method according to any of the preceding embodiments, wherein the clinical benefit is stabilization of lesion size.

[0815] 93. The method according to any one of the preceding embodiments, wherein the clinical benefit is a reduction in the number of tumor cells in the lesion.

[0816] 94. The method according to any of the preceding embodiments, wherein the size of the disease is reduced by at least 5%.

[0817] 95. The method according to any of the preceding embodiments, wherein the size of the disease is reduced by at least 10%.

[0818] 96. The method according to any of the preceding embodiments, wherein the size of the disease is reduced by at least 15%.

[0819] 97. The method according to any of the preceding embodiments, wherein the size of the disease is reduced by at least 20%.

[0820] 98. The method according to any of the preceding embodiments, wherein the size of the disease is reduced by at least 25%.

[0821] 99. The method according to any of the preceding embodiments, wherein the size of the disease is reduced by at least 30%.

[0822] 100. The method according to any of the preceding embodiments, wherein the size of the disease is reduced by at least 35%.

[0823] 101. The method according to any of the preceding embodiments, wherein the size of the disease is reduced by at least 40%.

[0824] 102. The method according to any of the preceding embodiments, wherein the size of the disease is reduced by at least 45%.

[0825] 103. The method according to any of the preceding embodiments, wherein the size of the disease is reduced by at least 50%.

[0826] 104. The method according to any of the preceding embodiments, wherein the clinical benefit is less than a 20% increase in lesion size.

[0827] 105. The method of any one of the preceding embodiments, wherein the clinical benefit is defined according to RECIST 1.1 guidelines.

[0828] 106. The method according to any one of the preceding embodiments, wherein the clinical benefit is improved quality of life.

[0829] 107. The method according to any one of the preceding embodiments, wherein the method achieves clinical benefit for at least 6 weeks after the response to treatment is first determined.

[0830] 108. The method according to any one of the preceding embodiments, wherein the method achieves clinical benefit for at least 12 weeks after the response to treatment is first determined.

[0831] 109. The method according to any one of the preceding embodiments, wherein the method achieves clinical benefit for at least 18 weeks after the response to treatment is first determined.

[0832] 110. The method according to any one of the preceding embodiments, wherein the method achieves clinical benefit for at least 24 weeks after the response to treatment is first determined.

[0833] 111. The method according to any of the preceding embodiments, wherein the method achieves clinical benefit for at least 30 weeks after the response to treatment is first determined.

[0834] 112. The method of any of the preceding embodiments, wherein the method achieves clinical benefit for at least 36 weeks after the response to treatment is first determined.

[0835] 113. The method of any of the preceding embodiments, wherein the method achieves clinical benefit for at least 42 weeks after the response to treatment is first determined.

[0836] 114. The method of any one of the preceding embodiments, wherein the clinical benefit is selected from complete remission (CR) according to RECIST 1.1 guidelines, partial remission (PR) according to RECIST 1.1 guidelines, or stable disease (SD) according to RECIST 1.1 guidelines.

[0837] 115. The method according to any one of the preceding embodiments, wherein the clinical benefit is a partial response (PR) according to RECIST 1.1 guidelines.

[0838] 116. The method according to any one of the preceding embodiments, wherein the clinical benefit is stable disease (SD) according to RECIST 1.1 guidelines.

[0839] 117. The method according to any one of the preceding embodiments, wherein the size of the lesion is assessed according to RECIST 1.1 guidelines.

[0840] 118. The method according to any of the preceding embodiments, wherein the size of the lesion is measured by CT scanning.

[0841] 119. The method according to any one of the preceding embodiments, wherein the clinical benefit is a reduction or elimination of metabolic activity in the lesion.

[0842] 120. The method of any one of the preceding embodiments, wherein the metabolic activity is assessed by PET scanning (eg, (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET)).

[0843] 121. The method of any one of the preceding embodiments, wherein the clinical benefit is assessed using tumor biomarkers.

[0844] 122. The method of any one of the preceding embodiments, wherein the clinical benefit is improvement in symptoms associated with the cancer.

[0845] 123. The method according to any of the preceding embodiments, wherein a clinical benefit is observed after two treatment cycles.

[0846] 124. The method of any of the preceding embodiments, wherein a clinical benefit is observed over at least 12 weeks of treatment.

[0847] 125. The method of any one of the preceding embodiments, wherein a clinical benefit is observed over at least 18 weeks of treatment.

[0848] 126. The method of any one of the preceding embodiments, wherein a clinical benefit is observed over at least 24 weeks of treatment.

[0849] 127. The method of any of the preceding embodiments, wherein a clinical benefit is observed over at least 30 weeks of treatment.

[0850] 128. The method of any of the preceding embodiments, wherein a clinical benefit is observed over at least 36 weeks of treatment.

[0851] 129. The method of any one of the preceding embodiments, wherein a clinical benefit is observed over at least 42 weeks of treatment.

[0852] 130. The method according to any one of the preceding embodiments, wherein upon the occurrence of docetaxel-related toxicity, the dose of docetaxel is reduced or docetaxel treatment is interrupted.

[0853] 131. The method of any of the preceding embodiments, wherein the method comprises administering at least one initial treatment cycle and at least one subsequent treatment cycle, wherein the initial treatment cycle and subsequent treatment cycle are the same or different.

[0854] 132. The method of any of the preceding embodiments, wherein each of the initial treatment cycle and subsequent treatment cycles comprises at least one dose of an anti-clusterin antibody or antigen-binding fragment thereof and at least one dose of docetaxel.

[0855] 133. The method of any of the preceding embodiments, wherein the initial treatment cycle and / or subsequent treatment cycles each independently comprise administration of an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 3 mg / kg to about 20 mg / kg once a week, once every two weeks, or once every three weeks, and administration of about 50 mg / m 2 Up to 100 mg / m 2Docetaxel was administered every two weeks or every three weeks.

[0856] 134. The method of any of the preceding embodiments, wherein the method comprises administering at about 75 mg / m 2 Docetaxel is administered at a dose of once every three weeks and the anti-clusterin antibody or antigen-binding fragment thereof is administered once a week, once every two weeks, or once every three weeks.

[0857] 135. The method of any of the preceding embodiments, wherein the method comprises administering the anti-clusterin antibody or antigen-binding fragment thereof once weekly at a dose of about 12 mg / kg and at a dose of about 75 mg / m 2 Docetaxel was administered once every three weeks.

[0858] 136. The method of any one of the preceding embodiments, wherein the method comprises administering an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg once every three weeks and administering docetaxel at a dose of about 75 mg / m2 once every three weeks.

[0859] 137. The method according to any one of the preceding embodiments, wherein the method comprises administering:

[0860] a. at least one initial treatment cycle comprising once weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg and once weekly administration of about 75 mg / m 2 Docetaxel is administered every three weeks at a dose of ;

[0861] b. at least one subsequent treatment cycle comprising administering an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 3 mg / kg to about 20 mg / kg once every three weeks and at about 75 mg / m 2 Docetaxel was administered once every three weeks.

[0862] 138. The method according to any one of the preceding embodiments, wherein the method comprises administering:

[0863] a. at least one initial treatment cycle comprising once weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg and once weekly administration of about 75 mg / m 2 Docetaxel is administered every three weeks at a dose of ;

[0864] b. at least one subsequent treatment cycle comprising administering an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg once every three weeks and at a dose of about 75 mg / m 2 Docetaxel was administered once every three weeks.

[0865] 139. The method of any of the preceding embodiments, wherein the method comprises administering at about 50 mg / m 2 Docetaxel is administered at a dose of once every two weeks and the anti-clusterin antibody or antigen-binding fragment thereof is administered once a week, once every two weeks, or once every three weeks.

[0866] 140. The method of any of the preceding embodiments, wherein the method comprises administering the anti-clusterin antibody or antigen-binding fragment thereof once weekly at a dose of about 12 mg / kg and at a dose of about 50 mg / m 2 Docetaxel was administered every two weeks at a dose of .

[0867] 141. The method of any of the preceding embodiments, wherein the method comprises administering the anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg once every two weeks and at a dose of about 50 mg / m 2 Docetaxel was administered every two weeks at a dose of .

[0868] 142. The method according to any one of the preceding embodiments, wherein the method comprises administering:

[0869] a) at least one initial treatment cycle comprising once weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg and once weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 50 mg / m 2 Docetaxel is administered every two weeks at a dose of ;

[0870] b) at least one subsequent treatment cycle comprising administering the anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 3 mg / kg to about 20 mg / kg once every two weeks and at about 50 mg / m 2 Docetaxel was administered every two weeks at a dose of .

[0871] 143. The method according to any one of the preceding embodiments, wherein the method comprises administering:

[0872] a) at least one initial treatment cycle comprising once weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg and once weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 50 mg / m 2 Docetaxel is administered every two weeks at a dose of ;

[0873] b) at least one subsequent treatment cycle comprising administering the anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg once every two weeks and at a dose of about 50 mg / m 2 Docetaxel was administered every two weeks at a dose of .

[0874] 144. The method of any of the preceding embodiments, wherein the combination therapy is administered for two or more treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once every two weeks and administration of docetaxel once every two weeks.

[0875] 145. The method of any of the preceding embodiments, wherein the combination therapy is administered for two or more treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once every three weeks and administration of docetaxel once every three weeks.

[0876] 146. The method according to any one of the preceding embodiments, wherein the combination therapy is administered for at least 2 cycles.

[0877] 147. The method according to any one of the preceding embodiments, wherein the combination therapy is administered for at least 3 cycles.

[0878] 148. The method according to any one of the preceding embodiments, wherein the combination therapy is administered for at least 4 cycles.

[0879] 149. The method according to any one of the preceding embodiments, wherein the combination therapy is administered for at least 5 cycles.

[0880] 150. The method according to any one of the preceding embodiments, wherein the combination therapy is administered for at least 6 cycles.

[0881] 151. The method according to any one of the preceding embodiments, wherein the combination therapy is administered for at least 7 cycles.

[0882] 152. The method according to any one of the preceding embodiments, wherein the combination therapy is administered for at least 8 cycles.

[0883] 153. The method according to any one of the preceding embodiments, wherein the combination therapy is administered for at least 9 cycles.

[0884] 154. The method according to any one of the preceding embodiments, wherein the combination therapy is administered for at least 10 cycles.

[0885] 155. The method according to any one of the preceding embodiments, wherein the combination therapy is administered for at least 11 cycles.

[0886] 156. The method according to any one of the preceding embodiments, wherein the combination therapy is administered for more than 11 cycles.

[0887] 157. The method according to any one of the preceding embodiments, wherein the combination therapy is administered for at least 12 cycles.

[0888] 158. The method according to any one of the preceding embodiments, wherein the combination therapy is administered for at least 14 cycles.

[0889] 159. The method according to any one of the preceding embodiments, wherein the combination therapy is administered for at least 16 cycles.

[0890] 160. The method according to any one of the preceding embodiments, wherein the combination therapy is administered for at least 18 cycles.

[0891] 161. The method according to any one of the preceding embodiments, wherein the combination therapy is administered for at least 20 cycles.

[0892] 162. The method according to any one of the preceding embodiments, wherein the combination therapy is administered for at least 22 cycles.

[0893] 163. The method of any one of the preceding embodiments, wherein the administration of the combination therapy is administered for at least one to at least five initial treatment cycles.

[0894] 164. The method according to any one of the preceding embodiments, wherein the combination therapy is administered for two or more subsequent treatment cycles.

[0895] 165. The method of any of the preceding embodiments, wherein the combination therapy is administered for at least one treatment cycle comprising weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof and every three weeks administration of docetaxel.

[0896] 166. The method of any of the preceding embodiments, wherein the combination therapy is administered for at least two treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and docetaxel once every three weeks.

[0897] 167. The method of any of the preceding embodiments, wherein the combination therapy is administered for at least three treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and docetaxel once every three weeks.

[0898] 168. The method of any of the preceding embodiments, wherein the combination therapy is administered for at least four treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and docetaxel once every three weeks.

[0899] 169. The method of any of the preceding embodiments, wherein the combination therapy is administered for at least four or more treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and docetaxel once every three weeks.

[0900] 170. The method of any of the preceding embodiments, wherein the combination therapy is administered for at least five treatment cycles, each treatment cycle comprising weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof and once every three weeks administration of docetaxel.

[0901] 171. The method of any of the preceding embodiments, wherein the combination therapy is administered for at least six treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and docetaxel once every three weeks.

[0902] 172. The method of any of the preceding embodiments, wherein the combination therapy is administered for at least seven treatment cycles, each treatment cycle comprising weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof and once every three weeks administration of docetaxel.

[0903] 173. The method of any of the preceding embodiments, wherein the combination therapy is administered for at least eight treatment cycles, each treatment cycle comprising weekly administration of an anti-clusterin antibody or antigen-binding fragment thereof and once every three weeks administration of docetaxel.

[0904] 174. The method of any of the preceding embodiments, wherein the combination therapy is administered for at least nine treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and docetaxel once every three weeks.

[0905] 175. The method of any of the preceding embodiments, wherein the combination therapy is administered for at least ten treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once per week and docetaxel once every three weeks.

[0906] 176. The method of any of the preceding embodiments, wherein the combination therapy is administered for at least eleven treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and docetaxel once every three weeks.

[0907] 177. The method of any of the preceding embodiments, wherein the combination therapy is administered for at least twelve treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once a week and docetaxel once every three weeks.

[0908] 178. The method of any of the preceding embodiments, wherein the combination therapy is administered for more than twelve treatment cycles, each treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof once per week and docetaxel once every three weeks.

[0909] 179. The method according to any of the preceding embodiments, wherein the treatment cycles are continuous.

[0910] 180. The method according to any of the preceding embodiments, wherein the combination therapy is administered as long as a clinical benefit is observed.

[0911] 181. The method according to any one of the preceding embodiments, wherein the combination therapy is administered until tumor progression.

[0912] 182. The method according to any of the preceding embodiments, wherein the combination therapy is administered until uncontrollable toxicity occurs.

[0913] 183. The method of any of the preceding embodiments, wherein administration of the anti-clusterin antibody or antigen-binding fragment thereof is maintained after clinical benefit occurs.

[0914] 184. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof inhibits epithelial to mesenchymal transition.

[0915] 185. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is capable of binding to the C-terminal portion of the α-subunit of human clusterin.

[0916] 186. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is capable of binding to amino acids 421 and 443 of the C-terminal portion of the α-subunit of human clusterin or an epitope contained within amino acids 421 and 443.

[0917] 187. A method according to any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprising the complementarity determining region (CDR) of the light chain variable region shown in SEQ ID NO:12, and the heavy chain variable region comprising the CDR of the heavy chain variable region shown in SEQ ID NO:13.

[0918] 188. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises a CDR having an amino acid sequence shown in SEQ ID NO: 1 (CDRL1), SEQ ID NO: 2 (CDRL2) and SEQ ID NO: 3 (CDRL3), and the heavy chain variable region comprises a CDR having an amino acid sequence shown in SEQ ID NO: 4 (CDRH1), SEQ ID NO: 5 (CDRH2) and SEQ ID NO: 6 (CDRH3).

[0919] 189. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises a CDR having an amino acid sequence shown in SEQ ID NO: 1 (CDRL1), SEQ ID NO: 2 (CDRL2) and SEQ ID NO: 3 (CDRL3), and the heavy chain variable region comprises a CDR having an amino acid sequence shown in SEQ ID NO: 7 (CDRH1), SEQ ID NO: 8 (CDRH2) and SEQ ID NO: 9 (CDRH3).

[0920] 190. The method of any one of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises:

[0921] a. a light chain variable region having an amino acid sequence that is at least 80% identical to the amino acid sequence shown in SEQ ID NO: 12, and a heavy chain variable region having an amino acid sequence that is at least 80% identical to the amino acid sequence shown in SEQ ID NO: 13, or;

[0922] b. a light chain having an amino acid sequence at least 80% identical to the amino acid sequence shown in SEQ ID NO:14, and a heavy chain having an amino acid sequence at least 80% identical to the amino acid sequence shown in SEQ ID NO:15.

[0923] 191. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region having the amino acid sequence shown in SEQ ID NO:12 and a heavy chain variable region having the amino acid sequence shown in SEQ ID NO:13.

[0924] 192. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain having the amino acid sequence shown in SEQ ID NO:14 and a heavy chain having the amino acid sequence shown in SEQ ID NO:15.

[0925] 193. The method of any of the preceding embodiments, wherein the subject is not immunosuppressed or has not received immunosuppressive medication within 7 days prior to treatment.

[0926] 194. The method according to any one of the preceding embodiments, wherein the subject has not previously received docetaxel treatment.

[0927] 195. The method of any of the preceding embodiments, wherein the subject is not receiving concurrent anti-cancer therapy with anti-clusterin antibody or antigen-binding fragment thereof and / or docetaxel combination therapy.

[0928] 196. The method of any of the preceding embodiments, wherein the subject is a human subject.

[0929] 197. The method of any of the preceding embodiments, wherein the subject has a functional immune system.

[0930] 198. The method of any of the preceding embodiments, wherein the subject has adequate organ and / or immune function.

[0931] 199. The method according to any one of the preceding embodiments, wherein the NSCLC is metastatic NSCLC.

[0932] 200. The method according to any one of the preceding embodiments, wherein the metastatic NSCLC is stage III NSCLC.

[0933] 201. The method according to any one of the preceding embodiments, wherein the metastatic NSCLC is stage IV NSCLC.

[0934] 202. The method according to any one of the preceding embodiments, wherein the metastatic NSCLC is stage III to IV NSCLC.

[0935] 203. The method of any one of the preceding embodiments, wherein the subject having NSCLC is a subject having metastatic NSCLC.

[0936] 204. The method of any one of the preceding embodiments, wherein the subject having metastatic NSCLC is a subject having stage III NSCLC.

[0937] 205. The method of any one of the preceding embodiments, wherein the subject having metastatic NSCLC is a subject having stage IV NSCLC.

[0938] 206. The method according to any one of the preceding embodiments, wherein the subject has or is selected to have stage III to IV NSCLC.

[0939] 207. The method of any of the preceding embodiments, wherein the method comprises the step of promoting infiltration of immune cells in the tumor microenvironment of one or more lesions.

[0940] 208. The method of any of the preceding embodiments, wherein the method promotes infiltration of immune cells in the tumor microenvironment of one or more lesions.

[0941] 209. The method of any of the preceding embodiments, wherein the method comprises administering immunotherapy subsequent to the combination therapy.

[0942] 210. The method according to any of the preceding embodiments, wherein the lesion is a tumor metastasis.

[0943] 211. The method according to any of the preceding embodiments, wherein the lesion is a primary tumor.

[0944] 212. The method of any of the preceding embodiments, wherein one or more lesions have a PD-L1 tumor proportion score (TPS) of ≤ 15%.

[0945] 213. The method of any of the preceding embodiments, wherein one or more lesions have a PD-L1 tumor proportion score (TPS) of <5%.

[0946] 214. The method of any of the preceding embodiments, wherein one or more lesions have a PD-L1 tumor proportion score (TPS) of ≤ 1%.

[0947] 215. The method of any of the preceding embodiments, wherein one or more lesions have a PD-L1 tumor proportion score (TPS) of <1%.

[0948] 216. The method of any of the preceding embodiments, wherein one or more lesions have a PD-L1 Comprehensive Positive Score (CPS) of <10%.

[0949] 217. The method of any of the preceding embodiments, wherein one or more lesions have a PD-L1 Comprehensive Positive Score (CPS) of <5%.

[0950] 218. The method of any of the preceding embodiments, wherein one or more lesions have a PD-L1 Comprehensive Positive Score (CPS) of <1%.

[0951] 219. The method of any one of the preceding embodiments, wherein PD-L1 expression is undetectable or not assessable.

[0952] 220. The method of any of the preceding embodiments, wherein one or more lesions are characterized as being immunologically cold.

[0953] 221. The method according to any one of the preceding embodiments, wherein the combination therapy is provided as first-line therapy.

[0954] 222. The method according to any one of the preceding embodiments, wherein the combination therapy is provided as a second-line therapy.

[0955] 223. The method according to any one of the preceding embodiments, wherein the combination therapy is provided as a follow-up therapy.

[0956] 224. The method of any of the preceding embodiments, wherein a therapeutically effective combination therapy is administered to the subject.

[0957] 225. The method according to any one of the preceding embodiments, wherein docetaxel is discontinued.

[0958] 226. The method according to any one of the preceding embodiments, wherein docetaxel is interrupted upon the appearance of signs of toxicity and treatment with the anti-clusterin antibody or antigen-binding fragment thereof is continued.

[0959] 227. The method according to any one of the preceding embodiments, wherein docetaxel is discontinued during one or more treatment cycles.

[0960] 228. The method of any of the preceding embodiments, wherein one or more cycles of docetaxel treatment are discontinued upon the appearance of signs of toxicity and treatment with the anti-clusterin antibody or antigen-binding fragment thereof is continued.

[0961] 229. The method of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is a conventional antibody.

[0962] 230. A combination therapy for use in the method of any one of the preceding embodiments.

[0963] 231. A combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and a taxane.

[0964] 232. A combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and a taxane for treating lung cancer.

[0965] 233. A therapeutically effective combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and a taxane for treating non-small cell lung cancer (NSCLC) in a subject in need thereof.

[0966] 234. A combination therapy comprising an anti-clusterin antibody or an antigen-binding fragment thereof and a taxane for treating a subject with non-small cell lung cancer, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12, and the heavy chain variable region comprises the CDRs of the heavy chain variable region shown in SEQ ID NO: 13.

[0967] 235. A combination therapy comprising an anti-clusterin antibody or an antigen-binding fragment thereof and a taxane for obtaining a clinical benefit for a subject with non-small cell lung cancer, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the complementarity determining regions (CDRs) of the light chain variable region set forth in SEQ ID NO: 12 and a heavy chain variable region comprising the CDRs of the heavy chain variable region set forth in SEQ ID NO: 13.

[0968] 236. The combination therapy according to any one of the preceding embodiments, wherein the taxane is docetaxel or paclitaxel.

[0969] 237. The combination therapy of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of between about 3 mg / kg and about 20 mg / kg.

[0970] 238. The combination therapy of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of between about 6 mg / kg and about 20 mg / kg.

[0971] 239. The combination therapy of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of between about 6 mg / kg and about 15 mg / kg.

[0972] 240. The combination therapy of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of between about 6 mg / kg and about 14 mg / kg.

[0973] 241. The combination therapy of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of between about 6 mg / kg and about 13 mg / kg.

[0974] 242. The combination therapy of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of between about 6 mg / kg and about 12 mg / kg.

[0975] 243. The combination therapy of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of between about 7 mg / kg and about 12 mg / kg.

[0976] 244. The combination therapy of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of between about 8 mg / kg and about 12 mg / kg.

[0977] 245. The combination therapy of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of between about 9 mg / kg and about 12 mg / kg.

[0978] 246. The combination therapy of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of between about 10 mg / kg and about 12 mg / kg.

[0979] 247. The combination therapy of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of between about 11 mg / kg and about 12 mg / kg.

[0980] 248. The combination therapy of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of about 12 mg / kg.

[0981] 249. The combination therapy according to any one of the preceding embodiments, wherein the taxane is docetaxel.

[0982] 250. The combination therapy of any of the preceding embodiments, wherein the taxane is docetaxel and is formulated at between about 50 mg / m 2 About 100 mg / m 2 Dosages between.

[0983] 251. The combination therapy of any of the preceding embodiments, wherein the taxane is docetaxel and is formulated at between about 60 mg / m 2 About 100 mg / m 2 Dosages between.

[0984] 252. The combination therapy of any of the preceding embodiments, wherein docetaxel is formulated at between about 60 mg / m 2 About 95 mg / m 2 Dosages between.

[0985] 253. The combination therapy of any of the preceding embodiments, wherein docetaxel is formulated at between about 60 mg / m 2 About 90 mg / m 2 Dosages between.

[0986] 254. The combination therapy of any of the preceding embodiments, wherein docetaxel is formulated at between about 60 mg / m 2 About 85 mg / m 2 Dosages between.

[0987] 255. The combination therapy of any of the preceding embodiments, wherein docetaxel is formulated at between about 60 mg / m 2 About 80 mg / m 2 Dosages between.

[0988] 256. The combination therapy of any of the preceding embodiments, wherein docetaxel is formulated at between about 50 mg / m 2 About 75 mg / m 2 Dosages between.

[0989] 257. The combination therapy of any of the preceding embodiments, wherein docetaxel is formulated at between about 60 mg / m 2 About 75 mg / m 2 Dosages between.

[0990] 258. The combination therapy of any of the preceding embodiments, wherein docetaxel is formulated at between about 75 mg / m 2 About 80 mg / m 2 Dosages between.

[0991] 259. The combination therapy of any of the preceding embodiments, wherein docetaxel is formulated at about 50 mg / m 2 dosage administration.

[0992] 260. The combination therapy of any one of the preceding embodiments, wherein docetaxel is formulated for administration at a dose of about 75 mg / m2.

[0993] 261. A combination therapy comprising an anti-clusterin antibody or an antigen-binding fragment thereof and docetaxel for obtaining a clinical benefit for a subject with non-small cell lung cancer, wherein the anti-clusterin antibody or antigen-binding fragment thereof is formulated for administration at a dose of about 12 mg / kg and comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises the complementarity determining regions (CDRs) of the light chain variable region set forth in SEQ ID NO: 12, and the heavy chain variable region comprises the CDRs of the heavy chain variable region set forth in SEQ ID NO: 13, and docetaxel is formulated for administration at a dose of about 50 mg / m 2 Up to about 75 mg / m 2 dosage administration.

[0994] 262. A combination therapy for obtaining clinical benefit in a subject with non-small cell lung cancer, wherein the combination therapy is used for at least two treatment cycles, each treatment cycle comprising administering an anti-clusterin antibody once weekly at a dose of about 3 mg / kg to about 20 mg / kg and administering at about 60 mg / m 2 Up to 100 mg / m2 The taxane is administered once every three weeks at a dose of 100 mg / kg to 100 mg / kg of taxane, wherein the anti-clusterin antibody comprises a light chain variable region comprising the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12 and a heavy chain variable region comprising the CDRs of the heavy chain variable region shown in SEQ ID NO: 13.

[0995] 263. A combination therapy for obtaining clinical benefit in a subject with non-small cell lung cancer, wherein the combination therapy is used for at least two treatment cycles, each treatment cycle comprising administering an anti-clusterin antibody once weekly at a dose of about 12 mg / kg and administering at a dose of about 50 mg / m 2 Up to about 75 mg / m 2 Docetaxel is administered once every three weeks at a dose of 100 mg / kg / day, wherein the anti-clusterin antibody comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12, and the heavy chain variable region comprises the CDRs of the heavy chain variable region shown in SEQ ID NO: 13.

[0996] 264. The combination therapy of any one of the preceding embodiments, wherein the combination therapy is for a subject described herein.

[0997] 265. The combination therapy of any one of the preceding embodiments, wherein the combination therapy is for use in subjects having or selected to have NSCLC that has failed prior treatment with an immune checkpoint antibody.

[0998] 266. The combination therapy according to any one of the preceding embodiments, wherein the combination therapy is for use in a subject having or selected to have NSCLC that has failed prior treatment with chemotherapy.

[0999] 267. The combination therapy of any one of the preceding embodiments, wherein the combination therapy is for use in subjects having or selected to have NSCLC that has failed prior treatment with an anti-PD-1 immune checkpoint antibody.

[1000] 268. The combination therapy of any one of the preceding embodiments, wherein the combination therapy is for use in subjects having or selected to have NSCLC that has failed treatment with a PD-L1 immune checkpoint antibody.

[1001] 269. The combination therapy of any one of the preceding embodiments, wherein the combination therapy is for use in subjects having or selected to have NSCLC that has failed prior treatment with an anti-PD-1 or PD-L1 immune checkpoint antibody.

[1002] 270. The combination therapy of any one of the preceding embodiments, wherein the combination therapy is for a subject having or selected to have NSCLC that has failed treatment with an immune checkpoint antibody and chemotherapy. The combination therapy of any one of the preceding embodiments, wherein the combination therapy is for a subject having or selected to have NSCLC that has failed treatment with an anti-PD-1 immune checkpoint antibody and platinum-containing double therapy.

[1003] 271. The combination therapy of any one of the preceding embodiments, wherein the combination therapy is for use in subjects having or selected to have NSCLC that has failed prior treatment with an anti-PD-L1 immune checkpoint antibody and platinum-containing doublet therapy.

[1004] 272. The combination therapy of any one of the preceding embodiments, wherein the combination therapy is for use in subjects having or selected to have NSCLC who have failed prior treatment with an anti-PD-1 or PD-L1 immune checkpoint antibody and platinum-containing doublet therapy.

[1005] 273. The combination therapy of any one of the preceding embodiments, wherein the combination therapy is used in subjects having or selected to have a PD-L1 Tumor Ratio Score of ≥50%.

[1006] 274. The combination therapy of any one of the preceding embodiments, wherein the combination therapy is for subjects having or selected to have a PD-L1 Tumor Ratio Score of <50%.

[1007] 275. The combination therapy according to any one of the preceding embodiments, wherein the combination therapy is for subjects having or selected to have a PD-L1 Tumor Ratio Score between 1% and 49%.

[1008] 276. The combination therapy of any one of the preceding embodiments, wherein the subject has or is selected to have one or more lesions with a PD-L1 Tumor Ratio Score ≤ 15%.

[1009] 277. The combination therapy of any one of the preceding embodiments, wherein the subject has or is selected to have one or more lesions with a PD-L1 Tumor Ratio Score <5%.

[1010] 278. The combination therapy of any one of the preceding embodiments, wherein the subject has or is selected to have one or more lesions with a PD-L1 Tumor Ratio Score ≤ 1%.

[1011] 279. The combination therapy of any one of the preceding embodiments, wherein the combination therapy is for subjects having or selected to have a PD-L1 Tumor Ratio Score of <1%.

[1012] 280. The combination therapy according to any one of the preceding embodiments, wherein the subject has or is selected to have one or more lesions with no evidence of PD-L1 expression.

[1013] 281. The combination therapy of any of the preceding embodiments, wherein the subject has or is selected to have NSCLC that is not suitable for treatment comprising an immune checkpoint antibody.

[1014] 282. The combination therapy of any of the preceding embodiments, wherein the subject has or is selected to have NSCLC and is unlikely to benefit from a treatment comprising an immune checkpoint antibody.

[1015] 283. The combination therapy according to any of the preceding embodiments, wherein the tumor proportion score is determined at baseline.

[1016] 284. The combination therapy according to any of the preceding embodiments, wherein the tumor proportion score is determined prior to administration of the combination therapy.

[1017] 285. The combination therapy of any one of the preceding embodiments, wherein the combination therapy is for use in a subject having NSCLC characterized as having a KRAS mutation.

[1018] 286. The combination therapy of any one of the preceding embodiments, wherein the combination therapy is for use in a subject having NSCLC comprising one or more lesions harboring a KRAS mutation.

[1019] 287. The combination therapy of any one of the preceding embodiments, wherein the combination therapy is used in subjects having or selected to have tumors with poor immune cell infiltration.

[1020] 288. The combination therapy of any of the preceding embodiments, wherein the combination therapy is used in a subject having or selected to have a lesion that exhibits one or more signs of EMT characteristics.

[1021] 289. The combination therapy of any of the preceding embodiments, wherein the combination therapy is used in a subject having or selected to have a lesion that exhibits one or more signs of EMT characteristics.

[1022] 290. The combination therapy of any of the preceding embodiments, wherein the combination therapy is for administration in a treatment cycle comprising administration of an anti-clusterin antibody or antigen-binding fragment thereof on days 1, 8, and 15 and administration of docetaxel on day 1.

[1023] 291. The combination therapy of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof is used as an IV infusion.

[1024] 292. The combination therapy according to any one of the preceding embodiments, wherein docetaxel is used as an IV infusion.

[1025] 293. The combination therapy according to any one of the preceding embodiments, wherein the clinical benefit is regression or lesions.

[1026] 294. The combination therapy of any one of the preceding embodiments, wherein the clinical benefit is a reduction in lesion size.

[1027] 295. The combination therapy of any one of the preceding embodiments, wherein the clinical benefit is stabilization of lesion size.

[1028] 296. The combination therapy of any of the preceding embodiments, wherein the clinical benefit is stabilization of lesion size.

[1029] 297. The combination therapy of any of the preceding embodiments, wherein the clinical benefit is a reduction in the number of tumor cells in the lesion.

[1030] 298. The combination therapy of any of the preceding embodiments, wherein clinical benefit is defined according to RECIST 1.1 guidelines.

[1031] 299. The combination therapy of any of the preceding embodiments, wherein the use achieves clinical benefit for at least 6 weeks after the response to treatment is first determined.

[1032] 300. The combination therapy according to any one of the preceding embodiments, wherein the use achieves clinical benefit for at least 12 weeks after the response to treatment is first determined.

[1033] 301. The combination therapy of any of the preceding embodiments, wherein the use achieves clinical benefit for at least 18 weeks after the response to treatment is first determined.

[1034] 302. The combination therapy of any one of the preceding embodiments, wherein the use achieves clinical benefit for at least 24 weeks after the response to treatment is first determined.

[1035] 303. The combination therapy of any one of the preceding embodiments, wherein the use achieves clinical benefit for at least 30 weeks after the response to treatment is first determined.

[1036] 304. The combination therapy of any one of the preceding embodiments, wherein the use achieves clinical benefit for at least 36 weeks after the response to treatment is first determined.

[1037] 305. The combination therapy of any one of the preceding embodiments, wherein the use achieves clinical benefit for at least 42 weeks after the response to treatment is first determined.

[1038] 306. The combination therapy of any one of the preceding embodiments, wherein the clinical benefit is selected from complete remission (CR) according to RECIST 1.1 guidelines, partial remission (PR) according to RECIST 1.1 guidelines, or stable disease (SD) according to RECIST 1.1 guidelines.

[1039] 307. The combination therapy of any one of the preceding embodiments, wherein the clinical benefit is a partial response (PR) according to RECIST 1.1 guidelines.

[1040] 308. The combination therapy according to any one of the preceding embodiments, wherein the clinical benefit is stable disease (SD) according to RECIST 1.1 guidelines.

[1041] 309. The combination therapy according to any of the preceding embodiments, wherein the size of the lesions is assessed according to RECIST 1.1 guidelines.

[1042] 310. The combination therapy according to any one of the preceding embodiments, wherein the clinical benefit is a reduction or elimination of metabolic activity in the lesion.

[1043] 311. The combination therapy of any one of the preceding embodiments, wherein the clinical benefit is improvement in symptoms associated with the cancer.

[1044] 312. The combination therapy according to any one of the preceding embodiments, wherein the combination therapy is for administration in at least two treatment cycles.

[1045] 313. The combination therapy of any of the preceding embodiments, wherein the combination therapy is used as long as a clinical benefit is observed.

[1046] 314. The combination therapy according to any of the preceding embodiments, wherein the combination therapy is used until tumor progression.

[1047] 315. The combination therapy according to any of the preceding embodiments, wherein the combination therapy is used until unmanageable toxicity occurs.

[1048] 316. The combination therapy of any of the preceding embodiments, wherein use of the anti-clusterin antibody or antigen-binding fragment thereof is maintained after clinical benefit occurs.

[1049] 317. The combination therapy of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof inhibits epithelial to mesenchymal transition.

[1050] 318. The combination therapy of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises a CDR having an amino acid sequence shown in SEQ ID NO: 1 (CDRL1), SEQ ID NO: 2 (CDRL2) and SEQ ID NO: 3 (CDRL3), and the heavy chain variable region comprises a CDR having an amino acid sequence shown in SEQ ID NO: 4 (CDRH1), SEQ ID NO: 5 (CDRH2) and SEQ ID NO: 6 (CDRH3).

[1051] 319. The combination therapy of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises a CDR having an amino acid sequence shown in SEQ ID NO: 1 (CDRL1), SEQ ID NO: 2 (CDRL2) and SEQ ID NO: 3 (CDRL3), and the heavy chain variable region comprises a CDR having an amino acid sequence shown in SEQ ID NO: 7 (CDRH1), SEQ ID NO: 8 (CDRH2) and SEQ ID NO: 9 (CDRH3).

[1052] 320. The combination therapy of any one of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises:

[1053] a. a light chain variable region having an amino acid sequence that is at least 80% identical to the amino acid sequence shown in SEQ ID NO: 12, and a heavy chain variable region having an amino acid sequence that is at least 80% identical to the amino acid sequence shown in SEQ ID NO: 13, or;

[1054] b. a light chain having an amino acid sequence at least 80% identical to the amino acid sequence shown in SEQ ID NO:14, and a heavy chain having an amino acid sequence at least 80% identical to the amino acid sequence shown in SEQ ID NO:15.

[1055] 321. The combination therapy of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region having the amino acid sequence shown in SEQ ID NO:12 and a heavy chain variable region having the amino acid sequence shown in SEQ ID NO:13.

[1056] 322. The combination therapy of any of the preceding embodiments, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain having the amino acid sequence shown in SEQ ID NO:14 and a heavy chain having the amino acid sequence shown in SEQ ID NO:15.

[1057] 323. The combination therapy of any one of the preceding embodiments, wherein the combination therapy is used in subjects who are not immunosuppressed or have not received immunosuppressive medication within 7 days prior to treatment,

[1058] 324. The combination therapy according to any one of the preceding embodiments, wherein the combination therapy is for a subject who has not previously received docetaxel treatment.

[1059] 325. The combination therapy of any one of the preceding embodiments, wherein the combination therapy is for use in a subject who is not receiving concurrent anti-cancer therapy with an anti-clusterin antibody or antigen-binding fragment thereof and / or docetaxel combination therapy.

[1060] 326. The combination therapy according to any one of the preceding embodiments, wherein the combination therapy is for use in humans.

[1061] 327. The combination therapy of any of the preceding embodiments, wherein the combination therapy is used in a subject with a functional immune system.

[1062] 328. The combination therapy of any of the preceding embodiments, wherein the combination therapy is used in subjects with adequate organ and immune function.

[1063] 329. The combination therapy according to any one of the preceding embodiments, wherein the combination therapy is used as a first-line therapy.

[1064] 330. The combination therapy according to any one of the preceding embodiments, wherein the combination therapy is used as a second-line therapy.

[1065] 331. The combination therapy according to any one of the preceding embodiments, wherein the combination therapy is used to treat non-small cell lung cancer.

[1066] 332. The combination therapy of any of the preceding embodiments, wherein the NSCLC is metastatic NSCLC.

[1067] 333. The combination therapy of any of the preceding embodiments, wherein the metastatic NSCLC is stage III non-NSCLC.

[1068] 334. The combination therapy of any of the preceding embodiments, wherein the metastatic NSCLC is stage IV non-NSCLC.

[1069] 335. The combination therapy of any one of the preceding embodiments, wherein the metastatic NSCLC is stage III to IV NSCLC.

[1070] 336. The combination therapy of any one of the preceding embodiments, wherein the subject suffering from NSCLC is a subject suffering from metastatic NSCLC.

[1071] 337. The combination therapy of any one of the preceding embodiments, wherein the subject having metastatic NSCLC is a subject having stage III NSCLC.

[1072] 338. The combination therapy of any one of the preceding embodiments, wherein the subject having metastatic NSCLC is a subject having stage IV NSCLC.

[1073] 339. The combination therapy according to any one of the preceding embodiments, wherein the subject has or is selected to have stage III to IV NSCLC.

[1074] 340. The combination therapy of any one of the preceding embodiments, wherein the combination therapy is used to obtain clinical benefit.

[1075] 341. The combination therapy of any of the preceding embodiments, wherein the combination therapy promotes infiltration of immune cells into the tumor microenvironment of one or more lesions.

[1076] 342. The combination therapy of any of the preceding embodiments, wherein the combination therapy is used to enhance the response to immunotherapy following the combination therapy.

[1077] 343. The combination therapy of any of the preceding embodiments, wherein the lesion is a tumor metastasis.

[1078] 344. The combination therapy of any of the preceding embodiments, wherein the lesion is a primary tumor.

[1079] 345. The combination therapy of any of the preceding embodiments, for use in the method of any of the preceding embodiments.

[1080] 346. The combination therapy of any of the preceding embodiments, wherein one or more lesions have a PD-L1 tumor proportion score (TPS) of ≤ 15%.

[1081] 347. The combination therapy of any of the preceding embodiments, wherein one or more lesions have a PD-L1 tumor proportion score (TPS) of <5%.

[1082] 348. The combination therapy of any of the preceding embodiments, wherein one or more lesions have a PD-L1 tumor proportion score (TPS) of ≤ 1%.

[1083] 349. The combination therapy of any of the preceding embodiments, wherein one or more lesions have a PD-L1 tumor proportion score (TPS) of <1%.

[1084] 350. The combination therapy of any of the preceding embodiments, wherein one or more lesions have a PD-L1 Comprehensive Positive Score (CPS) of <10%.

[1085] 351. The combination therapy of any of the preceding embodiments, wherein one or more lesions have a PD-L1 Comprehensive Positive Score (CPS) of <5%.

[1086] 352. The combination therapy of any of the preceding embodiments, wherein one or more lesions have a PD-L1 Comprehensive Positive Score (CPS) of <1%.

[1087] 353. The combination therapy of any of the preceding embodiments, wherein PD-L1 expression is undetectable or not assessable.

[1088] 354. The combination therapy of any of the preceding embodiments, wherein one or more lesions are characterized by being cold in immune properties.

[1089] 355. The combination therapy according to any one of the preceding embodiments, wherein the combination therapy is provided as a first-line therapy.

[1090] 356. The combination therapy according to any one of the preceding embodiments, wherein the combination therapy is provided as a second-line therapy.

[1091] 357. The combination therapy according to any one of the preceding embodiments, wherein the combination therapy is provided as a follow-up therapy. Example

[1092] Example 1-Phase II Clinical Study Design

[1093] Applicants are evaluating an anti-clusterin antibody in combination with docetaxel in previously treated subjects with metastatic non-small cell lung cancer.

[1094] This Phase II study enrolled 40 patients with metastatic non-small cell lung cancer who had failed treatment with platinum-containing doublet therapy and anti-PD1 or PDL-1 immune checkpoint antibodies administered simultaneously or sequentially. All enrolled patients received AB-16B5 (referred to herein as humanized 16B5) at a dose of 12 mg / kg once weekly and 75 mg / m every 3 weeks. 2 of docetaxel.

[1095] Purpose

[1096] A primary objective of this study was to determine the objective response rate (ORR) according to RECIST 1.1 (Eisenhauer, EA et al., European Journal of Cancer 45:228-247 (2009)) in subjects receiving AB-16B5 in combination with docetaxel.

[1097] Another primary objective of this study is to determine the objective response rate (ORR) according to RECIST 1.1 in subjects receiving AB-16B5 in combination with docetaxel.

[1098] Another primary objective of this study was to determine the safety and tolerability of AB-16B5 in combination with docetaxel.

[1099] A secondary objective of this study was to determine the clinical benefit rate (complete response (CR), partial response (PR), and stable disease (SD)) according to RECIST 1.1 in subjects who received AB-16B5 in combination with docetaxel.

[1100] Another secondary objective of this study was to determine the duration of response (CR and PR) according to RECIST 1.1 in subjects who received AB-16B5 in combination with docetaxel.

[1101] Another secondary objective of this study was to determine the duration of stable disease according to RECIST 1.1 in subjects receiving AB-16B5 in combination with docetaxel.

[1102] Another secondary objective of this study was to determine progression-free survival (PFS) according to RECIST 1.1 in subjects who received AB-16B5 in combination with docetaxel.

[1103] Another secondary objective of this study was to determine the overall survival (OS) of subjects who received AB-16B5 in combination with docetaxel.

[1104] Another secondary objective of this study was to determine the pharmacokinetics of AB-16B5 in this subject population.

[1105] An exploratory objective of this study was to conduct an exploratory pharmacodynamic evaluation of the effects of AB-16B5 in combination with docetaxel on biomarkers of epithelial to mesenchymal transition (EMT), immune cell biomarkers, and immune checkpoints in tumor biopsies.

[1106] An exploratory objective of this study was to assess disease response using iRECIST in subjects pursuing treatment beyond progression.

[1107] Study Design

[1108] The study is an open-label, single-arm, multicenter Phase II trial of AB-16B5 in combination with docetaxel in previously treated subjects with metastatic non-small cell lung cancer who have experienced disease progression following concurrent or sequential platinum-containing doublet therapy and anti-PD1 or PDL-1 immune checkpoint antibody therapy. Approximately 40 subjects were enrolled in the trial and received AB-16B5 administered once weekly on days 1, 8, and 15 in combination with 75 mg / m 2 The combination of AB-16B5 and docetaxel was administered at a dose of once every three weeks. One treatment cycle consisted of 21 days (3 weeks). The safety profile of the combination of AB-16B5 and docetaxel was examined during the safety lead-in period, and the first 8 subjects completed one treatment cycle.

[1109] Subjects were evaluated with radiographic imaging every 6 weeks to assess the response to treatment using the solid tumor efficacy evaluation criteria (RECIST) 1.1 criteria, which are used to determine the objective response rate (ORR) and progression-free survival (PFS). Ineffectiveness analysis was performed to minimize the exposure of subjects to ineffective treatment. Paired tumor biopsies were collected in all subjects (before and during treatment). Adverse events were monitored throughout the study and graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE). Study treatment was continued until disease progression (defined according to RECIST 1.1), unacceptable treatment-related adverse events of severity, subjects requested discontinuation, or the investigator determined that further treatment was not in the best interest of the subject. If the investigator believes that the subject is clinically stable, post-progression treatment is allowed. Subjects who must stop docetaxel due to toxicity continue to receive AB-16B5 treatment.

[1110] Safety introduction period

[1111] The safety run-in period examined the effects of AB-16B5 administered once weekly on days 1, 8, and 15 at 12 mg / kg versus 75 mg / m on day 1. 2 The safety profile of the combination of docetaxel administered once every 3 weeks was determined after the first 8 subjects completed a treatment cycle. The modified toxicity probability interval method (mTPI) can be used to decide whether to reduce the dose of AB-16B5.

[1112] Study treatment was considered acceptable if no more than 3 dose-limiting toxicities (DLTs) were observed during the first cycle in the first 8 subjects treated.

[1113] For these purposes, a DLT was defined as a grade ≥ 3 non-hematologic toxicity occurring during treatment cycle 1. In addition, the following hematologic toxicities were considered DLTs:

[1114] ● Grade ≥4 neutropenia or thrombocytopenia for >7 days

[1115] ● Grade ≥3 thrombocytopenia with bleeding

[1116] ● Febrile neutropenia, grade ≥ 3

[1117] Toxicity that was clearly and undisputedly caused by disease progression or external causes was not considered a DLT. In addition, the following non-hematologic toxicities were not considered a DLT:

[1118] ● Grade 3 arthralgia or myalgia that recovers to ≤1 within 7 days with appropriate supportive care

[1119] ● Grade 3 nausea, vomiting, or diarrhea that recovers to ≤1 in <72 hours with appropriate supportive care

[1120] Grade 3 fatigue lasting < 7 days

[1121] Grade 3 electrolyte abnormalities that last less than 72 hours and are not associated with clinical symptoms

[1122] Grade 3 amylase or lipase elevation not associated with symptoms or clinical manifestations of pancreatitis

[1123] If more than 3 DLTs were observed in the first 8 subjects treated, a stepwise dose reduction of AB-16B5 was performed.

[1124] In this case, the next three subjects received AB-16B5 administered weekly at 9 mg / kg AB-16B5 on days 1, 8, and 15 in combination with 75 mg / m 2 If 0 or 1 DLT is observed in cycle 1 of these 3 subjects, the dose of AB-16B5 at 9 mg / kg is considered acceptable.

[1125] If more than 1 DLT was observed, AB-16B5 was finally tapered to 6 mg / kg and safety was assessed using the same approach as above.

[1126] Inclusion criteria

[1127] The subjects participating in this study met the following inclusion criteria:

[1128] ● Subjects (male or non-pregnant female) who are 18 years of age or older on the day of signing the informed consent form.

[1129] ●Subjects with histologically or cytologically confirmed (stage III-IV) non-small cell lung cancer (NSCLC) with at least one measurable lesion as defined by RECIST 1.1.

[1130] ●Subjects who have experienced disease progression following treatment with an anti-PD1 or PD-L1 immune checkpoint antibody and platinum-containing doublet therapy administered concurrently or sequentially.

[1131] ●Subjects with targetable driver mutations in the EGFR or ALK genes who have failed available targeted therapies and have experienced disease progression following treatment with an anti-PD1 or PD-L1 immune checkpoint antibody and platinum-containing doublet therapy, administered either concurrently or sequentially, are permitted to participate in the trial.

[1132] Subjects with adequate organ and immune function as shown in Table 1 below:

[1133]

[1134] ●Subjects with tumor lesions suitable for biopsy and without contraindications to biopsy.

[1135] ●Subjects with Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

[1136] ●Subjects with a life expectancy of at least 3 months.

[1137] ● Subjects who have recovered from toxicity from their most recent cancer treatment to Grade 1 or less. If subjects underwent major surgery or radiation therapy, they have recovered from complications and / or toxicity.

[1138] ●Female subjects of childbearing potential with a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required. To be eligible, the subject's serum pregnancy test is preferably negative.

[1139] ● Subjects (males and females) of childbearing potential are willing to use highly effective contraceptive methods throughout the study and for up to 90 days after the last dose of study medication. Abstinence is acceptable if this is the subject's usual lifestyle.

[1140] Female subjects were considered to be of no reproductive potential if they had a history of surgical infertility or evidence of postmenopausal status, defined as any of the following:

[1141] ○≥45 years old and no menstruation for more than 2 years.

[1142] ○ Amenorrhea < 2 years, no hysterectomy and oophorectomy, and follicle stimulating hormone (FSH) value within the postmenopausal range at screening.

[1143] ○After hysterectomy, oophorectomy, or tubal ligation. A documented hysterectomy or oophorectomy must be confirmed by medical records of the actual surgery or ultrasound. Tubal ligation must be confirmed by medical records of the actual surgery.

[1144] It should be understood herein that the inclusion criteria are for the purpose of clinical trials only and are not to be considered as a limitation on the drugs approved for treatment.

[1145] Exclusion criteria

[1146] The subjects who participated in the study met the following exclusion criteria:

[1147] - Subjects who have received prior treatment with AB-16B5.

[1148] - Subjects who have received prior treatment with docetaxel for NSCLC.

[1149] ● Subjects who are currently participating in or have participated in a study of an investigational agent or a study using an investigational device within 21 days prior to the first dose of study treatment. The 21-day window should be calculated using the last dose of an antineoplastic investigational agent or the last use of an investigational device with antineoplastic intent.

[1150] ● Subjects who have received any anticancer therapy within 3 weeks or radiotherapy within 2 weeks prior to the first dose of study treatment, or subjects who have not recovered from an adverse event to grade 1 or less. Subjects with alopecia are eligible to participate.

[1151] ● Subjects who are expected to require any other form of systemic or local anti-tumor therapy during the trial. This includes maintenance therapy with another agent or radiation therapy.

[1152] ● Subjects who received prednisone (or equivalent) at a dose >10 mg / day within 7 days prior to the first dose of study treatment or any other form of immunosuppressive medication (prior to corticosteroid treatment and / or post-docetaxel treatment allowed).

[1153] ● Subjects who require treatment with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole). Subjects may be included if there is an alternative treatment with a weak CYP3A4 inhibitor and the subject is willing to change prior to randomization.

[1154] If a subject agrees to switch from a strong inhibitor to a weak CYP3A4 inhibitor, the strong inhibitor must be discontinued at least 7 days before receiving the first dose of study treatment.

[1155] ● Subjects with another malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or cervical carcinoma in situ.

[1156] ● Subjects with known active CNS metastases and / or carcinomatous meningitis. Subjects with previously treated brain metastases may participate if they have been clinically stable for at least 2 weeks prior to receiving the first dose of study treatment, if they have no evidence of new or enlarging brain metastases, and if they have not received prednisone (or equivalent) at a dose >10 mg / day within 7 days prior to receiving the first dose of study treatment.

[1157] - Subjects with clinically significant ECG abnormalities.

[1158] ●Subjects who have received or will receive a live vaccine within 30 days prior to the first dose of study treatment.

[1159] ●Subjects with a known history of human immunodeficiency virus (HIV).

[1160] ●Subjects with active hepatitis B or C infection.

[1161] ●Subjects with active infection requiring antibiotic therapy.

[1162] ●Subjects with a known history of alcohol or other substance abuse within the past year.

[1163] ●Subjects with known hypersensitivity to docetaxel or drugs formulated with polysorbate 80.

[1164] ● A subject with history or current evidence of any condition, therapy, or laboratory abnormality that could confound the trial results, interfere with the subject's participation for the full duration of the trial, or interfere with the subject's participation if participation in the trial is not in the subject's best interest.

[1165] ●Subjects with medical, social, or psychosocial factors that, in the opinion of the treating investigator, may affect safety or compliance with study procedures.

[1166] ● Subjects who are pregnant or breastfeeding or anticipate pregnancy or childbirth within 90 days after the last dose of AB-16B5 or the last dose of docetaxel.

[1167] It should be understood herein that the exclusion criteria are for the purpose of clinical trials only and are not to be considered as limitations on approved therapeutic drugs.

[1168] Study Treatment

[1169] Study drug, dose and route of administration

[1170] AB-16B5

[1171] AB-16B5 is a humanized IgG2 monoclonal antibody (humanized 16B5) targeting sCLU to inhibit cancer-related EMT. AB-16B5 is provided in a 10 mL vial at a protein concentration of 10.0 mg / mL. AB-16B5 is prepared in a citrate buffer solution at pH 6.0.

[1172] Store AB-16B5 vials upright at 2-8°C

[1173] Subjects will receive AB-16B5 via weekly 60-minute IV infusions on Day 1 (prior to docetaxel infusion), Day 8, and Day 15 (refer to the Pharmacy Manual for infusion conditions). The dose of AB-16B5 will be determined during the safety run-in period.

[1174] Subjects who experience infusion-related reactions will be treated with corticosteroids such as dexamethasone. Antihistamines and acetaminophen may also be used if deemed appropriate.

[1175] Premedication to prevent AB-16B5-related infusion reactions will not be administered initially. Subjects who experience an infusion-related reaction will receive premedication as follows:

[1176] Grade 1 (mild): No premedication regimen for subsequent medication

[1177] Grade 2 (moderate): Dexamethasone 8 mg PO BID one day prior to AB-16B5 infusion; acetaminophen 650 mg PO; and diphenhydramine 25 to 50 mg PO 30 to 60 minutes prior to AB-16B5 infusion

[1178] Grade 3 (severe) and 4 (life-threatening): Subjects will stop receiving further treatment with AB-16B5

[1179] If, at any time during the study, clinically significant infusion-related reactions are observed in more than one subject, the investigator, in consultation with the sponsor, may decide to administer premedication to all new subjects.

[1180] Docetaxel

[1181] 75 mg / m on day 1 2 Docetaxel will be administered by 60-minute IV infusion every 3 weeks at a dose of 100 mg / dL. Docetaxel will be prepared and administered in accordance with the approved product labeling / monograph.

[1182] All subjects should be premedicated with corticosteroids according to standard hospital practice. Intravenous extravasation and accidental spills should be managed according to standard hospital practice.

[1183] Duration of treatment

[1184] One treatment cycle will consist of 21 days (3 weeks).

[1185] Study treatment will continue until disease progression, unacceptable toxicity, subject request to discontinue study treatment, or the investigator feels that further treatment is not in the subject's best interest. Subjects who must discontinue docetaxel due to toxicity will continue to receive AB-16B5.

[1186] Post-progression therapy will be permitted if the investigator deems the subject clinically stable. Clinical judgment decisions at this site should be based on the subject's clinical stability as defined by:

[1187] Clinical stability is defined as follows:

[1188] Absence of symptoms and signs indicative of clinically significant progression of disease, including worsening of laboratory values

[1189] No decline in ECOG performance status

[1190] ●No rapid disease progression

[1191] The absence of progressive tumor in a critical anatomic location requiring urgent alternative medical intervention (eg, spinal cord compression)

[1192] Any subject considered clinically unstable should discontinue trial treatment at the first appearance of radiographic evidence of PD.

[1193] Study treatment, reduce dose after safe introduction

[1194] AB-16B5 dose reduction

[1195] Subjects who experience any Grade ≥ 3 adverse event judged to be possibly, probably, or possibly related to AB-16B5 and not requiring discontinuation of treatment should have their AB-16B5 dose reduced by one dose level (Table 2 below).

[1196] Treatment was restarted at a lower dose only after the adverse event recovered to grade ≤1.

[1197] Starting dose level Reduced dose 12 mg / kg 9mg / kg 9mg / kg 6mg / kg 6mg / kg Discontinue use of AB-16B5

[1198] Subjects whose initial AB-16B5 dose was reduced due to toxicity will not have their dose escalated again.

[1199] Docetaxel dose reduction

[1200] Febrile neutropenia, neutrophil count < 500 cells / mm 3 Subjects who experience skin reactions for more than one week, severe or cumulative skin reactions, or other grade ≥ 3 non-hematologic toxicities judged to be related to docetaxel should have treatment withheld until the toxicity resolves, then resume at 60 mg / m 2 Depending on the subject's condition, treatment with AB-16B5 may continue during this period.

[1201] 50 mg / m2 every two weeks has been found to be effective as second-line chemotherapy for advanced non-small cell lung cancer 2 The dose is 75 mg / m2 once every three weeks. 2 The dose of 1 mg / kg is as effective as that of 1 mg / kg (De Petris, L et al., Anticancer Research November 2005, 25: 4713-4717).

[1202] Additionally, although not part of the clinical protocol, the literature teaches that physicians can reduce the dose of docetaxel to 65 mg / m2 in subjects who experience febrile neutropenia. 2 or even 50 mg / m 2 .

[1203] Docetaxel should be discontinued in subjects who develop grade ≥3 peripheral neuropathy.

[1204] Example 2 - Phase II Clinical Study - Preliminary Results

[1205] The safety of the lead-in treatment phase was confirmed with a weekly dose of 12 mg / kg AB-16B5 and 75 mg / m 2 The dose of docetaxel was safe at 10 mg / dL and 10 mg / dL, so lower doses are also expected to be safe.

[1206] Figure 1is a graph showing the duration of treatment for patients with best response according to RECIST 1.1, wherein of the 34 evaluable patients, 6 patients showed partial response (PR), 18 patients showed stable disease (SD), and 10 patients showed progressive disease (PD), and also showing the lesion measurements at the specified treatment time according to RECISTv1.1.

[1207] Among patients who received AB-16B5 plus docetaxel for more than 12 weeks (19 patients), the best responses were 6 partial responses (PR), 12 stable disease (SD), and 1 progressive disease (PD). KRAS mutations were evaluated in several patients' tumors before first-line therapy. Of these 19 patients, tumors from 7 patients (4, 7, 12, 17, 18, 21) had KRAS mutations; 5 tumors were KRAS negative (3, 6, 8, 22, and 32), and KRAS status was not determined in the other 7 patients (1, 2, 5, 19, 23, 27, and 30) ( Figure 1 ).

[1208] If available from Figure 1 As seen in Figure 2, 4 of the 5 NSCLC patients (patients 1, 2, 4, and 12) who showed signs of partial response had low PD-L1 expression (TPS ≤ 15%).

[1209] Biopsies were obtained from some of the treated patients for analysis of various parameters. H&E staining was analyzed by a qualified pathologist. Tumor cell markers and immune cells were detected on serial tissue sections. TM Algorithms were created to digitize and analyze the slides.

[1210] exist Figure 2 a- Figure 2 Histological analysis of pre-treatment and treatment biopsies from two patients in the study is shown in d. Tumor sections were stained with hematoxylin and eosin. The pre-treatment samples were mainly composed of tumor cells without signs of inflammatory cells (a and c). In contrast, very few tumor cells can be detected in the samples in treatment (b and d). In addition, cytopathic effects (arrows in b and d) and active inflammatory infiltration caused by docetaxel were observed.

[1211] Patient 1 (PT1)

[1212] The PD-L1 TPS score determined during first-line treatment was 0%. The scan results after eight cycles of treatment showed a 50% reduction in the size of the target lesion. Therefore, this patient showed signs of partial response.

[1213] Analysis of the pre-treatment biopsies showed moderate lymphocytic infiltration in one sample and fibrosis and chronic inflammatory infiltration in another. However, the largest portion of the other core was replaced by tumor cells with extensive necrosis. No residual tumor cells were found on any of the four cores of the on-treatment biopsies. Fibrotic tissue with chronic lymphoplasmacytitis was observed in the on-treatment tissue cores. Lymphocytic and plasma cell infiltration was found to be prominent in certain areas. The on-treatment samples failed to show residual tumor cells. Notably, fibrosis and chronic inflammation were present in the on-treatment cores. Tumor cells were found only in the pre-treatment case.

[1214] Analysis of the Ki-67 proliferation biomarker showed intense staining in the pre-treatment condition, while the signal was significantly reduced in the on-treatment samples. Image analysis showed a 42% reduction in proliferating tumor cells after the second treatment cycle.

[1215] Image analysis of E-cadherin staining in pre-treatment biopsies showed a large number of tumor cells with an H-score of 166. No E-cadherin staining was observed in the on-treatment biopsies, indicating that the treatment was effective in eradicating tumor cells.

[1216] Image analysis of CD3 staining in pre-treatment biopsies showed that the tumors were poorly infiltrated with T lymphocytes before the start of treatment. However, a 45% increase in CD3 signal was observed in the on-treatment biopsies.

[1217] Image analysis of CD4 staining showed a 100% increase in CD4 T cells in the treated biopsies, ie, an increase from 4% to 8% of cells in the target area.

[1218] Image analysis of CD8 staining showed an 86% increase in CD8 T cells in the treated biopsies, an increase from 7% to 13% of cells in the target area.

[1219] Patient 2 (PT2)

[1220] The PD-L1 TPS score determined during first-line treatment was 0%. The patient stopped receiving docetaxel at week 33. CT scans were performed after cycles 2, 4, 6, 8, and 10, showing a decrease in the size of the target lesion that varied from 24% at the end of cycle 2 to 43% at the end of cycle 10. Therefore, this patient showed signs of partial response.

[1221] Analysis of tumor biopsies showed that pre-treatment samples were more basophilic, reflecting the presence of a large number of tumor cell aggregates. In contrast, samples during treatment (at the end of cycle 2) showed large areas of eosinophils, reflecting extensive stromal fibrosis. High-power views of pre-treatment conditions showed extensive tumor involvement. It is worth noting that tumor cell nuclei showed cytological abnormalities, but did not indicate changes in recent exposure to chemotherapy. There was no inflammatory reaction around the tumor foci. In the case of treatment, important findings were reported: cytopathic effect, fibrosis, and chronic lymphoplasmacytic and histiocytic inflammation. There were areas of dense sclerotic tissue with chronic inflammatory cells and a small amount of residual tumor cells with cytopathic changes consistent with chemotherapeutic agents acting on cell spindles. Large aneuploidy and giant cells may represent changes induced by docetaxel.

[1222] Analysis of the Ki-67 proliferation biomarker showed intense staining in the pre-treatment condition, while the signal was significantly reduced in the samples undergoing treatment. Image analysis showed a 67.2% reduction in proliferating cells after the second treatment cycle.

[1223] Image analysis of E-cadherin staining in pre-treatment biopsies showed a large number of tumor cells with an H-score of 166. No E-cadherin staining was observed in the on-treatment biopsies, indicating that the treatment was effective in eradicating tumor cells.

[1224] Image analysis of CD3 staining in pre-treatment biopsies showed that the tumors were poorly infiltrated with T lymphocytes before the start of treatment. However, a 304% increase in CD3 signal was observed in the on-treatment biopsies.

[1225] Image analysis of CD4 staining showed a 100% increase in CD4 T cells in the treated biopsies, ie, an increase from 4% to 8% of cells in the target area.

[1226] Image analysis of CD8 staining showed an 86% increase in CD8 T cells in the treated biopsies, an increase from 7% to 13% of cells in the target area.

[1227] Patient 3 (PT3)

[1228] The PD-L1 TPS score determined during first-line treatment was 90%. The patient remained on first-line treatment for 14 months until tumor progression. The CT scan results after the 6th treatment cycle showed a 12% decrease in the size of the tumor lesion. Therefore, the patient showed signs of stable disease.

[1229] Patient 4 (PT4)

[1230] The PD-L1 TPS score determined during first-line treatment was 15%. The results of the CT scan showed that the size of the tumor lesions decreased by 34.6% and 42% after two and four cycles of treatment, respectively. Therefore, the patient showed signs of durable partial remission (72 weeks at the time of disclosure).

[1231] These data indicate that the combination therapies, dosages, treatment regimens and / or administration schedules of the present invention are safe and show evidence of efficacy. These data also indicate that the combination therapies, dosages and treatment regimens, treatment regimens and / or administration schedules disclosed herein can be tolerated for up to several months, with some patients being treated for up to 66 weeks.

[1232] Indeed, the disclosed combination therapies, doses, and treatment regimens achieved clinical benefit in several patients, including some with PD-L1 tumor proportion scores <50% and <1% of lesions and some with tumors harboring KRAS mutations, despite failure of prior treatment with anti-PD-1 or PD-L1 immune checkpoint antibodies and platinum-containing doublet therapy.

[1233] In addition, if Figure 1 As seen in the literature, in some patients, clinical benefit was observed after just two treatment cycles and persisted for at least 6 weeks or more after a response to treatment was first determined.

[1234] Thus, the combination therapies of the present disclosure can be used, for example, in NSCLC patients who have progressed following treatment comprising an immune checkpoint antibody (e.g., alone or in combination with chemotherapy).

[1235] Relatively poor immune cell infiltration combined with low expression of PD-L1 may partially explain the failure of treatments containing immune checkpoint antibodies in NSCLC patients. It is conceivable that the combination therapy of the present disclosure may be beneficial to NSCLC patients with no signs of PD-L1 expression or with low PD-L1 expression (e.g., metastatic NSCLC patients). Therefore, the combination therapy of the present disclosure can be administered to NSCLC patients with PD-L1 TPS ≤ 15% in place of treatment containing immune checkpoint inhibitors.

[1236] In addition, the combination therapies of the present disclosure may be administered to NSCLC patients who are not suitable for or are unlikely to benefit from treatment with immune checkpoint inhibitors.

[1237] Preliminary pharmacokinetic data appear to show accumulation of anti-clusterin antibody in treated subjects over time (not shown). This observation may indicate the feasibility of administering anti-clusterin antibody every two weeks, every three weeks, once a month, or using lower doses of anti-clusterin antibody, such as between about 3 mg / kg and about 11 mg / kg. This modification in the treatment regimen may be used in subsequent treatment cycles, or in both the initial treatment cycle and subsequent treatment cycles.

[1238] This application claims priority to U.S. Provisional Application No. 63 / 307,533 filed on February 7, 2022 and U.S. Provisional Application No. 63 / 333,597 filed on April 22, 2022, the entire contents of which are incorporated herein by reference.

[1239] The embodiments and examples described herein are illustrative and are not meant to limit the scope of the claims. Variations of the foregoing embodiments, including substitutions, modifications and equivalents, are considered by the inventors to be covered in the claims. The citations listed in this application are incorporated herein by reference.

[1240] References

[1241] Al-Lazikani et al.,Standard conformations for the canonicalstructures of immunoglobulins.J Mol Biol 273:927-948,1997.

[1242] Brochet et al. IMGT / V-QUEST: the highly customized and integrated system for IG and TR standardized VJ and VD-Jsequence analysis. Nucl AcidsRes 36:W503-W508, 2008.

[1243] Andrew C.R.Martin,Antibody Engineering Vol.2,Chapter 3:ProteinSequence and Structure Analysis of Antibody Variable Domains.R.Kontermann andS.Dubel(eds.),DOI 10.1007 / 978-3-642-01147-4_3,#Springer-Verlag BerlinHeidelberg2010

[1244] Shibue,T.,Weinberg,R.EMT,CSCs,and drug resistance:the mechanisticlink and clinical implications.Nat Rev Clin Oncol 14:611-629(2017).

[1245] Terry,S.,Savagner,P.,Ortiz-Cuaran,S.,Mahjoubi,L.,Saintigny,P.,Thiery,J.-P.and Chouaib,S.,New insights into the role of EMT in tumor immuneescape.Mol Oncol,11:824-846(2017).

[1246] Lenferink,A.,Cantin,C.,Nantel,A.et al.Transcriptome profiling of aTGF-β-induced epithelial-to-mesenchymal transition reveals extracellularclusterin as a target for therapeutic antibodies.Oncogene 29:831-844(2010).

[1247] New response evaluation criteria in solid tumours:Revised RECISTguideline(version 1.1)”E.A.Eisenhauer,P.Therasse,J.Bogaerts,L.H.Schwartz,D.Sargent,R.Ford,J.Dancey,S.Arbuck,S.Gwyther,M.Mooney,L.Rubinstein,L.Shankar,L.Dodd,R.Kaplan,D.Lacombe,J.Verweij;Eur J Cancer,45(2009)228-247.

[1248] Cristiano Ferrario,Julie Laurin,Leon Van Kempen,Caroline Lambert,AlanSpatz,Oksana Markova,Gerald Batist,Adrian Langleben,Mario Filion,JacquesJolivet.Phase 1first-in-humanstudy of anti-clusterin antibody AB-16B5 inpatients with advancedsolid malignancies[abstract].In:Proceedings of theAmericanAssociation for Cancer Research Annual Meeting 2017;2017 Apr 1-5;Washington,DC.Philadelphia(PA):AACR;Cancer Res 2017;77(13Suppl):Abstract nrCT098.doi:10.1158 / 1538-7445.AM2017-CT098.

[1249] Hodge,J.W.Garnett,C.T.,Farsaci,B.,et al.Chemotherapy-inducedimmunogenic modulation of tumor cellsenhances killing by cytotoxic Tlymphocytes and is distinct fromimmunogenic cell death.Int.J.Cancer.133:624-636(2013).

[1250] Jiang X,Dudzinski S,Beckermann KE,et al.MRI of tumor Tcellinfiltration in response to checkpoint inhibitor therapy.JournalforImmunoTherapy of Cancer 2020;8:e000328.doi:10.1136 / jitc-2019-000328.

[1251] MacCallum,R.M.,Martin,A.C.R.and Thornton,J.T.'Antibody-antigeninteractions:Contact analysis and binding sitetopography'J.Mol.Biol.262:732-745,1996.

[1252] Ojima I.,Brendan,L.,Siyeon,L.,Wang,C.and Wang,X.,Taxane anticanceragents:a patent perspective,Expert Opin Ther Pat.2016:26(1):1-20

[1253] Seymour,L.et al.,iRECIST:Guidelines for response criteria foruse intrials testing immunotherapeutics,Lancet Oncol.18(3)e143-e152,2017.

[1254] Tremblay G.B.,Filion,M.,and Sulea,T.,Anti-ClusterinAntibodies andAntigen Binding Fragments and their Use to ReduceTumor Volume,internationalapplication No.PCT / CA2010 / 001882filed on November 24,2010 and published onJune 3,2011 undernumber WO2011 / 063523 A1.

[1255] Wu and Kabat,An analysis of the sequences of the variableregions ofBence Jones proteins and myeloma light chains and theirimplications forantibody complementarity.J Exp Med 132:211-250,1993.

[1256] Chi,K.N.,et al.,Randomized Phase II Study of Docetaxel andPrednisoneWith or Without OGX-011 in Patients With MetastaticCastration-ResistantProstate Cancer,J Clin Oncol.28:4247-4254,2010.

[1257] Zhou,J.et al.,Therapeutic targeting of myeloid-derivedsuppressorcells involves a novel mechanism mediated by clusterin,Scientific Reports,6:29521,2016.

[1258] Radvanyl,L.G.,Tumor-Infiltrating lymphocyte therapy:addressingprevailing questions,The Cancer Journal 21(6):450-464,2015.

[1259] Romeo,E.et al.,The Vicious Cross-Talk between Tumor Cellswith an EMTPhenotype and Cells of the Immune System,Cells:8(5):460,2019.

[1260] Peng,M.et al.,The Role of Clusterin in Canacer Metastasis,CancerManagement and Research 11:2405-2414,2019.

[1261] Taki,M.et al.,Tumor Immune Microenvironment duringEpithelial-Mesenchymal Transition,Clin Can Res.,27:4669-4679,2021.

[1262] International application No.PCT / CA2006 / 001505 filed onSeptember 13,2006 in the name of National Research Council ofCanada and published March22,2007,under No.WO2007 / 030930A1.

[1263] International application No.PCT / CA2021 / 050572 filed on April27,2021,in the name of Alethia Biotherapeutics Inc.and published onNovember 3,2022,under No.WO2022 / 226623 A1.

[1264] International application No. PCT / CA2022 / 050632 filed on April 26, 2022, in the name of Alethia Biotherapeutics Inc. and published on November 3, 2022, under No. WO2022 / 226637A1.

[1265] Alethia Biotherapeutics Inc. Clinical Trial Protocol entitled “AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer” identifier number: NTC043634620 published on clinicaltrials.gov on April 28, 2020.

[1266] De Petris, L et al., Docetaxel Administered Every Two Weeks as Second-line Chemotherapy for Advanced Non-small Cell Lung Cancer: A Phase II Study, Anticancer Research November 2005, 25:4713 - 4717.

[1267] Table 3: Sequence Listing

[1268]

[1269]

[1270]

[1271]

[1272]

[1273]

[1274]

[1275]

Claims

1. A method of treating a subject having non-small cell lung cancer (NSCLC), the method comprising administering to the subject a combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and a taxane.

2. The method of claim 1, wherein the taxane is docetaxel or paclitaxel.

3. The method of claim 1 or 2, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of between about 3 mg / kg and about 20 mg / kg.

4. The method of any one of claims 1 to 3, wherein the taxane is docetaxel and is administered at a dose of between about 50 mg / m 2 About 100 mg / m 2 Dosages between.

5. The method of any one of the preceding claims, wherein the combination therapy is administered as a therapeutically effective combination therapy.

6. The method of any of the preceding claims, wherein the method comprises administering the anti-clusterin antibody or antigen-binding fragment thereof once a week, once every two weeks, or once every three weeks at a dose between about 3 mg / kg and about 20 mg / kg, and at a dose between about 50 mg / m 2 About 100 mg / m 2 Docetaxel was administered every two weeks or every three weeks between doses.

7. The method of any of the preceding claims, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 3 mg / kg.

8. The method of any of the preceding claims, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 6 mg / kg.

9. The method of any of the preceding claims, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 9 mg / kg.

10. The method of any of the preceding claims, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered at a dose of about 12 mg / kg.

11. The method of any one of the preceding claims, wherein the taxane is docetaxel and is administered at about 50 mg / m 2 dosage administration.

12. The method of any one of the preceding claims, wherein the taxane is docetaxel and is administered at about 60 mg / m 2 dosage administration.

13. The method of any of the preceding claims, wherein the taxane is docetaxel and is administered at about 75 mg / m 2 dosage administration.

14. The method of any of the preceding claims, wherein the taxane is docetaxel and is administered at about 100 mg / m 2 dosage administration.

15. The method of any of the preceding claims, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered once a week.

16. The method of any of the preceding claims, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered once every two weeks.

17. The method of any of the preceding claims, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered once every three weeks.

18. The method of any one of the preceding claims, wherein docetaxel is administered once every two weeks.

19. The method of any one of the preceding claims, wherein docetaxel is administered once every three weeks.

20. The method of any of the preceding claims, wherein the method comprises administering at least one initial treatment cycle and at least one subsequent treatment cycle, wherein the initial treatment cycle and subsequent treatment cycle are the same or different and each comprises at least one dose of the anti-clusterin antibody or antigen-binding fragment thereof and at least one dose of docetaxel.

21. The method of claim 20, wherein the initial treatment cycle and / or subsequent treatment cycles each independently comprise administering the anti-clusterin antibody or antigen-binding fragment thereof once a week, once every two weeks, or once every three weeks at a dose of about 3 mg / kg to about 20 mg / kg, and administering the anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 50 mg / m 2 Up to 100 mg / m 2 Docetaxel was administered every two weeks or every three weeks.

22. The method of any one of claims 1 to 21, wherein the method comprises administering about 75 mg / m 2 Docetaxel is administered at a dose of once every three weeks, and the anti-clusterin antibody or antigen-binding fragment thereof is administered once a week, once every two weeks, or once every three weeks.

23. The method of any one of claims 1 to 22, wherein the method comprises administering the anti-clusterin antibody or antigen-binding fragment thereof once weekly at a dose of about 12 mg / kg and at a dose of about 75 mg / m 2 Docetaxel was administered once every three weeks.

24. The method of any one of claims 1 to 23, wherein the method comprises administering the anti-clusterin antibody or antigen-binding fragment thereof once every three weeks at a dose of about 12 mg / kg and at a dose of about 75 mg / m 2 Docetaxel was administered once every three weeks.

25. The method of any one of claims 1 to 24, wherein the method comprises administering: a. at least one initial treatment cycle comprising administering the anti-clusterin antibody or antigen-binding fragment thereof once weekly at a dose of about 12 mg / kg and at a dose of about 75 mg / m 2 Docetaxel and; b. at least one subsequent treatment cycle comprising administering the anti-clusterin antibody or antigen-binding fragment thereof once every three weeks at a dose of about 3 mg / kg to about 20 mg / kg and at about 75 mg / m 2 Docetaxel was administered once every three weeks.

26. The method of any one of claims 1 to 25, wherein the method comprises administering: a. at least one initial treatment cycle comprising administering the anti-clusterin antibody or antigen-binding fragment thereof once weekly at a dose of about 12 mg / kg and at a dose of about 75 mg / m 2 Docetaxel is administered every three weeks at a dose of b. at least one subsequent treatment cycle comprising administering the anti-clusterin antibody or antigen-binding fragment thereof once every three weeks at a dose of about 12 mg / kg and at a dose of about 75 mg / m 2 Docetaxel was administered once every three weeks.

27. The method of any one of claims 1 to 26, wherein the method comprises administering at about 50 mg / m 2 Docetaxel is administered at a dose of once every two weeks, and the anti-clusterin antibody or antigen-binding fragment thereof is administered once a week, once every two weeks, or once every three weeks.

28. The method of any one of claims 1 to 27, wherein the method comprises administering the anti-clusterin antibody or antigen-binding fragment thereof once weekly at a dose of about 12 mg / kg and at a dose of about 50 mg / m 2 Docetaxel was administered every two weeks at a dose of .

29. The method of any one of claims 1 to 28, wherein the method comprises administering the anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg once every two weeks and at a dose of about 50 mg / m 2 Docetaxel was administered every two weeks at a dose of .

30. The method of any one of claims 1 to 29, wherein the method comprises administering: a. at least one initial treatment cycle comprising administering the anti-clusterin antibody or antigen-binding fragment thereof once weekly at a dose of about 12 mg / kg and at a dose of about 50 mg / m 2 Docetaxel administered every two weeks at a dose of b. at least one subsequent treatment cycle comprising administering the anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 3 mg / kg to about 20 mg / kg once every two weeks and at about 50 mg / m 2 Docetaxel was administered every two weeks at a dose of .

31. The method of any one of claims 1 to 30, wherein the method comprises administering: a. at least one initial treatment cycle comprising administering the anti-clusterin antibody or antigen-binding fragment thereof once weekly at a dose of about 12 mg / kg and at a dose of about 50 mg / m 2 Docetaxel administered every two weeks at a dose of b. at least one subsequent treatment cycle comprising administering the anti-clusterin antibody or antigen-binding fragment thereof at a dose of about 12 mg / kg once every two weeks and at a dose of about 50 mg / m 2 Docetaxel was administered every two weeks at a dose of .

32. A method of treating non-small cell lung cancer (NSCLC) in a subject in need thereof, the method comprising administering a combination therapy for at least one treatment cycle, the treatment cycle comprising administering the anti-clusterin antibody at a dose of about 12 mg / kg once a week, once every two weeks, once every three weeks, or once every four weeks and at a dose of between about 50 mg / m 2 About 75 mg / m 2 Docetaxel is administered once every two to three weeks at a dose of 100 mg / kg / day, wherein the anti-clusterin antibody comprises a light chain variable region comprising the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12 and a heavy chain variable region comprising the CDRs of the heavy chain variable region shown in SEQ ID NO:

13.

33. The method of any of the preceding claims, wherein the anti-clusterin antibody or antigen-binding fragment thereof and docetaxel are administered on the same day.

34. The method of any one of the preceding claims, wherein the method is performed to achieve and / or maintain a clinical benefit.

35. The method of any of the preceding claims, wherein the anti-clusterin antibody or antigen-binding fragment thereof is capable of binding to the C-terminal portion of the beta subunit of human clusterin.

36. The method of any of the preceding claims, wherein the anti-clusterin antibody or antigen-binding fragment thereof is capable of binding to an epitope between amino acids 421 and 443 of the C-terminal portion of the human clusterin β subunit or contained within amino acids 421 and 443.

37. The method of any of the preceding claims, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the complementarity determining regions (CDRs) of the light chain variable region shown in SEQ ID NO: 12 and a heavy chain variable region comprising the CDRs of the heavy chain variable region shown in SEQ ID NO:

13.

38. The method of any one of the preceding claims, wherein the subject has or is selected to have NSCLC that has failed prior treatment comprising an immune checkpoint antibody and chemotherapy or comprising an immune checkpoint antibody but without chemotherapy.

39. The method of any one of the preceding claims, wherein the immune checkpoint antibody is an anti-PD-1 or anti-PD-L1 immune checkpoint antibody.

40. The method of any one of the preceding claims, wherein the subject has or is selected to have NSCLC that has failed prior treatment with an anti-PD-1 or PD-L1 immune checkpoint antibody and a platinum-containing doublet therapy.

41. The method of any one of claims 38 to 40, wherein the immune checkpoint antibody is selected from ipilimumab, nivolumab, pembrolizumab, cemiplizumab, atezolizumab, avelumab, or durvalumab.

42. The method of any one of the preceding claims, wherein the subject has or is selected to have NSCLC characterized as having a KRAS mutation.

43. The method of any one of the preceding claims, wherein the subject has or is selected to have one or more lesions with a PD-L1 Tumor Ratio Score ≤ 15%, < 5%, ≤ 1% or < 1% or no evidence of PD-L1 expression.

44. The method of any of the preceding claims, wherein the subject has or is selected to have NSCLC that is not suitable for treatment comprising an immune checkpoint antibody, or the subject will not likely benefit from treatment comprising an immune checkpoint antibody.

45. The method of any of the preceding claims, wherein the subject has or is selected to have one or more lesions characterized by poor immune cell infiltration or characterized as being cold in immune profile.

46. ​​The method of any one of the preceding claims, wherein the subject has or is selected to have one or more lesions that have or show signs of EMT characteristics.

47. The method of any of the preceding claims, wherein a treatment cycle lasts about 3 weeks.

48. The method of any of the preceding claims, wherein the anti-clusterin antibody or antigen-binding fragment thereof is administered by IV infusion.

49. The method of any one of the preceding claims, wherein docetaxel is administered by IV infusion.

50. The method of any one of the preceding claims, wherein the clinical benefit is a complete response (CR) according to RECIST 1.1 guidelines.

51. The method of any one of the preceding claims, wherein the clinical benefit is a partial response (PR) according to RECIST 1.1 guidelines.

52. The method of any one of the preceding claims, wherein the clinical benefit is stable disease (SD) according to RECIST 1.1 guidelines.

53. The method of any one of the preceding claims, wherein the clinical benefit is a reduction in lesion size as assessed according to RECIST 1.1 guidelines.

54. The method of any of the preceding claims, wherein the combination therapy is administered for at least 2 cycles comprising administration of the anti-clusterin antibody once per week and docetaxel once every three weeks.

55. The method of any of the preceding claims, wherein the combination therapy is administered for at least 2 cycles, 3 cycles, at least 4 cycles, at least 5 cycles, at least 6 cycles, at least 7 cycles, at least 8 cycles, at least 9 cycles, at least 10 cycles, at least 11 cycles, at least 12 cycles, at least 13 cycles, at least 14 cycles, at least 15 cycles, at least 16 cycles, at least 17 cycles, at least 18 cycles, at least 19 cycles, at least 20 cycles, at least 21 cycles, or at least 22 cycles.

56. The method of any one of the preceding claims, wherein the combination therapy is administered for at least one to at least five initial treatment cycles.

57. The method of any one of the preceding claims, wherein the combination therapy is administered for two or more subsequent treatment cycles.

58. The method of any of the preceding claims, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises: a. a light chain variable region having an amino acid sequence that is at least 80% identical to the amino acid sequence shown in SEQ ID NO: 12 and a heavy chain variable region having an amino acid sequence that is at least 80% identical to the amino acid sequence shown in SEQ ID NO: 13, or b. a light chain having an amino acid sequence that is at least 80% identical to the amino acid sequence shown in SEQ ID NO:14 and a heavy chain having an amino acid sequence that is at least 80% identical to the amino acid sequence shown in SEQ ID NO:

15.

59. The method of any of the preceding claims, wherein the anti-clusterin antibody or antigen-binding fragment thereof comprises: a. a light chain variable region having the amino acid sequence shown in SEQ ID NO: 12 and a heavy chain variable region having the amino acid sequence shown in SEQ ID NO: 13, or b. a light chain having the amino acid sequence shown in SEQ ID NO: 14 and a heavy chain having the amino acid sequence shown in SEQ ID NO:

15.

60. The method of any of the preceding claims, wherein the subject is not immunosuppressed or has not received immunosuppressive medication within 7 days prior to treatment.

61. The method of any one of the preceding claims, wherein the subject is a human subject.

62. The method of any one of the preceding claims, wherein the NSCLC is metastatic NSCLC.

63. The method of any one of the preceding claims, wherein the NSCLC is stage III to IV NSCLC.

64. The method of any of the preceding claims, wherein docetaxel is interrupted or discontinued for one or more treatment cycles upon the onset of signs of toxicity.

65. The method of claim 64, wherein the anti-clusterin antibody or antigen-binding fragment thereof is continued to be administered.

66. The method of any of the preceding claims, wherein the anti-clusterin antibody or antigen-binding fragment thereof is a conventional antibody.

67. A therapeutically effective combination therapy comprising an anti-clusterin antibody or antigen-binding fragment thereof and a taxane for treating non-small cell lung cancer (NSCLC) in a subject in need thereof.

68. The combination therapy of claim 67, wherein the subject in need thereof has metastatic NSCLC.

69. The combination therapy of claim 67 or 68, wherein the combination therapy is used in the method of any one of claims 1-66.